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Abstract 
The goal of the Encyclopedia of DNA Elements (ENCODE) project has been to 
characterize all the functional elements of the human genome. These elements include 
expressed transcripts and genomic regions bound by transcription factors (TFs), occupied 
by nucleosomes, occupied by nucleosomes with modified histones, or hypersensitive to 
DNase I cleavage, etc. Chromatin Immunoprecipitation (ChIP-seq) is an experimental 
technique for detecting TF binding in living cells, and the genomic regions bound by TFs 
are called ChIP-seq peaks. ENCODE has performed and compiled results from tens of 
thousands of experiments, including ChIP-seq, DNase, RNA-seq and Hi-C.  
These efforts have culminated in two web-based resources from our lab—
Factorbook and SCREEN—for the exploration of epigenomic data for both human and 
mouse. Factorbook is a peak-centric resource presenting data such as motif enrichment 
and histone modification profiles for transcription factor binding sites computed from 
ENCODE ChIP-seq data. SCREEN provides an encyclopedia of ~2 million regulatory 
elements, including promoters and enhancers, identified using ENCODE ChIP-seq and 
DNase data, with an extensive UI for searching and visualization. 
While we have successfully utilized the thousands of available ENCODE ChIP-
seq experiments to build the Encyclopedia and visualizers, we have also struggled with 
the practical and theoretical inability to assay every possible experiment on every 
possible biosample under every conceivable biological scenario. We have used machine 
learning techniques to predict TF binding sites and enhancers location, and demonstrate 
machine learning is critical to help decipher functional regions of the genome.  
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I. Chapter I: Introduction 
Our experience hitherto justifies us in trusting that nature is the realization  
of the simplest that is mathematically conceivable. 
–Albert Einstein, Herbert Spencer Lecture, 1933 
We, as humans, have an innate, natural curiosity about ourselves, how we work, and the 
myriad ways in which we malfunction. In many ways, this curiosity has been codified 
and matured by the scientific method into modern molecular biology. What we have 
found so far is that our human genome—our code—is beautifully innate and immensely 
complex. That there is structure in this code, though, is becoming clearer. The central 
dogma of molecular biology—that sequence information from DNA is transcribed into 
mRNA, and mRNA is ultimately translated into protein (Crick 1958)—belies an 
enormous amount of machinery controlling this biological flow of information.  
A genome is composed of coding and non-coding regions of DNA. Coding 
regions get processed into protein products, while non-coding regions have a myriad of 
functions. Large eukaryotic genomes must be packaged and folded multiple times to fit 
into a cell nucleus. The first level of DNA packaging into chromatin occurs by winding 
DNA around histone proteins, forming structures called nucleosomes. Eight histone 
proteins form the core of the nucleosome, with each of 4 histone proteins (H2A, H2B, 
H3, and H4) found twice. Histone protein tails can undergo a large number of post-
translational chemical modifications. For example, the 27th lysine residue of H3 can be 
acetylated (H3K27ac, for short), or the 4th lysine residue on H3 can be trimethylated 
(H3K4me3). These modifications have wide-ranging effects on cellular processes, 
regulating everything from gene expression and the cell cycle to DNA replication and 
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apoptosis (Wang et al. 2001; Koprinarova, Schnekenburger, and Diederich 2016; 
Eberharter and Becker 2002). Nucleosomes can then be further packaged into 
increasingly compact and complex chromatin structure. This 3D structure enables gnomic 
elements separated by large linear genomic distance to suddenly be able to interact; 
almost any genomic location has a non-zero probability of interacting with any other 
portion of the genome (Dekker, Marti-Renom, and Mirny 2013). The winding and 
unwinding of chromatin all the way down to modifications of histone tails changes the 
accessibility of the gnome; local DNA accessibility changes influence where transcription 
factors can bind promoter and enhancer regions, affecting gene expression. 
Experimentally, chromatin accessibility is indicated by DNase I (a nuclease) digestion 
(Neph et al., 2012). DNase digestion followed by next generation DNA sequencing 
(DNase-seq) (Boyle et al., 2008) is now a widely-used and reliable technique, with 
experimental data available for hundreds of biosamples in ENCODE.  
Certain patterns or signatures of chromatin accessibility and histone modifications 
have been found to have association with certain events. For example, the H3K27ac 
histone mark in a DNA-accessible region typically indicates that one or more activator 
proteins (called transcription factors) can bind and increase protein translation (Rada-
Iglesias et al. 2011). These regions that increase gene expression are typically within a ~1 
MB window of the gene (upstream or downstream), and are called enhancer regions 
(Gillies et al. 1983). Similarly, the H3K4me3 histone mark in a DNA-accessible region, 
within +/- 1,000 bases upstream of where transcription is initiated (the Transcription Start 
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Site (TSS)), and on the same strand as the gene generally indicates a promoter region 
(Heintzman et al. 2007).  
Transcription factors (TFs) are DNA-binding proteins that regulate transcription 
of genetic information from DNA to RNA. TFs have activating or repressing activity via 
many potential mechanisms: they may complex with other TFs (Maston, Evans, and 
Green 2006), coactivator proteins, RNA polymerase II, chromatin remodeling complexes, 
and/or noncoding RNA molecules (Phillips 2008). DNA-binding TFs bind short (6-15 
base pair) fragments of genomic DNA; a particular location is called a motif site or TF 
binding site. These sites demonstrate high evolutionary conservation (Chen & Rajewsky, 
2007). Motif sites show distinct cleavage patterns (called footprints) after digestion by 
DNase I. While DNase-seq provides footprint data reflecting the presence of any DNA-
binding proteins, additional evidence of a particular TF-DNA bound complex can be 
experimentally determined through chromatin immunoprecipitation (ChIP) with 
massively parallel DNA sequencing (ChIP-seq) (Johnson, Mortazavi, Myers, & Wold, 
2007). Thousands of ChIP-seq datasets are available for hundreds of DNA-binding TFs 
(Wang et al., 2012). There are, however, thousands of different DNA-bound TFs in the 
human genome (Wilson et al. 2008), and TF binding depends upon many factors, 
including cell type specificity, phase of development, and/or experimental design. It is 
increasingly clear that many diseases are a product of genetic variations in regulatory 
regions of the genome, frequently in regions impact regulatory TF binding (Lee and 
Young).  
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The role of genetics in understanding disease pathology has become a central 
aspect of medicine, with an explosion of research occurring in the past few years. It is 
increasingly apparent, however, that understanding how changes “above” the genome—
in the epigenome—is central to both advancement of basic science and to the translation 
of these findings to clinical therapy. Around 90% of disease-associated Single Nucleotide 
Polymorphisms (SNPs) have been found to be in intronic or intergenic regions across 
multiple Genome Wide Association (GWAS) studies (Hindorff et al. 2009). These 
genetic variants outside of protein-coding regions indicate that disease pathology may be 
altered by changes in regulatory regions of the genome, in functional regions such as 
enhancers and promoters (Hrdlickova et al. 2014). Better understanding of the 
epigenome, including building an encyclopedia of all functional elements that details how 
and why these elements work, is central to this advancement. 
Deciphering this complex orchestra of histone modifications, chromatin 
remodelers, transcription factors, etc. is central to better understanding the epigenome. 
Since 2003, the Encyclopedia of DNA Elements (ENCODE) project has collecting and 
analyzing data in a large-scale to characterize all the functional elements of the human 
genome. Thus far, ENCODE has successfully collected thousands of chromatin 
accessibility, transcription factor, and histone modification experiments, finding hundreds 
of millions of regions of putative regulatory function across hundreds of different 
biosamples. ENCODE has also been highly influential in developing and publishing 
standards guidelines for DNA-seq, ChIP-seq, and RNA-seq experiments, as well as 
cloud-scale, open-source pipelines for processing these experiments. ENCODE has also 
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collected hundreds of gene expression experiments, as well as developing (through 
GENCODE) a curated set of gene annotations.  
Making an actual Encyclopedia of functional genomic elements, though, has 
proven difficult. The diversity of chromatin accessible regions, histone modification 
patterns, and TF binding sites across all the different cell and tissue types of the human 
body has made clear there is a combinatorial number of activation signatures in the 
genome, as well as millions of potential functional elements. In this thesis, we develop 
systematic methods of selecting cell-type specific candidate Regulatory Elements (cREs), 
and demonstrate the biological usefulness of these regions. We have also assigned stable 
IDs (called accessions) to these regions, with the intent to construct a stable, curated 
annotation of functional genomic elements, just as Ensembl does for genes (Birney et al. 
2004; Aken et al. 2016). 
As the visual analytics field has shown, just being able to display raw data is not 
useful: the extracted analysis products are where the real value is (Keim 2010). Just 
making an Encyclopedia of cREs is insufficient unless there are ways to visualize and 
understand the genomic and epigenetic context the putative functional elements exist in. 
The great importance of being able to visualize highly-multidimensional omic data is 
clear; there are a multitude of examples available, with even entire frameworks being 
developed for pathways and gene expression visualization (Streit et al. 2009). Some of 
the most exciting developments include a Google-maps view of 3D chromatin structure 
analysis products (Perkel 2017). In this thesis, we develop two visualizers—SCREEN 
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and Factorbook—to assist users in searching and viewing the millions of elements and 
data points available from the ENCODE data. 
While we have successfully utilized the thousands of available ENCODE ChIP-
seq experiments to build the Encyclopedia and visualizers, we have also struggled with 
one of the core limitations of ChIP-seq TF experiments. The binding of a transcription 
factor at a particular motif site in the genome depends upon a diverse number of factors. 
While experimental methods seq have begun to shed light on these binding patterns, fully 
understanding regulation via transcription factor binding, though, will require an 
enormous number of ChIP-seq experiments. Given the wide variety of conditions 
affecting binding, millions of different experiments are required to comprehensively 
understand when and where transcription factors bind (Lee and Young). Accurately 
predicting transcription factor binding sites through statistical and machine learning 
methods could drastically reduce the number of experiments needed. Further, improved 
understanding of transcription factor binding would shed light on gene regulatory 
networks present during embryogenesis, development, and disease states. 
Several different labs have developed predictive models for motif site binding 
over the last decade. Previous predictive models (such as CENTIPEDE and PIQ) 
demonstrate the initial feasibility of probabilistically predicting the bound state of a motif 
site in the genome. For experimental input data, these models primarily utilize DNase-seq 
data for elucidation of chromatin state and, ultimately, motif site binding probability. In 
this thesis, we develop several predictive models based upon supervised learning 
methods. These models leverage ChIP-seq data already acquired by ENCODE 
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participants, as well as other ENCODE and Roadmap Epigenomics datasets. We also 
develop a large number of features for model training, using supervised approaches, and 
have achieved some success in predicting TF binding sites. We have also utilized some of 
these techniques while competing in the ENCODE-DREAM in vivo Transcription Factor 
Binding Site Prediction Challenge.  
This thesis describes efforts toward better understanding and visualizing the 
epigenome. Chapter II will introduce our current version of the ENCODE Encyclopedia. 
In it, we demonstrate how we locate regions of the genome with open chromatin and 
enhancer-like or promoter like signatures based on histone modification marks and other 
genomic distance information. These regions—candidate Regulatory Regions (cREs)—
are our first approximation of a systematic, accessioned, genomic-wide catalog detailing 
regions that are involved with functional control of the genome. Chapter II will introduce 
the latest version of an aggregated, peak-centric visualizer for transcription factor binding 
sites (TFBS). Chapter IV discusses our work on imputing entire epigenetic experiments, 
first focusing on predicting locations of TFBS. Lastly, Chapter V introduces SnoPlowPy, 
our tool driving metadata and job management functionality for large-scale analysis 
projects. 
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II. Chapter II: Building and Visualizing an Encyclopedia of 
ENCODE candidate Regulatory Elements 
II.1 Preface 
This research chapter encompasses work performed by Jill Moore, myself, Henry Pratt, 
Zhiping Weng, and >500 other collaborators in the ENCODE Consortium. The chapter 
combines one manuscript currently in review (as of December 2017) with another 
manuscript on SCREEN (with Henry Pratt) that is currently in draft.  
With more than 14,000 experimental datasets, consuming more than 0.5 petabytes 
of storage space across hundreds of thousands of files, the ENCODE project has built a 
vast catalog of gene expression, chromatin accessibility, histone medication, and 
transcription factor binding data. While investigating these data, I found the data difficult 
to utilize to answer fundamental biological questions, such as where putative enhancers 
and promoters are located, or how gene expression levels vary across disease conditions 
or developmental time points. These questions were impossible to answer without 
manually curating, downloading, and processing the data. Just determining which files to 
use for such analyses was also non-intuitive and essentially undocumented, and the wide-
variety of data processing techniques added many subtle problems when integrating data 
across labs, let alone different experiments. I decided to ameliorate these problems and 
allow straightforward analysis of the data and generation of actionable biological insights 
and hypotheses.  
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While individual tools to interrogate particular regions of the genome have 
existed for more than two decades (Kent et al. 2002), and epigenetic annotations have 
been available for years (Frankish et al. 2015), no tool has integrated as much genetic and 
epigenetic data in one location as SCREEN. SCREEN solves many of the problems (both 
biological and practical) described above. Inside of SCREEN, I have integrated and 
condensed thousands of ENCODE experiments into an easy-to-use product that allows 
researchers to intuitively explore the available data. I am the overall architect of 
SCREEN, having designed and implemented the database system, data import pipeline, 
and much of the software architecture. SCREEN excels at allowing the user to develop 
hypotheses for potential functional regulation across millions of region in the human and 
mouse genomes.  
SCREEN offers new solutions to help navigate the vast sea of data. I am also one 
of the first to build an online database of hundreds of millions of DNase and ChIP-seq 
peaks that could then be intersected with candidate regulatory regions at the click of a 
button. The accessioning system for peaks I implemented is the start of a critical new 
stage of epigenetics, where individual regions can be tracked not just through 
publications, but across hundreds to thousands of experiments. Current projects like 
ENCODEproject.org are designed to ascension a few hundred thousand objects; the 
systems are not capable of supporting millions of objects. Comparing how these regions 
change across developmental or disease states becomes not just far more straightforward, 
but, in fact, doable in seconds, not hours or days it would take before. This approach of 
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systematically cataloging regions of the genome will become as integral to the field as 
plant taxonomy became for the field of botany. 
II.2 Summary 
Many human genomes have been sequenced, yet we still lack comprehensive maps of 
genomic functional elements and do not fully understand how they specify cell and tissue 
types. Such information is critical to assess how genomic variants affect development, 
ageing, and susceptibility to diseases. The goal of the Encyclopedia of DNA Elements 
(ENCODE) project is to discover and characterize the full repertoire of elements 
(www.encodeproject.org). Here, we summarize the data generated in Phase III of the 
project and introduce the ENCODE Encyclopedia, an evolving collection of annotations 
derived from assay-specific and integrative analyses. At the heart of the Encyclopedia is a 
new Registry of candidate Regulatory Elements (cREs), defined by a biochemical 
signature that uses chromatin accessibility, histone modification and transcription factor 
occupancy data. The Registry currently contains 1.31 M human and 0.43 M mouse cREs, 
covering hundreds of biosample types. The cRE landscape recapitulates the current 
understanding of cellular identity, tissue composition, developmental progression, and 
disease-associated genetic variants. Aided by a dedicated visualization engine called 
SCREEN (screen.encodeproject.org), the Registry is a resource for exploring noncoding 
DNA elements and their variants. 
II.3 Introduction 
The genome contains the blueprint for organismal development and function. 
Deciphering genomes, particularly the vast noncoding regions, is an ongoing challenge 
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that motivates many individual research labs and organized consortium efforts. Among 
these efforts is the Encyclopedia of DNA Elements (ENCODE) Project, launched by the 
National Human Genome Research Institute (NHGRI) in 2003. The overarching goal of 
ENCODE is to provide an integrated resource to aid the scientific community in studying 
mammalian biology and human diseases. 
In pursuit of this goal, ENCODE develops and applies high-throughput 
experimental technologies and computational approaches to catalogue candidate 
functional elements in the human and mouse genomes, including transcripts and their 
regulatory elements. The pilot phase of ENCODE focused on 44 carefully selected 
regions covering 1% of the human genome using array-based techniques (Birney et al. 
2007). Phase II used deep-sequencing-based biochemical assays to interrogate the entire 
human genome, producing 1,640 datasets, and integrative analyses of these datasets 
identified an extensive set of candidate functional elements (Consortium 2012). The 
related Mouse ENCODE (Yue et al. 2014) and modENCODE projects (Gerstein et al. 
2010; Roy et al. 2010) performed thousands of genome-wide experiments on the mouse, 
fly, and worm. Complementary projects, including the NIH Epigenomics Project 
(Kundaje et al. 2015) and the International Human Epigenome Consortium have also 
produced thousands of epigenomic maps for human cells and tissues (Stunnenberg, 
International Human Epigenome, and Hirst).  
Despite this progress, the human and mouse genomes remain only partially 
annotated, limited by the depth of biochemical element types mapped for any one cell 
type and the breadth of cell types mapped for any single biochemical feature. 
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Accordingly, our understanding of the diversity of transcripts and their regulatory 
elements in each cellular context is far from complete. To begin to address these 
limitations, ENCODE Phase III expanded data collection in both depth and breadth—
studying additional chromatin features, regulatory factors and RNA types with an 
emphasis on primary cells and tissue samples.  
All data are submitted to the ENCODE Data Coordination Center, reviewed for 
quality and released to the scientific community via the freely accessible ENCODE web 
portal (www.encodeproject.org). ENCODE members have reported new findings 
throughout the past five years based on data generated and released during Phase III. 
Additionally, we have now assembled the ENCODE Encyclopedia of predicted and 
confirmed functional elements, based on all ENCODE data collected during Phases II 
and III, supplemented by data from the NIH Epigenomics Project. This chapter describes 
the ENCODE Encyclopedia and presents illustrative examples of its use. 
A new focus in ENCODE Phase III has been to build a Registry of candidate 
Regulatory Elements (abbreviated as cREs). This effort is guided by the current 
understanding that robust biochemical signatures, including chromatin accessibility and 
particular histone modifications, are preferentially associated with major classes of 
noncoding regulatory DNA elements—transcriptional promoters, enhancers, insulators, 
and silencers. While the biochemical signatures are neither causal nor perfect predictors 
of element activity, they enable the selection of an enriched set of cREs that are 
assembled here, together with other genome annotations and their underlying 
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experimental data, for exploration by users via a specifically designed visualization tool 
called SCREEN (screen.encodeproject.org). 
II.4 Results 
II.4.1 Summary of Encode Phase 3 Data Production 
The ENCODE Consortium has produced data on three main aspects of genome activity—
transcriptomes, DNA-based regulatory elements for transcription and replication, and 
RNA-based elements for post-transcriptional regulation. Phase III greatly expanded the 
number of experiments in each category and released 4,903 experiments (3,797 on human 
and 1,106 on mouse; see Figure II-1 on page 87). Table II-1 on page 78 summarizes these 
experiments by category. We define an experiment as the application of a genomic assay 
(such as ChIP-seq, RNA-seq, DNase-seq, or ATAC-seq) to a particular biosample type 
(such as a tissue, a cell line, primary cells, or stem cells). In this section, we summarize 
the new assays and highlight the results of Phase III data production. 
New polyA and short RNA transcriptome data production has focused on primary 
cells from different body locations and various embryological origins. Single-cell long-
RNA-seq was further developed for laser-capture microdissection of human and mouse 
brain tissues. To better define full-length transcripts, we analyzed captured RNAs using 
long-read sequencing. This effort, in collaboration with the GENCODE project, 
improved the annotations of gene and transcript structures for 14,667 human and 8,708 
mouse long noncoding RNAs (Lagarde et al., in review). 
A new 5´-complete cDNA sequencing assay called RAMPAGE quantifies gene 
expression, identifies promoter locations, and assigns 5´ capped termini to their 
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corresponding RNA isoforms (Batut et al. 2013). RAMPAGE yields data at single-
nucleotide resolution and is more accurate than RNA-seq for quantifying expression 
(Batut et al. 2013)—advances which enable it to improve transcription start site (TSS) 
annotation and transcript quantification. For example, the gene ARHGAP23, which 
encodes Rho GTPase-activating protein 23, has 12 GENCODE-annotated transcripts and 
11 different TSSs. RAMPAGE data revealed a novel TSS in the testis (Figure II-2a on 
page 88), located 9.2 kb upstream of the nearest annotated TSS, and another novel TSS in 
exon 7 specific to the spleen (Figure II-2b on page 88). As another example, two different 
TSSs, 824 bp apart, are annotated by GENCODE V26 and UCSC for EP300, which 
encodes a widely studied histone acetyltransferase important for enhancer activity. 
RAMPAGE data across six cell and tissue types showed that although both TSSs are 
active, one TSS is used far more frequently than the other (Figure II-3 on page 89). 
The coverage of noncoding, biochemically marked DNA elements, many of 
which have potential regulatory functions, has been greatly expanded during ENCODE 
Phase III. We completed 163 new DNase accessibility maps, including deep sequencing 
DNase-seq datasets on hundreds of cell and tissue samples, thus facilitating the prediction 
of regulatory protein occupancy by footprinting (Hesselberth et al. 2009). The ATAC-seq 
assay (Buenrostro et al. 2013), which assesses chromatin accessibility via insertion by the 
Tn5 transposome, was conducted on tens of human and mouse tissues and primary cells. 
We expanded the application of ChIP-seq to map the locations of modified histones, 
histone variants, and 33 chromatin regulators and modifiers in a carefully selected 
collection of five human cell lines—K562, H1, GM12878, HepG2, and A549. Over 600 
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ChIP-seq experiments were completed in Phase III for 493 different transcription factors 
(TFs) in at least one cell type (1,622 experiments on 549 different TFs in Phases II and III 
combined). For these ChIP-seq experiments, we used either TF-specific antibodies or 
epitope-tagged TFs created by BAC transfections or CRISPR/Cas9 genome editing. 
ChIA-PET of Rad21 and CTCF, which are involved in the nuclear organization, along 
with Hi-C experiments, provide 3D linkage data that include many regulatory regions and 
cognate target genes. Through the ENCODE Portal (encodeproject.org/antibodies/), we 
provide quality metrics for all datasets as well as detailed information about the 
antibodies used in our experiments to help users evaluate and use the data most 
effectively. 
DNA replication timing provides insights into gene regulation and spatiotemporal 
genome compartmentalization (Gilbert 2002). We measured replication timing during 
fate commitment of human embryonic stem cells, thus yielding 84 datasets for 26 cell 
types representing the embryonic layers endoderm, mesoderm, ectoderm, and neural crest 
(Rivera-Mulia et al. 2015) (see Figure II-4 on page 90). Because replication timing 
differs across cell types, we expected that clustering of these datasets would recapitulate 
their developmental lineages, and that was indeed observed (see Figure II-5 on page 91). 
The mouse component of ENCODE Phase III focused on embryo development at 
daily intervals between embryonic day 10.5 (e10.5) and postnatal day 0 (p0), with 6-12 
tissues sampled per day. RNA-seq of polyA RNAs and miRNAs, ChIP-seq for eight 
histone modifications, ATAC-seq, and whole-genome bisulfite sequencing were 
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performed on all the samples of the mouse embryonic developmental series, augmented 
by DNase-seq and ChIP-seq of three TFs in selected samples. 
A new project in ENCODE Phase III was to identify and characterize functional 
RNA elements bound by RNA-binding proteins (RBPs) (van Nostrand et al., in 
preparation). Four types of related data were generated: RIP-seq and enhanced UV 
crosslinking and immunoprecipitation of RBPs followed by sequencing (eCLIP-seq) 
(Van Nostrand et al. 2016) to identify bound RNAs in vivo and pinpoint the portions of 
these RNAs involved in binding interactions; RNA-seq on cells depleted of specific 
RBPs by shRNA or CRISPR; RNA Bind-N-Seq (RBNS)(Lambert et al. 2014) to 
determine the relative binding affinity of RBPs in vitro for all possible RNA sequences; 
and subcellular localization of RBPs by immunostaining.  
The breadth of our RBP data enables integrative analyses to relate genetic 
variation to RBP regulation. For the 18 RBPs with eCLIP, RBNS and, RBP-knockdown 
RNA-seq data, we identified 26 variants from the Exome Aggregation Consortium 
(ExAC)(Lek et al. 2016) that overlapped an eCLIP peak, disrupted an RBNS motif, and 
produced a splicing change upon knockdown of the corresponding RBP (van Nostrand et 
al., in preparation). For example, intron 66 of UTRN (dystrophin-related protein 1) 
harbors an RBFOX2 eCLIP peak downstream of an alternatively spliced exon (Figure 
II-6c on page 92), which overlaps an ExAC variant (Lek et al. 2016). This G→C variant 
disrupts the RBFOX2 binding motif (GCAUG) at the first position. RBNS data reveal 
that this variant substantially changes the RBFOX2 binding site—the top 5-mer has an 
enrichment value of 13.58 for the major G allele but 0.89 for the C variant (Figure II-6d 
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on page 92), thus suggesting that the mutation disrupts RBFOX2 binding in vivo. To 
determine whether the disruption of RBFOX2 binding would alter splicing, we performed 
RNA-seq on HepG2 cells after knocking down RBFOX2. In wild-type cells, the upstream 
exon was included in 87% of messages, whereas the inclusion was decreased to 28% in 
the RBFOX2 knockdown cells (Figure II-6c on page 92). Taken together, these data 
argue that this G→C variant disrupts RBFOX2 binding, leading to decreased inclusion of 
the upstream exon in over half of UTRN messages, and resulting in an altered 
composition of protein isoforms. Overall, the actual number of variants that influence 
RNA metabolism is larger than the 26 ExAC variants identified in this way, because they 
may affect aspects of RNA biology other than splicing. 
II.4.2 The Encode Portal and Uniformly Processed Data 
The ENCODE portal (www.encodeproject.org) is the primary interface for retrieving all 
ENCODE data, metadata, data standards, and experimental protocols (Sloan et al. 2016). 
It also provides entry to the ground and integrative levels of the ENCODE Encyclopedia 
(Figure II-7 on page 93), which is described in the next section. The Portal is designed to 
provide users with extensive metadata that describe how ENCODE experiments were 
performed, processed, and connected in common biological themes (Hong et al. 2016). 
All experiments followed data production guidelines 
(www.encodeproject.org/about/experiment-guidelines/#guideline). An experiment 
typically comprises two biological replicates, with some exceptions; in the case of single-
cell assays or assays utilizing human donor tissues of limited availability, for example, no 
cell is a conventional replicate of another. A released experiment includes the “raw” 
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sequencing data (typically FASTQ files) and all analysis output files (such as alignment 
files, signal files, or peak files) from the uniform processing pipelines. These pipelines 
are central to ENCODE data, and the major pipelines are available for users to apply to 
their own data, either by downloading the code and running it locally or by accessing the 
pipelines at the DNAnexus cloud provider. 
The Portal was completely redesigned during Phase III for better data access and 
metadata clarity. The homepage presents summaries of the numbers and types of 
experiments, with intuitive links for data access. Experiments are annotated by key 
features (called facets) so that users can easily find experiments via a faceted search. A 
matrix view displays the search results (encodeproject.org/matrix/?type=Experiment; see 
Figure II-1 on page 87), which can be switched to list or table views. Entries in the matrix 
are hyperlinked to underlying datasets, along with metadata and quality metrics.  
II.4.3 The Encode Encyclopedia 
The raw data described above and their signal maps across the human and mouse 
genomes are valuable for interrogating genome function in myriad ways, from browsing 
individual loci to large-scale data integration. To aid users in data mining and hypothesis 
building, we have derived summaries of key aspects of the raw data and organized them 
into the ENCODE Encyclopedia. The Encyclopedia presently has two levels of 
annotations (Figure II-7 on page 93). The ground level includes peaks and quantifications 
produced by the uniform data-processing pipelines for individual data types, and the 
integrative level contains annotations derived from combined analyses across multiple 
data types and ground-level annotations. 
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II.4.4 Encyclopedia Ground Level 
The ground level currently has nine components (Figure II-7 on page 93). The chromatin 
accessibility component contains DNase hypersensitive sites (DHSs)—genomic regions 
significantly enriched in DNase-seq reads—and their constituent DNase peaks, as well as 
ATAC-seq peaks. Locations of histone marks and histone variants are provided in the 
histone modification component as histone peaks, which are regions of the genome 
significantly enriched in histone ChIP-seq reads. The transcription factor binding 
component provides TF peaks, or genomic regions significantly enriched in TF ChIP-seq 
reads; these peaks are further characterized by enriched sequence motifs (identified using 
the MEME-ChIP tool (Machanick and Bailey 2011)) and the average histone mark ChIP 
signals and nucleosome occupancy signal surrounding them in each cell type. The TF 
peaks and associated information can be viewed in the wiki-style web resource 
Factorbook (see page 136). The gene and TSS expression components give quantitative 
estimates of the abundance of the various types of RNA molecules in each of the assayed 
cell types based on ENCODE RNA-seq and RAMPAGE data. These estimates are 
provided at the gene and TSS levels for GENCODE-annotated genes, plus activity levels 
for novel TSSs identified by RAMPAGE. Gene or TSS expression profiles across cell 
types can be visualized using the SCREEN tool described below (see Figure II-8 on page 
94).  
The RNA binding protein (RBP) component provides RBP peaks, which are 
regions of the transcriptome enriched for binding by an RBP, as determined by the 
CLIPper pipeline for eCLIP-seq data. The eCLIP protocol and CLIPper pipeline take into 
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account variations in transcript abundance and processing(Van Nostrand et al. 2016). The 
DNA methylation component analyzes whole-genome bisulfite sequencing data and 
provides the methylation state for each cytosine in the genome. The 3D chromatin 
interaction component provides interaction frequency estimates between genomic loci, 
such as between promoters and distal enhancers, as computed from ChIA-PET data. 
Finally, the component for chromatin domains and compartments provides topologically 
associated domains (TADs) and A/B compartments called using Hi-C data. 
New data are processed and added to the ground level of the Encyclopedia as 
soon as they are available. Thus the ground level is continually updated ("live"), and 
these updates do not constitute new versions. More components will be added as 
additional analysis pipelines are developed and existing pipelines are improved. 
Components of the integrative level of the Encyclopedia are versioned as described 
below. 
II.4.5 Encyclopedia Integrative Level 
A longstanding goal of functional genomics is to discover and map the full regulatory 
element repertoire of the genome and then to delineate which elements are active or 
repressed in individual cell types. In pursuit of this goal, ENCODE and Roadmap 
Epigenomics Consortia have now produced basic epigenetic signals broadly in hundreds 
of human and mouse cell types and tissues. ENCODE has also examined a few cell types 
much more extensively for diverse transcription factor occupancy, genome-wide DNA 
methylation, RNA-binding protein occupancy and other “deep” assays. These differences 
in assay breadth versus depth have motivated two complementary computational 
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approaches to build catalogues of candidate transcriptional regulatory elements, and our 
Encyclopedia offers both.  
The first approach started in ENCODE II. It uses machine learning methods such 
as ChromHMM(Ernst and Kellis 2010; Ernst and Kellis 2012) and Segway (Hoffman et 
al. 2012) to integrate many different types of epigenetic signals. ChromHMM and 
Segway are unsupervised probabilistic models that integrate a specified number of 
epigenetic signals to define a large repertoire of chromatin states, many of which 
correlate with known functional element types and activity levels, e.g., active promoters, 
enhancers, or heterochromatin domains. ChromHMM have been augmented to 
accommodate cell types with some missing assays and then applied to the contemporary 
Roadmap (Ernst and Kellis 2015a) and ENCODE III cell types and tissues that achieved 
sufficient assay coverage. A strategy was developed in ENCODE III to train separate 
Segway models on each cell type—allowing for different assay coverages in different cell 
types—and then automatically interpret these results across all cell types using a Random 
Forests classifier. The chromatin states of 164 human cell types have been annotated 
using this strategy by integrating 1,615 genomics datasets (Libbrecht et al. 2016). We 
similarly applied ChromHMM to the mouse embryo development series—66 complete 
epigenomes each assayed by ChIP-seq of eight histone marks— and defined 15 
chromatin states that showed coordinated changes with gene expression measured by 
RNA-seq for each of the 66 samples (Gorkin et al., in preparation, Tsuji et al., in 
preparation). The resulting chromatin state maps from this section are all included in the 
integrative level of the Encyclopedia.  
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The second approach is motivated by the substantially increased number of 
experiments on primary cells and tissues during ENCODE Phase III. The limited 
quantities of primary cells and tissues have led to incomplete assay coverage for many of 
these samples. Thus we have developed an approach that uses a highly parsimonious 
combination of just four types of assays to maximize the coverage of cell and tissue 
types, though at the expense of subtler inferences about each element’s possible activity. 
The rest of the chapter focuses on the second approach that has led to the new Registry of 
candidate Regulatory Elements. 
II.4.6 The Registry of candidate Regulatory Elements 
Given the breadth of biosamples in the union of ENCODE and Roadmap data, we aspired 
to build an initial Registry covering a majority of cREs in the genome. The most direct 
approach to identifying cREs would be to include all relevant epigenetic signals in a 
comprehensive statistical model and then train the model with experimentally validated 
regulatory elements. Indeed, such methods have been developed (Rajagopal et al. 2013; 
Erwin et al. 2014). However, at this time, relatively few enhancers and insulators have 
been systematically tested across many cell environments with functional assays: without 
such a “gold standard,” it is not possible to train a general statistical model that remains 
predictive in new cell types.  
Therefore, we pursued a different approach that is based on just four epigenetic 
signals that we found to be most predictive of regulatory elements: chromatin 
accessibility (measured by DNase-seq), the histone modifications H3K4me3 and 
H3K27ac, and CTCF binding. This selection was initially motivated by substantial prior 
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work in the field. DNase hypersensitive sites delineate all the main classes of cis-
regulatory elements in a cell-type-specific manner, including promoters, enhancers, 
insulators, and locus control regions (Thurman et al. 2012). H3K4me3 and H3K27ac are 
the two histone marks most enriched at promoters and enhancers respectively (Heintzman 
et al. 2007; Visel et al. 2009). CTCF is the established insulator binding protein in 
mammals (Kim et al. 2007) and its binding sites are enriched at interacting chromatin loci 
(Rao et al. 2014).  
To further test our selection, we compared the effectiveness of ten different types 
of epigenetic signals in predicting enhancers in the corresponding tissue: DNase 
hypersensitivity, eight histone marks (H3K4me1, H3K4me2, H3K4me3, H3K27ac, 
H3K9ac, H3K9me3, H3K36me3, and H3K27me3), and DNA methylation. These 
epigenetic signals were all assayed with specific mouse e11.5 tissues during ENCODE 
III, and the tissue-specific e11.5 enhancers tested using in vivo transgenic assays were 
from obtained the VISTA database (Visel et al. 2007). We found that DNase and 
H3K27ac were the best single features for predicting tissue-specific enhancers. We then 
used RNA-seq to evaluate the effectiveness of these same epigenetic signals in predicting 
gene expression levels and found H3K4me3 to the best single feature. We found that 
DNase offers high spatial precision in defining cREs: DHSs are ~350 bp long and 
typically correspond to the core of regulatory elements. In contrast, the H3K27ac and 
H3K4me3 signals are more diffuse: they tend to be low at the center of a regulatory 
element—presumably because of the lack of a nucleosome there—but are elevated at 
flanking nucleosome positions. DNase, therefore, presents the best localization of a cRE, 
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while H3K27ac and H3K4me3 suggest the recent activity state, and the coincidence of 
significant signals from at least two assay types increases the overall confidence in the 
cRE.  
To experimentally test the enhancer branch of our predictor, we used the average 
rank of the DNase and H3K27ac signals to identify previously untested TSS-distal (> 2 
kb from the nearest TSS) candidate enhancers in the mouse e11.5 hindbrain, midbrain, 
and limb. The boundaries for the predicted regions were defined using the H3K27ac 
ChIP-seq peaks called by the MACS2 algorithm (Zhang et al. 2008) (see Figure II-9 on 
page 95). For each tissue, we tested 20, 15 and 15 new regions around the ranks 1-20, 
1500-1520, and 3000-3020, respectively. In total, we tested 151 regions (for results, see 
online Supplementary Table 4). Representative e11.5 transgenic embryos for the 
enhancers that validated in the expected tissues are shown in Figure II-10 on page 96. 
Consistently, higher ranking regions were more likely than lower ranking regions to show 
enhancer activity in their predicted tissue (Figure II-11 on page 97; e.g., 75%, 26.6%, and 
20% for the hindbrain). When enhancers were active in multiple tissues, these tissues also 
had high H3K27ac signals across the predicted enhancer regions (Figure II-12c-e on page 
98). For example, a predicted enhancer in the hindbrain was also active in the midbrain 
and neural tube; accordingly, high H3K27ac signals were observed in all three tissues 
(Figure II-12d on page 98). In contrast, an enhancer active almost exclusively in the limb 
(Figure II-12e on page 98) did not show high H3K27ac signals in other tissues assayed. 
These results suggest that combining DNase and H3K27ac can identify active enhancers 
in a particular tissue and quantify their tissue selectivity patterns. 
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In aggregate, our evaluations showed that combining DNase with two histone 
marks, H3K4me3 and H3K27ac, is an effective way to build a first version of the 
Registry of candidate promoters and enhancers active in specific cell types. We extended 
this predictor by adding CTCF, a highly conserved architectural protein that binds to 
insulators and contributes to the establishment and maintenance of three-dimensional 
chromatin structure (Ong and Corces 2014). Our final algorithm anchors cREs on a 
representative set of all DHSs, and then evaluates cRE types and activities based on 
H3K4me3, H3K27ac, and CTCF signals. To maximize coverage, we applied the 
algorithm to all cell types interrogated by at least one of these assays, making it possible 
to include data from 301 human cell types (620 when primary cells or tissues from 
different donors are counted separately) and 58 mouse cell types (138 with 
developmental time-points counted separately) with all ENCODE and Roadmap data 
considered. It is thus important to note that we distinguish two classes of cREs displaying 
no activity in a given cell type: cREs for which necessary assays are missing in the cell 
type, and cREs for which the necessary assays are present but the associated signals did 
not score as significantly positive. 
The first release of the Registry presented here includes 1.31 million human cREs 
and 0.43 million mouse cREs; future versions will be released periodically, and are 
already under development. Based on the levels of the four core epigenetic signals and 
the distance to the nearest annotated TSS, we also classify cREs as those that have 
promoter-like signatures (PLS) or enhancer-like signatures (ELS) or as those that lack 
these signatures but are bound by the insulator-binding protein CTCF. 
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II.4.7 Selection of cREs for the Registry 
We define cREs as DHSs supported by at least one additional type of epigenetic signal 
among H3K4me3, H3K27ac, and CTCF in at least one cell type. We first condensed all 
DHSs from individual samples into a set of non-overlapping representative DHSs 
(rDHSs) as described in Methods. We then filtered out the rDHSs with Z-scores less than 
1.64—a threshold corresponding to the 95th percentile of a one-tailed test. 
Approximately 1.6 M human and 0.63 M mouse rDHSs remained. The rDHSs that have 
high H3K4me3, H3K27ac, or CTCF signals (a high signal is defined as a Z-score > 1.64 
throughout) in at least one cell type are designated cREs. In total, there are 1,310,152 
human cREs (Figure II-13 on page 99) and 431,202 mouse cREs. Among them, 724,590 
human cREs and 228,027 mouse cREs have high DNase and high H3K4me3, H3K27ac, 
or CTCF in the same cell type, and these cREs are recognized for having "concordant" 
support, labelled with an asterisk by their accessions in SCREEN. The remaining 585,562 
human and 203,175 mouse "non-concordant" cRE result from high DNase signal in one 
cell type and high H3K4me3, H3K27ac, or CTCF signals in a different cell type. As more 
data become available, we anticipate that many of the non-concordant cREs will move 
into the concordant class, and will be updated to reflect that. 
cREs are further designated as TSS proximal if they lie within ±2 kb of a 
GENCODE-annotated TSS. There are 242,739 TSS-proximal cREs in human and 92,405 
in mouse. The cREs that overlap a TSS are called TSS-containing cREs; there are 46,749 
and 24,549 TSS-containing cREs in human and mouse respectively. TSS-overlapping 
cREs are significantly longer than the rest of the TSS-proximal cREs and TSS-distal 
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cREs (median length = 548, 317, 342 for human and 589, 320, 339 for mouse; Wilcoxon 
test p-values < 2.2E-16 for all tests).  
II.4.8 Comprehensiveness of the current Registry of cREs 
In defining the Registry of cREs based on rDHSs, our working hypothesis is that a 
collection of rDHSs derived from hundreds of DNase-seq experiments will represent a 
large fraction of all cREs in the genome and that a new cell type is likely to use as its cRE 
repertoire a subset of the cREs already in the Registry. To test this hypothesis, we set out 
to analyse how comprehensive the Registry is in three ways. 
First, we examined how many of the GENCODE-annotated TSSs (V19 for human 
and M4 for mouse) were covered by the current version of the Registry of cREs. To the 
extent that GENCODE is a mature repository of expressed RNAs across all cell types and 
states in the human and mouse life cycle, this test provides an informative estimate for 
the completeness of promoters and promoter-proximal regulatory elements in our 
Registry. For human, 67% (121,692/181,177) of all annotated TSSs and 72% 
(105,196/145,671) of the TSSs of protein-coding genes overlap a cRE in the Registry. 
For mouse, 61% (57,459/93,719) of all annotated TSSs and 66% (52,066/78,782) of the 
TSSs of protein-coding genes overlap a cRE in the Registry.  
Second, we analyzed how rapidly the total number of unique rDHSs saturated as 
more and more cell types were added. In ENCODE Phase II, we modelled DHS 
saturation using a Weibull distribution and estimated that we had discovered around half 
of the total DHSs. We performed this analysis again using all human DNase-seq data 
generated by ENCODE and Roadmap projects. The saturation curves of rDHSs continue 
29 
 
 
 
to follow Weibull distributions, revealing at the plateau 1.66 M rDHSs with FDR < 0.1% 
and Z-score > 1.64. Because only a subset of such rDHSs can be cREs—those with a 
high H3K4me3, H3K27ac, or CTCF Z-score in at least one cell type—we have identified 
at least 78.9% cREs in human. We performed the same saturation analysis for mouse but 
could not reach a reliable estimate due to the smaller number of input tissue types.  
Third, we computed the Registry's coverage of H3K27ac, H3K4me3, and CTCF 
peaks (FDR<0.01) in those cell types with the corresponding ChIP-seq data but without 
DNase-seq data. The Registry covered 90 ± 8% of H3K4me3 peaks (74 cell types), 87 ± 
5% of H3K27ac peaks (54 cell types), and 99 ± 1% of CTCF peaks (31 cell types). The 
coverage was equally high for mouse, despite a smaller number of DNase-seq 
experiments for building the mouse Registry: 88 ± 5% of H3K27ac peaks (69 tissue–
time-points) and 96 ± 8% of H3K4me3 peaks (74 tissue–time-points) were accounted for. 
(There were no cell types with CTCF but without DNase data for mouse.) The coverages 
for H3K4me3 peaks were low for several human and mouse cell types. The average -
log(FDR) of the H3K4me3 peaks in these datasets were low. We visually inspected the 
two datasets with the lowest coverage (CD-1 megakaryocyte and GR1-ER4 in mouse) 
and confirmed that the peaks that were not covered by the Registry had low signals and 
were likely false positives by the peak calling algorithm. 
In conclusion, the human Registry appears to be comprehensive: by the above 
criteria, it covers two-thirds of all cREs and 85% of elements marked by H3K4me3 or 
H3K27ac or bound by CTCF in any cell type. A cautionary note is that we do not yet 
know the extent of coverage on highly cell-type-specific cREs active in rare cell types 
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(numerically minor in their tissues of origin) that have not yet been sensitively assayed. 
The mouse Registry is less comprehensive than the human Registry, but we expect that it 
will continue to grow with experiments performed on additional cell types.  
II.4.9 Classifying cREs in the Registry 
Gene catalogues such as GENCODE define gene models irrespective of their varying 
expression levels and alternative transcripts across different cell types. By analogy, we 
provide a general, "cell type agnostic" classification of cREs based on the maximal Z-
score of each feature across all cell types with ENCODE and Roadmap data, abbreviated 
henceforth as max-Z. The goal is to provide a useful overview of the entire cRE 
landscape by integrating all input cell types for the four epigenetic features. We then 
classify cREs according to these four features at two levels of detail—the state 
classification and group classification—described below in turn. 
As described above, all cREs must have a high DNase max-Z and furthermore 
must have a high max-Z for least one of three epigenetic signals—H3K4me3, H3K27ac, 
or CTCF. The state classification is simply a delineation of all possible combinations of 
high (max-Z ≥ 1.64) or low (max-Z < 1.64) H3K4me3, H3K27ac, and CTCF signals, 
with each combination called a state. This classification captures the fact that while some 
cREs are marked by just one high signal (41% of human and 59% of mouse cRE), many 
cREs have two or three high signals (Figure II-14 on page 100). Because the all-low state 
is not allowed, a cRE can adopt one of seven states. Furthermore, each cRE is classified 
as being proximal or distal (within or outside the ±2 kb window) to the nearest 
GENCODE-annotated TSS. The state classification simply indicates which of the seven 
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states a cRE is in and is displayed in SCREEN with a color code alongside the 
information on TSS proximity and whether the cRE is supported by concordant signals 
from the same cell type. 
The group classification is an abbreviated abstraction that assigns each cRE to a 
group according to its biochemically dominant signature. As reported above for 
transgenic mouse enhancer assays, the intensity of biochemical signals is positively but 
modestly predictive of functional enhancer activity. We define broad, mutually exclusive 
groups of elements in the expectation that they will be enriched in the respective 
promoter-like, enhancer-like, or CTCF-mediated functions. We currently use three 
groups assigned in the following order (Figure II-13 on page 99):  
1. cREs with promoter-like signatures (cRE-PLS) must have high H3K4me3 max-
Zs. If they are TSS-distal, they must also have low H3K27ac max-Zs.  
2. cREs with enhancer-like signatures (cRE-ELS) must have high H3K27ac max-
Zs. If they are TSS-proximal, they must also have low H3K4me3 max-Zs.  
3. CTCF-only cREs are the remaining cREs. They do not fall into either of the 
first two groups and thus by definition must have high CTCF max-Zs to qualify as cREs. 
Classifications are assigned in the above order; thus, a cRE possessing high 
histone mark signals and a high CTCF signal will be classified as either PLS or ELS. 
This simplified classification scheme is designed to give users a first-cut idea of the most 
likely function for each cRE, although we are acutely aware that regulatory elements are 
known to play multiple roles. For example, the IFITM3 promoter is bound by CTCF and 
a SNP that interrupts the binding is associated with severe influenza risk in humans 
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(Allen et al. 2017). Massively parallel reporter assays indicate that some promoters also 
have enhancer activities while some enhancers also have promoter activities (Nguyen et 
al. 2016). A tiling-deletion-based CRISPR screen of the 2-Mb POU5F1 locus identified 
45 cis-regulatory elements, among which 17 are promoters of functionally unrelated 
genes (Diao et al. 2017). CapStarr-seq data revealed that 2-3% of the coding-gene 
promoters display enhancer activity in a given mammalian cell line (Diao et al. 2017). 
Thus, the group classification is intended to ease analysis and simplify discussion, and we 
emphasize that many cREs belong to multiple groups. 
As currently formulated, the Registry does not explicitly define negative 
elements, but we aim to include them in the next version of the Registry. We note that 
some of the cREs in the Registry may be repressive in the appropriate cellular contexts. 
Repression can be achieved through diverse mechanisms: binding a sequence-specific 
repressor, replacing the binding of a strongly activating transcription factor by a weakly 
activating one, competing for transcription factors with low abundance, attracting 
repressive epigenetic regulator such as Polycomb group proteins, or establishing DNA 
methylation. Indeed, depending on the cellular context, 25% of Drosophila 
developmental enhancers can also function as Polycomb response elements, silencing 
transcription in a Polycomb-dependent manner (Erceg et al. 2017). Such findings 
underscore the notion that many cREs belong to multiple groups. 
We analyzed the fraction of the genome covered by each group of cREs, 
considering only regions of the genome which are mappable by 36-nt long sequences in 
DNase-seq experiments (~2.65 billion bases for human and 2.29 billion bases for mouse). 
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In total, 20.8% of the mappable genome is covered by cREs (4.2% by cREs-PLS, 15.9% 
by cREs-ELS, and 0.7% by CTCF-only cREs) and 8.8% of the mappable mouse genome 
is covered by cREs. The lower coverage for mouse is due to the smaller number of cell 
types with data available with which to define cREs. 
The state classification scheme extends naturally to a specific cell type, by 
characterizing the biochemical activity of each cRE with the DNase, H3K4me3, 
H3K27ac, and CTCF data in that cell type. All cREs with low DNase Z-scores in a 
particular cell type are bundled into one “inactive” state for that cell type; the remaining 
“active” cREs are divided into eight states according to their H3K4me3, H3K27ac, and 
CTCF Z-scores.  
The group classification scheme also extends naturally to a specific cell type, but 
two additional groups are needed: an inactive group, containing all cREs with low DNase 
Z-scores, and a DNase-only group, containing cREs with high DNase Z-scores but low 
H3K4me3, low H3K27ac, and low CTCF Z-scores within that cell type. 
Using GM12878 lymphoblastoid cells as an example, Figure II-15 on page 101 
summarises the cREs states, with each state further stratified by TSS proximity. The bar 
graph reveals that cREs with high H3K4me3 are mostly TSS-proximal, regardless of 
whether or not they have high H3K27ac or CTCF, while cREs with low H3K4me3 are 
mostly TSS-distal. We used additional ChIP-seq data for three factors in GM12878 to 
evaluate the group classification of cREs in this cell type (Figure II-14 on page 100): 
RNA polymerase II (POL2), which binds most active promoters; EP300, a histone 
acetyltransferase that binds many enhancers; and RAD21, another component of the 
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cohesin complex which includes CTCF. cREs-PLS have the highest median Pol II signal, 
cREs-ELS have the highest median EP300 signal, and CTCF-only cREs have the highest 
median RAD21 signal.  
II.4.10 Relative abundance of cREs-PLS vs. cREs-ELS 
In GM12878, there are 36,022 cREs with promoter-like signatures, 27,739 cREs with 
enhancer-like signatures, 10,913 CTCF-only cREs, 16,085 DNase-only cREs, and 
1,219,393 inactive cREs. The higher abundance of cREs-PLS over cREs-ELS may be 
surprising, given the widely held perception that enhancers outnumber promoters. It is 
important to note that different cell types share many promoters but they share far fewer 
enhancers. Indeed, we identify far more cREs-ELS than cREs-PLS across all available 
cell types (991,173 vs. 254,880, respectively). Also, many of the cREs-PLS could be 
TSS-proximal enhancers. Among the 34K TSS-proximal cREs-PLS, over 14K directly 
overlap a TSS, making them strong candidates to contain promoters active in GM12878. 
The remaining 20K lack a known TSS, and these are likely to be a mixture of active 
promoters and enhancers. Enhancers near basal promoters are common in gene 
architecture, effectively creating a functional continuum (Nguyen et al. 2016) that are 
likely to carry both enhancer and promoter-like marks. Furthermore, the H3K4me3 
histone mark is known to spread around active TSSs, and thus a TSS-proximal regulatory 
region, including an enhancer, can be reproducibly marked by H3K4me3 but still lack 
promoter activity. Users can inspect the contributing signals individually in the state 
classification and also integrate other richer data-types, including RNA-seq and 
RAMPAGE, to refine their understanding of these cREs-PLS and cREs-ELS.  
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II.4.11 Comparison between cREs and the corresponding ChromHMM states 
As described above, there are two approaches to building catalogues of regulatory 
elements, with the Registry of cREs representing one and ChromHMM representing the 
other. We asked how the simple, rDHS-anchored, one-additional-support approach of 
defining cREs compared with the more sophisticated, hidden Markov model based 
approach of chromHMM which also incorporates more histone marks.  
The cREs-PLS and cREs-ELS in GM12878 are consistent with the respective 
chromatin states called by ChromHMM using eight histone marks and CTCF in this cell 
type (Consortium 2012). Figure II-16a on 102 shows that 90% of top cREs-PLS (ranked 
by H3K4me3 Z-scores) overlap with ChromHMM promoters. Figure II-16b on 102 
reveals that over 85% of the top cREs-ELS (ranked by H3K27ac Z-scores) overlap with 
ChromHMM high-signal enhancers. The overlap decreases for lower ranking cREs-ELS, 
but the overlap with ChromHMM low-signal enhancers increases; 82% of the cREs-ELS 
ranked above 20,000 overlap with ChromHMM enhancers or low-signal enhancers. 
We also compared the cREs for five e11.5 and six e14.5 mouse tissues with the 
ChromHMM states called using eight histone marks in the corresponding tissues, as 
described in a companion paper (Tsuji et al., in preparation). We observed that 95 ± 2% 
of cREs-PLS overlapped ChromHMM-annotated promoters and 78 ± 3% of cREs-ELS 
overlapped ChromHMM-annotated enhancers in the corresponding tissue and time point. 
II.4.12 Cell and tissue type clustering 
To examine whether the Registry of cREs captured the regulatory landscapes, we 
clustered primary cell types and tissues on the basis of the DNase or H3K27ac Z-scores 
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at each cRE as being either high or low in the particular cell type. The dendrograms 
indeed recapitulate relationships among cell and tissue lineages (see online Extended 
Data Fig. 13-15), in agreement with findings from a previous report (Stergachis et al. 
2013). As described in a companion paper, we analyzed gene expression data in a panel 
of primary cells and uncovered four clusters of primary cells with similar expression 
patterns, and we related these expression patterns to those of histological tissues (Breschi 
et al., in preparation). 
II.5 SCREEN: A Web Engine for Searching and Visualizing cREs 
With millions of cREs in the Registry, providing an easy access to these data to the end 
users is the next challenge. ENCODE has four major goals in making these annotations 
available to end users: 
1. dynamic and interactive interfaces: provide a search interface allowing users to 
filter cREs in real time without leaving or reloading the search page, and display 
dynamically-generated analyses related to subsets of cREs with interactive plots 
2. integrated: provide the ability to view all the low-level annotations, such as 
transcription factor ChIP-seq, RNA-seq, RAMPAGE, and histone ChIP-seq 
results, associated with cREs through one interface, and make customizable 
visualizations of these annotations easily accessible in the UCSC Genome 
Browser 
3. reproducible: provide dynamic and interactive plots for published figures relating 
to the cREs within the web interface, and facilitate users’ generation of these 
figures with custom data 
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4. extensible: provide for the inclusion of analyses involving external annotations 
and user-submitted annotations 
Meeting these goals posed numerous challenges for the existing ENCODE Portal 
architecture. The scale of the annotations far exceeds the scale of the datasets and 
experiments cataloged by the Portal, which number in the tens of thousands, posing 
challenges both for accessioning of the annotations and for rapid dynamic searching. 
Further, the dataset-centric model of the portal is not easily generalized to the concepts of 
genomic coordinates, activity profiles, and the like, nor to analysis involving intersection 
with large collections of peaks or with external datasets. Finally, the Portal is not 
equipped to accept external or user-provided data for the generation of analysis plots. 
Numerous tools exist for cataloging epigenomic annotations and regulatory 
elements; however, to our knowledge, none of the existing tools catalog epigenomic 
annotations on the scale of the ENCODE Encyclopedia, nor provide the feature set 
required to meet ENCODE’s goals for visualization of the Encyclopedia’s annotations. 
The Broad Institute’s HaploReg provides an interface for searching SNPs and associated 
annotations and can tailor results to uploaded user input; however, the search results may 
not be dynamically filtered and no analytical plots are provided (Ward and Kellis 2012). 
The WashU and Roadmap Epigenome Browsers provide rich feature sets for dynamic 
plot generation and exploration of low-level annotations, but they are not engineered for 
cataloging or searching higher-level annotations like the cREs (Zhou et al. 2011). DENdb 
(Ashoor et al. 2015) and Enhancer Atlas (Gao et al. 2016) both provide enhancer 
databases, but the former does not incorporate visualizations of search results, the latter 
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provides only static searching, and neither provides for the display of peak intersections 
or element overlap with external datasets. 
GeneCards (Stelzer et al. 2002) and Ensembl (Yates et al. 2016) provide more 
complete epigenomic catalogs. GeneCards offers detailed information on individual 
genes, complete with a list of candidate enhancers predicted to regulate them, provided 
by the recently-published GeneHancer feature (Fishilevich et al. 2017) which integrates 
enhancers from various sources including ENCODE enhancer predictions. Similarly, the 
Ensembl Regulatory Build (Zerbino et al. 2015) uses Segway to create genome-wide 
epigenomic annotations on the basis of DNase-seq, CTCF ChIP-seq, and various histone 
ChIP-seq results; the database containing these annotations is directly accessible via the 
BioMart web UI and the annotations are also presented in association with SNPs. Both 
these projects provide resources similar to the ENCODE Encyclopedia, but the 
Encyclopedia expands on both in scale, with 1.3 million human cREs compared to 
approximately 285,000 human regulatory elements in GeneHancer and approximately 
447,000 elements in the Ensembl Regulatory Build. Additionally, GeneCards is 
predominantly gene-centric and Ensembl is predominantly SNP-centric; although both 
provide locus-based searches for regulatory elements, neither provides the rich, 
regulatory-element-centric features ENCODE aims to incorporate into its Encyclopedia 
viewer, particularly the ability to filter regulatory elements by activity within particular 
cell types and to view intersecting low-level annotations from the thousands of ENCODE 
ChIP-seq experiments. Additionally, although both tools are well-suited for identifying 
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regulatory elements associated with particular genes and SNPs of interest, they do not 
provide features allowing for coanalysis of external datasets. 
In order to meet our goals for cRE visualization, we designed an original web-
based visualizer, SCREEN (Search Candidate Regulatory Elements by ENCODE). 
SCREEN is divided into three apps, each providing a unique perspective on the cREs and 
a unique approach to searching and interpreting them. The locus-centric search app 
provides a keyword search and a dynamic filtering interface for browsing cREs both by 
genomic coordinates and activity profiles across available cell types. The gene-centric 
expression app provides dynamic plots of gene and TSS expression data derived from 
ENCODE RNA-seq and RAMPAGE datasets, as well as a differential expression plot 
which compares differential gene expression with differential activity of nearby cREs. 
Finally, the SNP-centric GWAS app is SCREEN’s first app involving external datasets, 
displaying the interaction of SNPs from GWAS studies and cREs. 
In order to catalog all the Encyclopedia’s annotations and provide rapid, efficient 
searching, SCREEN utilizes two separate databases and an extensive pre-processing 
pipeline implemented in C++ and Python. SCREEN’s frontend takes advantage of 
HTML5’s support for embedded vector graphics to produce dynamically-generated and 
interactive plots which reproduce published figures relating to the cREs; these figures 
provide easy access to the underlying annotations, update automatically to include new 
data as they become available at ENCODE, and are extensible to support external and 
user-submitted annotation sets. SCREEN’s Genome Browser configuration feature 
allows users to select custom subsets of cell types and pre-loaded cRE-related tracks to 
40 
 
 
 
view in the UCSC Genome Browser, making visualization of both low-level and 
integrated annotations dramatically easier. Finally, SCREEN’s design permits easy 
extension to new data types and analyses via the addition of new apps. Together, these 
features represent a new paradigm for the dynamic visualization and analysis of 
epigenetic annotations genome-wide. 
II.5.1 SCREEN Methods 
II.5.1.1 General architecture 
SCREEN consists of a CherryPy-based webserver backed by PostgreSQL and Apache 
Cassandra for data storage (Figure II-17 on page 103). Its front-end UI is based upon the 
ReactJS Javascript library and utilizes the Redux Javsacript library to manage application 
state. The front-end is written in ES6 Javascript; package management and compilation to 
pure Javascript is handled by Facebook’s yarn. In order to permit dynamic searching and 
visualizations, page updates after the initial page load are handled via JSON-based AJAX 
requests. Plots are rendered dynamically on the client side as scalable vector graphics 
(SVG). Computationally expensive operations are pre-computed using a C++ and Python 
pipeline. 
II.5.1.2 Storage of cREs and supporting analyses 
Storing the cREs, performing searches, and retrieving requested subsets are the core 
challenges underlying SCREEN’s design. SCREEN aims to do all three dynamically: as 
ENCODE data expands, so must SCREEN’s capacity to catalog regulatory elements and 
cell types, yet SCREEN’s storage system must be able to respond to user queries in real 
time to support filtering of cREs without a full page reload. In order to support both 
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dynamic expansion and dynamic searching, we use PostgreSQL, an open-source object-
relational database system, to store the cREs. Postgresql’s integer range operations allow 
for rapid searching by genomic coordinates, its array data types allow for scaling of cell-
type-specific data points as new cell types are added, and its JSON and binary JSON data 
types facilitate representation of nested metadata and precomputed parameters for SVG 
plots and visualizations. The core of the database schema, showing the representation of 
cREs with associated gene and cell type information, is presented in Figure II-18 on page 
104. Fields marked with a capital I are indexed; indexing cREs by chromosome 
dramatically improves search performance when searching for cREs on a single 
chromosome, and indexing the cREs by their maximum Z-scores allows rapid searching 
for elements of a particular activity profile, such as strong promoters or enhancers, across 
all cell types. We also use PostgreSQL to store several supporting datasets, including 
RAMPAGE and RNA-seq results, differential gene expression datapoints, TAD 
information, and cRE-SNP intersection. 
II.5.1.3 Ground level annotations and pre-computed analyses 
Analyses involving the ground-level annotations are too large scale to perform 
dynamically. Reading signal and peaks directly from BigWig and Bed format files, and 
performing intersections between cREs and hundreds of millions of peaks, is 
prohibitively slow. Because these analyses are highly computationally expensive, we 
designed an extensive pre-processing pipeline, written predominantly in C++ with some 
supporting Python; this pipeline performs analyses involving the cREs and ground-level 
annotations, and then formats the output for import into SCREEN’s databases. The 
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pipeline utilizes OpenMP for parallelization of its most expensive analyses, and utilizing 
a 64-core server with 512 GB of RAM the pipeline can complete its computations in 
approximately 6 hours. This allows SCREEN to be rapidly updated as new data become 
available at ENCODE. 
Overlap between cREs and peaks from all available ENCODE transcription factor 
and histone ChIP-seq experiments is pre-computed by SCREEN’s peak_intersection 
package, a Python package utilizing bedtools (Quinlan 2014). Support for intersection 
with peaks from Cistrome (Liu et al. 2011) is also included by default, and the package is 
easily extensible to other external datasets as well. SCREEN’s Signal Profile display 
provides snapshots of the signal from H3K4me3, H3K27ac, and CTCF ChIP-seq 
experiments in the region surrounding a selected cRE. These signal snapshots are pre-
computed by SCREEN’s minipeaks package, which down-samples and bins signal 
extracted from downloaded ENCODE signal files in BigWig format. The minipeaks 
package also utilizes ZentLib, a C++ wrapper of ENCODE’s kentUtils (Kent et al. 2010), 
to process signal files. 
The output from the peak_intersection package is stored in PostgreSQL and is 
available to the user in real time. The output from the Minipeaks package, however, 
includes hundreds of signal datapoints across thousands of experiments, and is too large 
scale to permit storage, indexing, and querying using PostgreSQL. Instead, the signal 
values are stored using Apache Cassandra, an open-source NoSQL data store offering 
linear scalability. Cassandra allows SCREEN to present snapshots of the signal within a 
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cRE and the associated summit signal values in real-time; these profiles are rendered 
dynamically on the client side using SVG. 
II.5.1.4 Web server 
SCREEN’s web server is implemented in Python and is based on the CherryPy 
framework. Support for dynamic filtering of search results and generation of figures 
requires numerous AJAX requests and large volumes of data to be transferred between 
the server and the client; to support this volume, the current production site consists of 
several simultaneous Docker instances. SCREEN supports sharing of necessary state 
information between Docker instances using redis, an in-memory data store. 
The server employs a model-view-controller design, which separates the logic of 
processing data, rendering content to HTML, and handling user input; this improves both 
security and code maintainability. The controllers primarily receive user input from 
CherryPy and retrieve data from the database models; the AJAX service, for example, 
consists primarily of the data_ws controller. The models perform any processing and 
reformatting necessary before data may be returned and rendered by the client. The 
gene_expression model, for example, pre-sorts expression data from the database 
according to several different criteria and performs log-transformation before the data are 
returned to the client; this reduces the amount of processing necessary within the user’s 
web browser to improve page responsiveness, and also allows SCREEN’s backend to 
incorporate caching mechanisms to reduce database queries and thus the time required to 
perform searches. The view component of the controller handles initial page requests 
only, which are rendered from templates using Jinja2; subsequent updates via AJAX are 
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handled dynamically on the client side by ReactJS and Redux, which allows search 
results and plots to update without requiring a full page reload. 
SCREEN’s web user interface code is written in ES6 Javascript; package 
management and compilation of the ES6 code into pure Javascript are performed by 
Webpack. ES6 provides numerous advantages over pure Javascript, including better 
cross-browser compatibility, standardized incorporation of external libraries, and support 
for embedded HTML and rich object-oriented code. Currently, the server outputs a static 
Javascript bundle which is served by CherryPy; future work aims to take full advantage 
of the hot module reloading functionality provided by Webpack. 
II.5.1.5 User interface and dynamic plots 
In order to provide dynamic searching and plot generation, SCREEN’s user interface is 
rendered nearly entirely on the client side using ReactJS, an open-source library for 
building component-based applications. ReactJS handles updates efficiently using a 
virtual representation of the web page’s browser’s internal document object model 
(DOM), which incorporates embedded SVG figures as well. This efficient update model 
is critical for SCREEN’s ability to update its dynamically-generated plots, some of which 
render several thousand datapoints, with little to no observable delay for the user. 
Because of the complexity of SCREEN’s state, we use the Redux library to 
handle component-generated actions. Redux provides a central store which manages the 
application’s state; components connect to the store to receive properties and may 
dispatch actions to the store to update the state. Actions dispatched to the store are 
handled by the store’s reducers, which operate on the current state to produce a new 
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state. Reducers never alter the current state directly in order to prevent race conditions, 
and components never communicate with each other directly, which improves code 
maintainability. The use of Redux also allows SCREEN’s dynamic plots to interact with 
other components of the page, allowing datapoints within figures to link directly to more 
information about their underlying annotations, for example. 
II.5.1.6 Custom trackhubs 
In addition to its own visualizations, SCREEN aims to provide easy access to the full 
collection of ENCODE’s ground-level annotations. SCREEN provides custom trackhubs 
for the UCSC Genome Browser (Kent et al. 2002), which include tracks for every 
ENCODE DNase-seq, H3K4me3 ChIP-seq, and H3K27ac ChIP-seq dataset available. 
SCREEN offers a configuration view to allow users to select which cell types to view and 
to create custom orderings of the tracks before being redirected to the Genome Browser. 
Tracks are also available in two separate formats for visualizing the cREs. The 9-state 
format displays four tracks, one each for DNase-seq, H3K4me3 ChIP-seq, H3K27ac 
ChIP-seq, and CTCF ChIP-seq Z-scores; cREs with a Z-score >1.64 for a given mark are 
colored and the remaining cREs are gray. The 5-group format displays a single 
condensed track, with active cREs colored according to their activity (red for promoter-
like cREs, yellow for enhancer-like cREs, etc.) and inactive cREs colored gray. 
Trackhubs are accessed via buttons available across SCREEN. Future plans include 
expansion of the tracks to include other data types, such as transcription factor ChIP-seq, 
as well as external data sources such as Cistrome. 
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II.5.2 SCREEN Usage 
Usage of SCREEN begins at the homepage, which provides access to the locus-centric 
search app (see Figure II-19 on page 105) and the gene-centric expression app (see Figure 
II-20 on page 106) via a keyword search box and the SNP-centric GWAS app via a 
“browse GWAS” button.  
Here we present a use case of SCREEN which explores how a user might use the 
GWAS app to form a hypothesis about the functional role of a SNP in a particular disease 
state. Clicking the “browse GWAS” button on the SCREEN homepage produces the 
GWAS app (Figure II-21 on page 107). The user first selects a GWAS study of interest; 
we have selected a 2012 study on inflammatory bowel disease for illustration (Jostins et 
al. 2012). The app will display how many SNPs from the study, as well as SNPs in 
linkage disequilibrium with SNPs from the study, overlap cREs (Figure II-22 on page 
108), along with a list of the ENCODE cell types with the most active overlapping cREs. 
In the case of the selected inflammatory bowel disease study, the top ten cell types 
include nine leukocyte cell types, as might be expected given IBD’s autoimmune nature, 
along with a cell type from the rectal mucosa. When the user clicks to select a cell type, a 
list of the cell type’s active cREs is displayed; we select the top cell type, a T-cell line 
from an adult male donor, for illustration (Figure II-23 on page 109). 
The first search result is cRE EH37E1089569, overlapping SNP rs11041476. The 
symbols in the left two columns reveal that the region surrounding this cRE is enriched in 
H3K4me3 ChIP-seq, H3K27ac ChIP-seq, and CTCF ChIP-seq signal in at least one 
ENCODE cell type each, and that the former two are enriched in the selected T-cell line. 
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The “P” symbol indicates that this cRE is within 2kb of a TSS for LSP1; following the 
LSP1 link in the second column from the right to GeneCards reveals that this gene is 
thought to play a role in immune cell chemotaxis, adherence to matrix proteins, and 
migration through the epithelium, and following the rs11041476 link to Ensembl reveals 
that the A allele of this SNP is correlated with LSP1 expression changes. Clicking the 
UCSC button in the far right column allows the user to visualize the region surrounding 
the cRE in the UCSC genome browser. Raw signal and cRE annotations are available for 
all ENCODE datasets, and subsets may be selected using the configuration view (Figure 
II-24 on page 110, top); here, we have selected GM12878 and T-cells from an adult male 
donor. Visualized in the UCSC Genome Browser (Figure II-24 on page 110, bottom), the 
data suggest that the cRE represents methylation of the histone adjacent to the first 
promoter for LSP1, resulting in increased chromatin accessibility for transcription. 
To obtain more information about EH37E1089569, the user may click the link in 
the leftmost column, which produces the search results page for EH37E1089569 (Figure 
II-25a on page 111). Clicking the cRE’s row in the results table produces the details 
view. The default view displays the cRE’s Z-scores for the four core marks across all 
available cell types, which are highest in various immune cell types (H3K4me3 and 
CTCF shown). The user may use the signal profile tab at the far right to view the raw 
data contributing to these Z-scores as well (Figure II-25b on page 111). The user may use 
the Nearby Genomic Features tab to identify the nearest genes, SNPs, and other cREs to 
the selected cRE, and the TF and his-mod intersection tab to view ENCODE transcription 
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factor ChIP-seq and histone mark ChIP-seq experiments with peaks intersecting the cRE 
(not shown). 
The Associated Gene Expression tab displays a component of the expression app, 
here showing LSP1 expression. Grouping by tissue indicates that this gene is most 
strongly expressed in immune cells (blood tissue) as well as the adrenal gland and spleen 
according to ENCODE RNA-seq results (Figure II-26 on page 112). The RAMPAGE tab 
gives greater insight into this expression profile by displaying transcription activity at all 
of LSP1’s transcription start sites; grouping RAMPAGE signal by tissue max suggests 
that the TSS closest to EH37E1089569 is most strongly expressed in the spleen, with 
adrenal LSP1 expression arising predominantly from other TSSs. 
Together, these results suggest that EH37E1089569 is the first promoter for LSP1, 
that the corresponding TSS is most active in immune cells and tissues, and that an A 
allele at rs11041476 likely impacts expression of isoforms of LSP1 which include the 
first exon, which are likely expressed predominantly in immune tissues. If the user is 
interested in studying Lsp1 in mouse, for example as a component of a mouse IBD 
model, the orthologous cREs in mm10 tab reveals that there is an orthologous cRE, 
EM10E0419598, in mouse. A similar workflow reveals that this cRE as well as Lsp1 
have similar activity profiles within immune cells as their human counterparts. 
Also available in SCREEN mm10 is the ability to duplicate the differential gene 
expression plot for developmental tissues, accessed via delta symbols adjacent to gene 
names in the search results table; for further discussion, see “II.6.1 Comparing cREs 
across mouse developmental timepoints” (below) and Figure II-27 on page 113. 
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II.5.3 Testing SCREEN User Interface 
The user interface of SCREEN went through many iterations. To gauge usability, we 
developed a series of tasks we requested beta testing users to complete. The tests covered 
as much of the functionality of SCREEN as possible. We requested feedback on how 
difficult each task was to complete; if the tasks were unclear; if finding the functionalities 
in SCREEN for performing the task were difficulty, and how many attempts were made 
to perform the task. As recommended by Paul Flicek at Ensembl, users were encouraged 
to record their SCREEN session using a screen capture application, and, optionally, to 
also record a user voice-over as the user talked out-loud, to future give insight on the 
users’ experience.  
The user tasks were as follows: 
 Visit the ENCODE Encyclopedia page 
o Do you see a description about the Registry of candidate Regulatory 
Elements (cREs)? 
o Do you see an entry to SCREEN? 
o What is the relationship between the ENCODE Encyclopedia, the Registry 
of cREs, and SCREEN? 
 Use SCREEN to find all candidate Regulatory Elements (cREs) in the beta globin 
locus by its genomic location in the human genome (build hg19): chr11:5226493-
5403124.  
o How many cREs are there? 
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o Download these cREs as a file in the comma-separated-values (CSV) 
format (an Excel friendly format). 
 Identify the cRE in the beta globin locus (identified in task 1) that has a DNase Z-
score > 1.64 AND the highest H3K27ac Z-score in K562.  
o What is the accession for this cRE? 
o Is this cRE classified as a promoter-like cRE, enhancer-like cRE, or 
CTCF-only cRE? 
o What is its nearest protein coding gene? How far is this gene? 
o In which tissues does this cRE have the highest DNase Z-score? 
 Find all the cREs within the gene body of human Actin alpha 1.  
o How many cREs are there? 
o What is the official gene symbol of Actin alpha 1? 
o Can you find all the cREs within 25 kb upstream of Actin alpha 1 
transcription start site? 
 Examine the expression profile of HNF1A across cell types in human.  
o Can you choose only tissues, and not other types of samples such as 
primary cells or cell lines?  
o Can you ask SCREEN to display expressions only in the nuclear 
compartment? 
 Examine the activity profiles of the multiple transcription start sites (TSSs) of 
HNF1A across cell types in human, measured by RAMPAGE.  
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o Do some TSSs of HNF1A have different activity profiles than other TSSs 
of this gene? 
o Are the activity profiles for some of HNF1A’s TSSs similar to the 
expression profile of the HNF1A gene? 
 Use SCREEN to find the human cRE with accession EH37E0579839.  
o Can you find its “Signal Profile”, i.e., cropped out signal peaks across cell 
types? 
o Can you find other cREs that are within a topologically associated domain 
(TAD) of this cRE? 
o Which transcription factors bind to this cRE? In which cell types? 
o How many H3K4me1 ChIP-seq experiments have overlapping peaks at 
this cRE? In which cell types are these ChIP-seq experiments? 
 Use SCREEN to find the human cRE with accession EH37E0579839.  
o What is the nearest human gene of this cRE? 
o Can you find the mouse ortholog of this human cRE? What is the nearest 
mouse gene of the mouse cRE? Is the mouse gene the ortholog of the 
human gene? 
o Are the cRE classifications (i.e. promoter-like cRE, enhancer-like cRE, or 
CTCF-only) consistent between human and mouse? 
o Do the two orthologous genes have similar expression profiles across cell 
types between human and mouse? 
 Compare the differential expression levels of the mouse Ogn gene.  
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o Compare embryonic day 11.5 limb vs. embryonic day 15.5 limb.  
o Compare between limb and forebrain, both at embryonic day 14.5. 
 Search SCREEN twice, with the first time searching for cREs in the beta globin 
locus (human genome build hg19, chr11:5226493-5403124) and the second time 
searching for cREs in the HNF1A gene body. 
o Can you download the cREs that you found in these two searches in two 
CSV files (one for each search)? 
o Can you download the cREs that you found in these two searches in a 
single CSV file? 
 Browse the list of genome-wide association studies (GWAS) in SCREEN and 
find the study on QT interval by Arkin et al.  
o What is the cell type with enhancer-like cREs that most significantly 
overlaps SNPs identified in this GWAS? 
 Please read the About page and watch the tutorial videos.  
o Are they informative? 
o Is there additional information we should add? 
 Please feel free to browse and give other comments. Is SCREEN easy enough to 
use? What improvements would you like to see? Which ones are essential to have 
before this is launched? 
II.6 Use Cases of the Encode Encyclopedia and SCREEN 
We foresee many applications for the ENCODE Encyclopedia and SCREEN. The various 
annotations at the ground level of the Encyclopedia can be downloaded from the 
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ENCODE Portal and further analyzed along with users’ own data. SCREEN allows users 
to directly search for cREs in the Registry and explore all associated annotations. Here, 
we provide three use cases for the Registry of cREs through SCREEN. The first use case 
explores mouse data as a panel of tissue types over a series of developmental time-points. 
We use SCREEN to present differentially expressed genes in a locus between pairs of 
time-points or tissues, along with differential H3K4me3 and H3K27ac signal levels of 
nearby cREs with promoter-like or enhancer-like signatures. One major application of the 
Encyclopedia is to interpret GWAS variants; the other two use cases illustrate how to 
characterize GWAS SNPs using the Registry of cREs. 
II.6.1 Comparing cREs across mouse developmental timepoints 
We have performed differential gene expression analysis for all GENCODE-annotated 
mouse genes between all available pairs of tissues and time-points. SCREEN displays 
differentially expressed genes in a locus alongside the differential activities of cREs 
within 500 kb of the gene of interest—activity here is defined as the H3K4me3 Z-score 
for cREs-PLS and the H3K27ac Z-score for cREs-ELS. As an example, Ogn encodes 
osteoglycin, a protein involved in bone formation. Ogn exhibits a dramatic increase in 
expression corresponding to bone development which occurs on mouse embryonic day 
12 (Taher et al. 2011). SCREEN displays Ogn and nearby differentially expressed genes 
in the limb between e11.5 and e15.5 (identified using DESeq2 (Love, Huber, and Anders 
2014), FDR < 0.01) as bars, with the heights of the bars corresponding to the log2 fold 
change in expression between the two time-points and the widths representing the lengths 
of the genes in base pairs (Figure II-27a on page 113). cREs-PLS and cREs-ELS are 
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shown in the plot as red and yellow dots respectively, with the y-coordinates of the cREs 
designating the differences in activity Z-scores between the two time-points. This view 
over a large domain helps to identify cREs that might account for the increase in Ogn 
expression—specifically, cREs proximal to Ogn are likely to play a role in regulation, 
because their increase in signal is concomitant with the increase in Ogn expression. The 
UCSC genome browser view of the Ogn locus across six time-points, which can be 
directly launched from SCREEN, reveals the change in Ogn expression over 
developmental time (Figure II-28 on page 114), which is correlated with increases in 
H3K27ac, H3K4me4, and DNase signals. Ogn expression increases most notably after 
e12.5, in agreement with previous findings (Taher et al. 2011). This increase in gene 
expression correlates with the increases in H3K27ac and H3K4me3 Z-scores of nearby 
cREs (Figure II-27c on page 113).  
II.6.2 Using the Registry of cREs to annotate GWAS SNPs 
Previous studies have repeatedly demonstrated that most GWAS variants reside outside 
exons. Furthermore, independent annotation of noncoding regions can be used to guide 
the interpretation of GWAS variants by predicting disease-relevant cell types and 
regulatory factors (Ernst et al. 2011; Maurano et al. 2012; Consortium 2012; Andersson 
et al. 2014; Farh et al. 2015; Dickel et al. 2016). With the broad coverage of cell types 
and rich epigenetic and transcription factor binding data associated with the cREs, the 
Registry can be particularly useful for annotating GWAS SNPs. 
To facilitate GWAS exploration, we have preloaded SCREEN with a subset of 
studies from the NHGRI-EBI GWAS catalogue (Hindorff et al. 2009; MacArthur et al. 
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2017) that were performed on the Caucasian-European (CEU) population (see online 
Supplementary Table 7), and we plan to include other populations in the near future. For 
each GWAS, we tested each cell type for whether its set of cREs-ELS was significantly 
enriched in the GWAS SNPs after accounting for SNPs in linkage disequilibrium (LD). 
SCREEN displays the cell types in descending order of enrichment, and users can browse 
the cREs in each cell type that overlap with GWAS SNPs. Figure II-29 on page 115 
shows a heat map of the enriched cell types for a subset of GWAS, and the results are 
summarized in Figure II-30 on 116. 
The user can first select a GWAS study of interest (Figure II-21 on page 107 and 
Figure II-31a on page 117), and SCREEN displays the fraction of LD blocks with at least 
one GWAS SNP overlapping cREs, which estimates the portion of GWAS signal that can 
be explained by cREs in the Registry using all available cell types (Figure II-31b on page 
117). A list of cell and tissue types is provided on the basis of enrichment in the H3K27ac 
signal. The user can narrow the search by selecting a cell type, such as GM12878 for 
multiple sclerosis, the left ventricle tissue for QT interval, or HepG2 for cholesterol 
levels (Figure II-31c on page 117). After a cell type is selected, SCREEN updates to 
show the list of cREs in that cell type overlapping the LD blocks (e.g., 473 GM12878 
cREs overlap multiple sclerosis SNPs) and denote the cREs with promoter-like or 
enhancer-like signatures (Figure II-31d on page 117). SCREEN also returns a list of 
SNPs for users to search and view in a genome browser along with the cRE and other 
supporting data, thus aiding in fine annotation of the SNPs and prediction of their 
functional impact.  
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As an example, rs1250568 is in LD (r2=0.7) with two SNPs associated with 
multiple sclerosis, rs1250542 (Patsopoulos et al. 2011) and rs1250540 (De Jager et al. 
2009). rs1250568 is predicted to be a causal SNP by the deltaSVM algorithm (Lee et al. 
2015). GM12878 has previously been suggested to be a relevant cell type for multiple 
sclerosis (Maurano et al. 2015), and SCREEN computes an FDR of 2.6E-7 for the 
enrichment of GM12878’s cREs. rs1250568 lies in cRE EH37E0182314, which has a 
high H3K27ac Z-score in GM12878 (Figure II-31d on page 117). It overlaps a ChIP-seq 
peak for the transcription factor ELF1 and disrupts an ELF1 motif site (Figure II-32e on 
page 118). ELF1 is primarily expressed in lymphoid cells and is involved in the IL-2 and 
IL-23 immune response pathways, both of which have been implicated in multiple 
sclerosis (Gallo et al. 1992; Vaknin-Dembinsky, Balashov, and Weiner 2006). RNA Pol 
II ChIA-PET data links EH37E0182314 with both ZMIZ1, the gene containing rs1250568 
in an intron, and PPIF, a downstream gene also known as Cyclophilin D. ZMIZ1 is in the 
androgen receptor signaling pathway and is expressed at lower levels in patients with 
multiple sclerosis than in controls (Fewings et al. 2017). ZMIZ1 is highly expressed in 
neurons and cardiac muscle cells (Figure II-33 on page 119) and has been reported in the 
GWAS but PPIF has not (Patsopoulos et al. 2011; De Jager et al. 2009). PPIF encodes a 
mitochondrial permeability transition pore protein and is expressed in cardiac muscle 
cells, lymphocytes and hepatocytes (Figure II-34 on page 120). We predict that PPIF 
performs functions in lymphocytes which are associated with the demyelination of 
neighboring neurons. Knockdown or knockout of Ppif leads to neuroprotective effects in 
murine disease models of multiple sclerosis (Forte et al. 2007; Warne et al. 2016). In 
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summary, SCREEN enables users both to identify the cell types that are likely implicated 
in a disease and to explore possible mechanisms by which cREs and SNPs may cause the 
disease. 
II.6.3 Combining orthologous cREs to fine-map GWAS SNPs 
One particular strength of the Registry is its inclusion of both human and mouse cREs 
and the definition of orthologous cREs in these two species. Mouse cREs are mostly 
defined using tissues during embryonic development; such developmental tissues are 
impractical to obtain for humans. Thus the orthologous mouse cREs can complement the 
human cREs in applications such as interpreting GWAS variants associated with 
developmental diseases, especially those that affect the brain. 
For example, rs13025591 has been reported by two studies to be associated with 
schizophrenia (p-values 8E-8 and 6E-6) (2011; Bergen et al. 2012). rs13025591 lies in 
the intron of the AGAP1 gene, and is most highly expressed in bipolar spindle neurons 
and the eye in human and all assayed embryonic brain regions in mouse according to 
results contained in the Encyclopedia (Figure II-35 on page 121). rs13025591 does not lie 
within a cRE. Therefore, we hypothesized that the signal driving this genetic association 
arises from SNPs in high LD with rs13025591. There are five cREs that overlap such 
SNPs (Figure II-36 on page 122), four of these cREs show enhancer-like signatures and 
one shows a promoter-like signature. None of the five cREs show a high H3K27ac or 
H3K4me3 signal in the surveyed adult human brain tissues associated with 
schizophrenia, such as the frontal temporal cortex or the angular gyrus (Niznikiewicz et 
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al. 2000; Nierenberg et al. 2005; Weinberger, Berman, and Zec 1986); nevertheless, 
EH37E0579839 has high H3K27ac signals in neural cells and bipolar spindle neurons. 
SCREEN's Activity Profile tool, which displays DNase or histone modification 
signals at cREs as “mini-peaks” across cell types, reveals that EH37E0579839 has high 
DNase signals in human fetal brain and eye tissues, but the signals disappear in older 
fetal brain and adult brain tissues (Figure II-37b on page 123). EH37E0579839 is 
orthologous to the mouse cRE EM10E0042108, which shows enhancer-like signatures in 
brain tissues. Consistently with its human ortholog, EM10E0042108 has high DNase 
signals in embryonic brain and retina. Across twelve tissues at eight time-points of 
embryonic development, EM10E0042440 has the highest H3K27ac signals in brain 
regions (Figure II-38 on page 124). In the forebrain, midbrain, and hindbrain, H3K27ac 
signals increase over time, reaching a maximum at e13.5. Then, similarly to those of the 
human ortholog, H3K27ac signals at the cRE decrease after this time-point through birth 
(Figure II-37c on page 123). These results indicate that this cRE is active only during a 
narrow window of brain development. 
The region harboring these two orthologous cREs is conserved across mammals 
(Figure II-37d on page 123). Although we do not have TF ChIP-seq data in fetal brain or 
mouse embryonic brain tissues, motif analysis using both HaploReg and RegulomeDB 
(Ward and Kellis 2012; Boyle et al. 2012) reveals that the LD SNP rs13031349 overlaps 
an SP3 motif and improves the match from a log-odds score of 8.1 to 19. Additional 
experiments are needed to test whether the SNP improves SP3 binding, but using 
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SCREEN and the ENCODE Encyclopedia, we were able to narrow down a region to 
guide experimental testing for biological function. 
II.7 Methods 
II.7.1 Identifying rDHSs 
We used all DNase-seq datasets as of February 1, 2017 with HOTSPOT2 calls on the 
hg19 or mm10 genomes (see online Supplementary Table S8). For each dataset, we 
calculated the Z-score of the log of the DNase signals across the DHSs—see below for an 
explanation of Z-score of log(signal). We then selected a representative set of DHSs 
(rDHS) in the following steps. All DHSs passing an FDR threshold of <0.1% were 
clustered across all DNase-seq experiments, and we selected the DHS with the highest 
signal (normalized as a Z-score to enable the comparison of signal levels across samples) 
as the representative DHS for each cluster. All the DHSs that overlapped with this rDHS 
by at least one bp were removed. We updated the clusters, identified the next rDHS with 
the highest signal, and removed all the DHSs that it represented. This process was 
repeated until it finally resulted in a list of non-overlapping rDHSs representing all DHSs. 
Using a modified version of a script from John Stamatoyannopoulos's laboratory, we 
iteratively cluster rDHSs and report those with the highest Z-score. This pipeline is 
available on GitHub (Create-rDHSs.sh). 
II.7.2 Normalizing epigenomic signals 
For each rDHS, we computed the Z-scores of the log of DNase, H3K4me3, H3K27ac, 
and CTCF signals. Z-score computation is necessary for the signals to be comparable 
across all cell and tissue types, because the uniform processing pipelines of DNase-seq 
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and ChIP-seq data produce different signals—the DNase-seq signal is in raw read counts, 
whereas the ChIP-seq signal is the fold change of ChIP over input. We converted the 
DNase raw read counts into Z-scores to remove the effect of different sequencing depths.  
Even for the ChIP-seq signal, which is normalized using a control experiment, 
substantial variation remains in the ranges of signals between cell types. To illustrate this 
effect, we examined the distributions of H3K27ac signals for 100k randomly selected 
rDHSs across five different cell-types (Figure II-39a on page 125). Even though these 
datasets were processed uniformly by the same pipeline, the ranges and distributions of 
signals differ among the datasets. After taking the log of the signals (Figure II-39b on 
page 125), we observed that the distribution in each dataset roughly follows a normal 
distribution. The Z-scores of log(signal) values have the same distribution across cell 
types (Figure II-39c on page 125).  
To implement this normalization, we used the UCSC tool 
BigWigAverageOverBed to compute the signal for each cRE (averaged across the entire 
cRE for DNase and CTCF and across the entire cRE plus 500 base-pairs on each end for 
H3K4me3 and H3K27ac), and, using a custom Python script, we took the log of these 
signals and computed a Z-score for each rDHS compared with all other rDHSs within a 
cell type. rDHSs with a raw signal of 0 were assigned a Z-score of -10. This pipeline is 
available at GitHub (Process-rDHS-Signals.sh). 
II.7.3 Saturation analysis of rDHSs  
To determine the percentage of all possible rDHSs that have been sampled using our 440 
DNA-seq datasets, we used a modified approach from ENCODE Phase II. We randomly 
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selected X cell types, where X is between 10–440 in intervals of 10. We then selected all 
corresponding DHSs for these cell types (including their biological replicates) and 
calculated the number of resulting rDHS using the rDHS selection pipeline (described 
above). Adapting the R script by Steven Wilder and Ian Dunham (Consortium 2012), we 
calculated the complete set of rDHSs to be at 95% saturation for each curve using a 
Weibull distribution. 
II.7.4 Overlap of cREs in cell types without DNase-seq data 
To determine the comprehensiveness of the Registry, we overlapped cREs with ChIP-seq 
peaks (H3K4me3, H3K27ac, and CTCF) from cell types lacking DNase data. Using 
bedtools merge, we merged all ChIP-seq peaks within 200 bp of one another and 
assigned each merged peak the maximal -log(FDR) score of the original peaks. We then 
filtered out all peaks with -log(FDR) < 2. Using bedtools intersect with the "-u" flag, we 
intersected the merged peaks with cREs and counted the number of unique peaks that 
overlapped at least one cRE. This pipeline is available at GitHub (Calculate-Peak-
Overlap.sh).  
II.7.5 Classifying cREs 
For cell type agnostic classification of cREs with promoter-like, enhancer-like, or CTCF-
only signatures, we first calculate the maximal DNase, H3K4me3, H3K27ac, or CTCF Z-
scores across all cell and tissue types (called max-Z). Then, using these max-Zs and 
distance from the nearest TSS (GENCODE V19), we classify rDHSs into seven states 
according to the high-low combinations of their H3K4me3, H3K27ac, or CTCF max-Zs. 
These seven states are grouped into three general, mutually exclusive groups using the 
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classification trees in Figure II-13 on page 99. The rDHSs that were classified as having 
promoter-like, enhancer-like, or CTCF-only signatures are deemed cREs and assigned an 
accession; the rDHS that are not classified in any of these categories are discarded. This 
pipeline is available at GitHub (Create-cREs.sh). 
To classify cREs in a particular cell type, we use DNase, H3K4me3, H3K27ac, or 
CTCF Z-scores in that cell type. We have all four types of data for 21 cell types. The 
cREs in each of these cell types are assigned to one of eight states—one inactive state 
(low DNase Z-scores) regardless of H3K4me3, H3K27ac, and CTCF Z-scores and seven 
active states (high DNase Z-scores) depending on the high-low combinations of their 
H3K4me3, H3K27ac, and CTCF Z-scores. The seven active states are further classified 
into five general, mutually exclusive groups: cRE-PLS, cRE-ELS, and CTCF-only are 
assigned according to the classification trees, the DNase-only group contains cREs with 
high DNase Z-scores but low H3K4me3, H3K27ac, and CTCF Z-scores, and the inactive 
group coincides with the inactive state, containing cREs with low DNase Z-scores 
regardless of their H3K4me3, H3K27ac, and CTCF Z-scores.  
To classify cREs in a particular cell type that lacks one or more data types, we 
must make approximations. The scheme is summarized as follows. If both H3K4me3 and 
H3K27ac data are available, then we incorporate the TSS proximity information by 
following the (above) classification trees; otherwise, we classify PLS if only H3K4me3 
data are available and ELS if only H3K27ac data are available, without considering TSS 
proximity of the cREs. For cell types lacking DNase data, we also use the same 
classification scheme but without the DNase Z-score > 1.64 requirement. In these cell 
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types, cREs with low H3K4me3, H3K27ac, or CTCF signals are labelled “unclassified” 
because we are unable to definitively classify them as “inactive” without DNase data. 
II.7.6 Saturation of cREs group with increasing numbers of cell types 
To determine the relative saturation of cREs with promoter-like, enhancer-like or CTCF-
only signatures, we used 21 cell types with all four core epigenomic marks (DNase, 
H3K4me3, H3K27ac, and CTCF). For X in the range of 1–21, we randomly selected X 
cell types 100 times. For each selection, we calculated the number of cREs in each of the 
three groups—promoter-like, enhancer-like, and CTCF-only signatures. Then, using the 
R script adapted from Steven Wilder and Ian Dunham (Consortium 2012), we calculated 
the cREs in each group to be at 95% saturation for each curve using a Weibull 
distribution. This pipeline is available on GitHub (Run-Calculate-cRE-Saturation.sh). 
II.7.7 Overlap of cREs with ChromHMM states 
We compared cREs with promoter-like and enhancer-like signatures to the chromatin 
states called by ChromHMM. We combined similar chromHMM states to generate seven 
broad states, as seen in Table II-2 on page 81. Each cRE was assigned to only one 
chromHMM state—the state that overlapped the largest number of basepairs.  
For human, we analyzed the chromHMM regions for GM12878 cells from the 
ENCODE 2012 paper (ENCFF001TDH). We selected all cREs with promoter-like or 
enhancer-like signatures and ranked them by H3K4me3 and H3K27ac Z-scores, 
respectively. Then, we calculated the percentage of cREs in each 1 k bin that overlapped 
regions with each chromHMM state. This pipeline is available at GitHub (Ranked-
ChromHMM-Overlap.sh). 
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For mouse, we analyzed 11 tissue–time-point combinations (from e11.5 and 
e14.5) for which we had DNase, H3K4me3, and H3K27ac data. We overlapped cREs 
with promoter-like or enhancer-like signatures with chromHMM states derived from 
eight histone marks in the same tissue–time-point. This part of the pipeline is available at 
GitHub (Overall-ChromHMM-Overlap.sh). 
II.7.8 Clustering cell types on the basis of their cRE activities 
To examine whether the Registry of cREs captured the regulatory landscapes of cell and 
tissue types, we performed hierarchical clustering on all primary cells and tissues with 
DNase-seq data by classifying the DNase Z-score at each cRE as either high (Z-score > 
1.64) or low within each cell type. We also performed the same analysis using the Z-
scores of H3K27ac, H3K4me3, or CTCF. We clustered tissues and primary cells 
separately because each tissue comprises multiple types of primary cells with different 
embryonic origins. For each cell or tissue type, we selected all cREs with a Z-score > 
1.64 for each epigenomic mark and then calculated the Jaccard index for pairwise tissue 
or cell type comparisons. We clustered the tissues according to the pairwise Jaccard index 
using the hclust function in R. This pipeline is available at GitHub (Cluster-Cell-
Types.sh). 
II.7.9 Enrichment of GWAS variants in cREs 
We curated studies from the NHGRI-EBI Catalogue (see Table II-3 on page 82) that were 
performed on European populations and used minor allele frequencies (MAF) and 
linkage disequilibrium (LD) of these populations to generate control SNPs. Because 
MAF and LD differ across populations, we limited the scope of our initial analysis to the 
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populations with the most data. We used CEU-specific data of linkage disequilibrium 
(LD; correlation coefficient r2>0.7) to perform statistical tests. 
For each study, we generated a matching set of control SNPs as follows: for each 
SNP in the study (p < 1E-6) we selected a SNP on Illumina and Affymetrix SNP ChIPs 
that fell within the same minor allele frequency (MAF) quartile and the same distance to 
TSS quartile (Table II-4 on page 84). We repeated this process 100 times, generating 100 
random control SNPs for each GWAS SNP. Then, for both GWAS and control SNPs, we 
retrieved all SNPs in high linkage disequilibrium (LD r2 > 0.7), creating LD groups. 
To assess whether the cREs in a cell type were enriched in the GWAS SNPs, we 
intersected GWAS and control LD groups with cREs with an H3K27ac Z-score > 1.64 in 
the cell type. To avoid over-counting, we pruned the overlaps, counting each LD group 
once per cell type. We modified the Uncovering Enrichment through Simulation (UES) 
method (Hayes et al. 2015) with Fisher's exact tests for performing statistical testing. We 
calculated enrichment for overlapping cREs, comparing the GWAS LD groups with the 
100 matched controls. Finally, we applied an FDR of 5% to each study. 
II.7.10 Best single features for predicting tissue-specific enhancers 
We used mouse embryonic enhancers in the VISTA database (Visel et al. 2007) to 
compare the effectiveness of the following ten types of epigenetic signals in predicting 
enhancers: DNase hypersensitivity, eight histone marks (H3K4me1, H3K4me2, 
H3K4me3, H3K27ac, H3K9me3, H3K36me3, and H3K27me3), and DNA methylation. 
VISTA enhancers have been tested with mouse transgenic assays, a widely 
acknowledged in vivo test for enhancer function (Pennacchio et al. 2006). At the time of 
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our evaluation (2015), over 2100 TSS-distal regions in the human and mouse genomes 
had been tested for reporter gene expression at embryonic day 11.5 (e11.5), and the 
results are available via the VISTA Enhancer database (enhancer.lbl.gov). Each region 
was tested for enhancer activities in all mouse tissues at e11.5.  
The ENCODE Phase III data across the mouse developmental series are an ideal 
source of epigenetic data for evaluating enhancer prediction because they are from the 
same tissues and stage of development assayed for reporter gene expression by mouse 
transgenic assays. Four tissues at e11.5—the midbrain, hindbrain, neural tube, and 
limb—were covered by all assays, and there were hundreds of VISTA regions active in 
each of the tissues. We asked which of the ten epigenetic signals were predictive of 
VISTA enhancers in each tissue. Our positive test set comprised all VISTA enhancers in 
that tissue; our negative set contained the remaining VISTA regions (i.e., those that were 
tested but showed no activity in that tissue). The VISTA regions used in our analysis are 
listed in online Supplementary Table 2. Among four epigenetic signals (H3K4me3, 
H3K4me1, H3K27ac and DNase), the average DNase signal in a window anchored at 
DHSs was the most predictive feature for enhancer activity in the hindbrain, limb, and 
neural tube, with the area under the precision-recall curve AUPR=0.38, 0.39, and 0.29, 
respectively (Figure II-40 on page 126; Table II-5 on page 85). H3K27ac, anchored at 
H3K27ac peaks was the second-most predictive feature in these three tissues: AUPR = 
0.33, 0.33, and 0.26, 9-17% lower than DNase. For midbrain enhancers, H3K27ac 
(AUPR=0.41) was the most predictive features followed by DNase (AUPR = 0.37). 
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DNase performs better than H3K27ac due to its higher precision in defining 
regulatory elements. DHSs are ~300 bp long and often correspond to the core of 
regulatory elements. In contrast, the H3K27ac signal is more diffuse: it tends to be low at 
the center of a regulatory element, which lacks a nucleosome, but is high at the two 
flanking nucleosomes. Anchoring predictions on DHSs, we then tested different methods 
of ranking predictions testing both histone mark and DNase signals. On average, ranking 
with H3K27ac signal outperformed DNase signal in predicting of enhancer activity when 
averaged over a window centered DHSs (Figure II-41 on page 127; Table II-5 on page 
85). Signals for other histone marks and DNA methylation individually were far less 
predictive (Table II-5 on page 85). The average rank of the DNase and H3K27ac signals 
was slightly better than that of DNase. Incorporating additional histone marks or DNA 
methylation using a linear model did not further improve performance. We did not test 
more complex models because of the small number of VISTA enhancers—only 200-300 
genomic regions tested positive in each tissue.  
II.7.11 Combining signals accurately predicts active promoters 
We further evaluated whether an adaptation of the above-described enhancer prediction 
model could be used to map cell-type-specific promoter regions. Judged by transcript 
expression levels measured by RNA-seq in the e11.5 midbrain, limb, neural tube, and 
hindbrain, the single most predictive feature among the ten we evaluated (DNase, eight 
histone marks, and DNA methylation) was the H3K4me3 signal. When averaged over a 
±1.5 kb window centered on TSS-proximal DHSs, H3K4me3 correlated with expression 
levels at r = 0.75 averaged over the four tissues (Table II-6 on page 86; Figure II-42 on 
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page 128 for the hindbrain). This correlation is substantially higher than that of the 
H3K4me3 signal centered on H3K4me3 peaks (r = 0.57) or the DNase signal centered on 
TSS-proximal DHSs (r = 0.39). Repeating this analysis with human RNA-seq data in 
GM12878, K562, and HepG2 yielded consistent results (r = 0.72, 0.73, 0.71). In 
conclusion, the high spatial precision offered by DHSs improves the accuracy of 
H3K4me3 for predicting gene expression.  
II.7.12 Evaluating the group classification of cREs in GM12878 cells 
Figure II-15 on page 101 summarizes the five-group classification of cREs in GM12878. 
We used ChIP-seq data of RNA Pol II, EP300, and RAD21 in GM12878 to evaluate the 
group classification of cREs in this cell type. The TSS-proximal cREs in the high-
H3K4me3, high-H3K27ac, high-CTCF state had the highest median POL2 signal (25.0; 
compared with 7.3 for the second highest state; Figure II-43 on page 129), yet moderately 
high EP300 signals (median = 10.9; Figure II-44 on page 130). Some of these cREs may 
function as both promoters and enhancers, but collectively they are more promoter-like 
than enhancer-like, as judged by their POL2 and EP300 signals. In contrast, the high-
H3K27ac, low-H3K4me3 states, regardless of CTCF status or proximity to TSS, showed 
the highest EP300 signals but low POL2 signals, supporting their assignment as cREs 
with enhancer-like signatures (Figure II-45 on page 131). The most challenging 
assignments were for the relatively few high-H3K4me3, low-H3K27ac, TSS-distal cREs 
(450 high-CTCF and 1,584 low-CTCF). These cREs had slightly, yet significantly, 
higher POL2 binding than DNase-only cREs, which supported a promoter-like 
classification (Figure II-46 on page 132).  
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Figure II-47, Figure II-48, and Figure II-49 show the nine-state and five-group 
classifications of cREs and the underlying DNase-seq, H3K4me3, H3K27ac and CTCF 
data for three cell types—hepatocytes, B cells, and bipolar spindle neurons. Three loci are 
displayed, each specifically active in one of the three cell types as indicated by RNA-seq 
data: hepatocyte nuclear factor 4 (HNF4a) (Figure II-47) , active in hepatocytes; 
hematopoietic transcription factor PU.1 (SPI1) (Figure II-48), active in B cells; and 
neuronal PAS domain protein 4 (NPAS4) (Figure II-49), active in bipolar spindle 
neurons. Both the general, cell-type-agnostic classification of cREs and the classifications 
in each cell type are shown. The cREs surrounding each locus are active specifically in 
the corresponding cell type.  
II.7.13 Uniform Data Processing and Data Quality Control 
We have developed uniform processing pipelines for RNA-seq, DNase-seq, ATAC-seq, 
TF ChIP-seq, histone mark ChIP-seq, and WGBS data. These pipelines are implemented 
in the DNAnexus cloud computing environment and are freely available on GitHub 
(github.com/ENCODE-DCC). We track the dependency, or provenance, of each derived 
or processed file via a graph describing the input files, genome references, and specific 
versions of software packages and parameter values used in every step (Sloan et al. 
2016). Both the graph and the intermediate results of these pipelines are available at the 
ENCODE Portal. Three additional data types—eCLIP-seq, Hi-C, and ChIA-PET—were 
processed by the respective data production labs, and the analysis results have submitted 
to the ENCODE Portal. All data files with their metadata can be downloaded, and all are 
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accessible via an application program interface (API). Metadata can also be retrieved via 
a RESTful JSON API. 
Each ENCODE dataset is required to have two biological replicates; exceptions, 
typically resulting from a lack of cell or tissue samples that can serve as replicates, are 
noted. We have developed quality control (QC) metrics for each data type 
(www.encodeproject.org/data-standards/), established thresholds for these metrics as the 
quality standards, and integrated the calculation of the metrics into the respective uniform 
processing pipelines. For example, the TF ChIP-seq pipeline calculates mapping 
statistics, library complexity, cross-correlation between signals (number of mapped reads 
per position) in the two strands of the genomic DNA, correlation between biological 
replicates, enrichment of reads in peaks (genomic regions with significantly high signals), 
and agreement between peaks called in the two biological replicates (Li et al. 2011). The 
ENCODE Portal displays the QC metrics for each dataset. Data sets that did not meet the 
quality standards were replaced with new experiments, and low-coverage data sets were 
augmented with additional sequencing whenever possible. If it is not feasible to meet the 
quality standards (often because of limited experimental material), a dataset is still 
released if deemed valuable to the community, along with an audit flag stating the QC 
metrics that were not met. 
Four ENCODE uniform processing pipelines are summarized below. More 
information can be found at the GitHub (github.com/ENCODE-DCC). 
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II.7.13.1 DNase-seq 
The ENCODE DNase-seq processing pipeline consumes raw sequencing reads 
from technical replicates of experiments in the form of FASTQ files. Indexing and 
alignment of the FASTQ reads is performed with the Burrows-Wheeler Aligner (BWA) 
(Li and Durbin 2009), which outputs alignments in BAM format. Alignments from sets 
of technical replicates are merged and filtered prior to peak calling with HOTSPOT2, 
which generates peaks in BED format. Input FASTQs must meet minimum criteria to be 
processed, and various quality control metrics are also generated at each step. Further 
detail and basic workflows are available at github.com/ENCODE-DCC/dnase_pipeline. 
II.7.13.2 ChIP-seq 
The ENCODE consortium has developed two distinct ChIP-seq pipelines, one for 
transcription factor (TF) ChIP-seq data and one for histone ChIP-seq data, which take 
into account the different binding distributions of the respective immunoprecipitation 
targets across the genome. The ChIP-seq pipelines consume raw reads in FASTQ format; 
alignment of the reads is performed with BWA to generate alignment BAMs. Signal 
tracks are produced from the alignments using MACS2; these are output in two separate 
BigWigs, which represent fold-change over control and signal p-value. 
Peaks are also called from the alignments, using MACS2 in the case of histone 
data and SPP in the case of TF data. Additionally, the pipelines call peaks from the 
pooled alignments of each experiment’s isogenic replicates. For TF experiments, the 
pooled peaks are compared with the peaks called for each replicate individually using 
IDR and thresholded to generate a conservative set of peaks and an optimal set of peaks; 
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for histone data, sets of replicated peaks are generated by comparing the pooled and 
individual peaks using overlap_peaks. Further detail and basic workflows are available at 
github.com/ENCODE-DCC/chip-seq-pipeline. 
II.7.13.3 RNA-seq 
There are two distinct ENCODE uniform RNA-seq pipelines, one for RNAs 
longer than 200 bp and the other for RNAs shorter than 200 bp. The long RNA pipeline is 
appropriate for processing libraries generated from mRNA, rRNA-depleted total RNA, or 
poly-A(–) RNA. The pipeline consumes RNA-seq reads in FASTQ format; alignment is 
performed with STAR and gene and transcript quantification is performed by RSEM 
against a gene annotation file, which contains by default GENCODE annotations. STAR 
also outputs normalized RNA-seq signal for both the (+) and (–) strands. Further details 
are available at github.com/ENCODE-DCC/long-rna-seq-pipeline.  
II.7.13.4 RAMPAGE  
Like the long RNA-seq pipeline, the ENCODE RAMPAGE pipeline is 
appropriate for libraries generated with RNAs longer than 200bp, and it consumes reads 
in FASTQ format and produces alignments and normalized signal for both the (+) and (–) 
strands with STAR. PeaOverlap of cREs with H3K4me3, H3K27ac, and CTCF peaks in 
cell types without DNase-seq data. To determine the comprehensiveness of the Registry, 
we overlapped cREs with ChIP-seq peaks (H3K4me3, H3K27ac, and CTCF) from cell 
types lacking DNase data. Using bedtools merge, we merged all ChIP-seq peaks within 
200 bp of one another and assigned each merged peak the maximal -log(FDR) score of 
the original peaks. We then filtered out all peaks with -log(FDR) < 2. Using bedtools 
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intersect with the "-u" flag, we intersected the merged peaks with cREs and counted the 
number of unique peaks that overlapped at least one cRE. This pipeline is available on 
GitHub at Calculate-Peak-Overlap.sh. ks, representing transcription start sites, are called 
from the alignments using GRIT, and output in BED, bigBED, and GFF formats. QC is 
performed for the peaks, and IDR is used to identify reproducible peaks between 
replicates. 
II.7.14 Testing single features for predicting tissue-specific enhancers 
We downloaded all regions from the VISTA Enhancer database in November, 2015. 
Merging overlapping regions yielded 1,994 unique regions. Because we had histone mark 
ChIP-seq, DNase-seq, and RNA-seq data for the midbrain, hindbrain, limb, or neural tube 
at embryonic day 11.5, we selected all regions active in these four tissues at e11.5, thus 
resulting in 301, 271, and 193 active regions, respectively (see online Supplementary 
Table 2). 
We determined the best method for anchoring enhancer predictions (i.e., which 
peaks should be used to center the genomic regions as predicted enhancers) and then 
tested metrics for ranking these predictions. We tested the metrics using DHSs and 
H3K4me3, H3K4me1, and H3K27ac peaks for anchors. To make comparisons across the 
different data types and to account for differences in their genome coverage, we 
developed a uniform comparison pipeline with the following requirements:  
1. Uniform number of peaks across cell types. We restricted the DHSs and histone 
mark peaks to the same number in each cell type, using the minimal number of 
peaks and DHSs across all datasets. For example, in the midbrain, there are 168 k 
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DHSs, 28 k H3K27ac peaks, 81 k H3K4me1 peaks, and 21 k H3K4me3 peaks, 
and we selected the top 21 k peaks of all four datasets for analysis. 
2. Uniform width for predicted enhancers. We resized each DHS or histone mark 
peak to the same length of 300 bps, centered on the midpoint of DHSs and the 
summit of histone peaks (the position with the highest ChIP signal), and used 
these as enhancer predictions. 
We intersected DHSs and histone mark peaks with all VISTA regions. If a VISTA region 
overlapped a DHS or peak, we assigned the region the score of the DHS or peak, i.e., its 
–log(p-value) or signal. If a VISTA region overlapped multiple DHSs or peaks, we 
assigned it the maximal score of the overlapping DHSs or peaks. If a VISTA region did 
not overlap any DHSs or peaks, we assigned it a score of 0. To evaluate the performance 
of each method, we calculated the area under the Precision-Recall Curve (AUPRC) using 
the ROCR package and custom R scripts. This pipeline is available on GitHub at: 
Evaluate-VISTA-Enhancers.sh. 
Averaged over the four tissues, DHSs performed the best as anchors for enhancer 
predictions, followed by H3K27ac peaks (Figure II-40 on page 126). Anchoring all 
enhancer predictions on DHSs, we tested different metrics for ranking the regions. 
Overall, the best performing metric was the average rank of H3K27ac and DNase signals 
(Figure II-41 on page 127).  
II.7.15 Prediction of expression levels 
To test methods of promoter prediction, we used transcript expression values from the 
RNA-seq uniform processing pipeline. We computed Pearson correlations between the 
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ranks of TSS-proximal (± 2 kb) DHSs or H3K4me3 peaks (by DNase or H3K4me3 
signal) and the ranks of the expression levels of nearby transcripts. We tested all four 
combinations of ranking schemes (DHSs ranked by DNase signal, H3K4me3 peaks 
ranked by DNase signal, DHSs ranked by H3K4me3 signal, and H3K4me3 peaks ranked 
by H3K4me3 signal). The method with the highest correlation was centering predictions 
on DHSs and ranking by H3K4me3 signal. This pipeline is available on GitHub. 
II.8 Discussion 
The genetics revolution has fundamentally changed our understanding of medicine over 
the past several decades. More recently, however, we are learning that epigenetics is as 
important, if not more so, to our understanding of disease. There are already catalogs of 
hundreds of epigenetic changes affecting disease (Mirabella, Foster, and Bartke 2016). 
With ~90% of disease-associated Single Nucleotide Polymorphisms (SNPs) occurring to 
be in intronic or intergenic regions (Hindorff et al. 2009), the systematic location and 
study of genetic variants outside of protein-coding regions is critical to better 
understanding and potentially treating disease pathology. There are millions of these 
potentially functional regions in the genome, working as enhancer, promoters, repressors, 
or insulators; having a catalog of these elements, and a way to easily interrogate these 
regions, will be essential to keep researchers afloat in an ocean of data. Researchers 
require tools to aid in both biological questions and practical bioinformatics problems; 
users require an encyclopedia synthesizing the low-level data into a more manageable 
product that can be analyzed and effectively investigated.  
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We have identified the first real catalog of putative regulatory regions, locating 
nearly 2 millions cREs across human and mouse genomes in regions with open chromatin 
and enhancer-like or promoter-like signatures (based on histone modification marks and 
other genomic distance information). These elements are numbered and versioned, 
permitting direct reference in future papers. cREs are anchored on DNase-seq 
representative DHSs (rDHSs), condensed first from >30 million DHS sites across more 
than 400 individual samples into a set of non-overlapping regions number ~1.3 million in 
human and ~400 thousand in mice. We have found a wealth of putative regulatory 
regions that correlate with experimental datasets within and outside of ENCODE. These 
regions greatly simplify the search for putative regulatory regions genes or SNPs of 
interest. 
To interrogate these regions, we needed a tool with several requirements, 
including dynamic and interactive interfaces that allow users to search and filter cREs in 
real time, as well as display interactive plots of cREs. The tool needed to integrate and 
view all the low-level data in some sort of genome browser. The interactive plots also 
needed to be reproducible, and near-publication quality. Finally, we also needed a 
mechanism to facilitate users’ generation of these figures with custom data. The tool 
needed to be extensible, providing for the inclusion of analyses involving external 
annotations and user-submitted annotations.  
To fulfill these requirements, we developed SCREEN, the visualizer for cREs. 
This tool is maturing into an integrated approach to examining cREs in the context of the 
genome and epigenome. We already have a multi-part visualization platform, with 
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mechanisms to search and investigate cREs, show gene expression information, and 
explore GWAS studies for SNP overlap with cREs. SCREEN is the start of central 
repository for accessing information on functional regions of human and mouse genomes, 
integrating cRE searching, sorting, and visualization. It will (hopefully) become an easily 
adaptable tool widely utilized.  
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II.9 Tables 
Table II-1 | ENCODE Project data production as of June 20, 2017 
Category Assay 
# 
Tissues 
# 
primary 
cell 
# 
Cell 
Line 
# 
IPSC 
# in 
vitro 
# 
Stem 
cell 
Number of 
Experiments 
(Phase III) 
Number of 
Experiments 
(All 
ENCODE) 
Number of 
Experiments  
(All 
ENCODE + 
ROADMAP) 
Human 
Transcriptome 
Bru-seq 0 0 1 0 0 0 0 1 1 
CAGE 1 32 37 
 
1 7 0 78 78 
CRISPR 
genome 
editing 
followed by 
RNA-seq 
0 0 27 0 0 0 27 27 27 
CRISPRi 
followed by 
RNA-seq 
0 0 147 0 0 0 0 147 147 
RAMPAGE 104 16 27 1 6 1 155 155 155 
RNA-PET 1 7 22 0 0 1 0 31 31 
polyA 
depleted 
RNA-seq 
0 13 15 0 1 3 1 32 32 
polyA 
mRNA 
RNA-seq 
197 73 89 3 24 19 27 132 405 
small RNA-
seq 
68 33 57 1 8 6 86 173 173 
total RNA-
seq 
114 60 47 2 13 5 210 239 241 
microRNA 
counts 
24 2 5 1 5 1 37 38 38 
microRNA-
seq 
52 38 5 1 5 6 36 38 107 
shRNA 
knockdown 
followed by 
RNA-seq 
0 0 526 0 0 0 524 526 526 
siRNA 
knockdown 
followed by 
RNA-seq 
0 0 55 0 0 0 50 55 55 
single cell 
isolation 
followed by 
RNA-seq 
0 26 13 1 1 0 41 41 41 
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RNA 
microarray 
78 108 82 10 7 6 0 179 291 
Transcriptional 
regulation and 
replication 
DNase-seq 322 168 160 11 28 14 163 372 703 
ATAC-seq 34 0 0 0 0 0 33 0 34 
DNAme 
array 
124 54 71 1 6 3 0 259 259 
FAIRE-seq 7 4 25 0 0 1 0 37 37 
MNase-seq 0 0 2 0 0 0 0 2 2 
MRE-seq 3 35 2 0 0 5 0 2 45 
MeDIP-seq 8 37 2 0 0 4 0 2 51 
RRBS 31 44 48 6 7 7 0 103 143 
WGBS 74 35 3 2 13 6 9 9 133 
ChIP-seq, 
histone 
727 534 360 49 274 127 495 852 2071 
ChIP-seq, 
TF 
225 76 1222 5 15 79 615 1622 1622 
ChIP-seq, 
RNA 
binding 
protein 
0 1 76 1 1 4 48 83 83 
ChIP-seq, 
recombinant 
0 0 218 0 0 0 178 218 218 
ChIP-seq, 
control 
359 138 404 15 46 33 393 742 995 
ChIP-seq, 
other post-
translational 
modification 
0 0 3 0 2 0 4 4 5 
Repli-ChIP 0 5 5 2 27 6 36 45 45 
Repli-seq 0 24 60 0 0 6 0 90 90 
5C 0 1 11 0 0 1 0 13 13 
ChIA-PET 0 0 39 0 0 0 31 39 39 
HiC 0 2 12 0 0 0 12 14 14 
Post-
transcriptional 
regulation via 
RBPs 
RIP-chip 0 0 29 0 0 3 0 32 32 
RIP-seq 0 0 43 0 0 0 35 43 43 
RNA Bind-
N-Seq 
0 0 0 0 158 0 158 158 158 
eCLIP 3 0 318 0 0 0 320 321 321 
iCLIP 0 0 5 0 0 0 5 5 5 
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genotyping  
DNA-PET 0 0 6 0 0 0 0 6 6 
genotyping 
array 
16 54 62 2 4 4 59 123 142 
genotyping 
HTS 
8 1 0 0 0 0 9 9 9 
Human Total 
       
3797 7096 9665 
Mouse 
Transcriptome 
polyA 
mRNA 
RNA-seq 
78 8 21 0 2 2 0 111 
 total RNA-
seq 
83 14 8 0 0 3 104 108 
 microRNA 
counts 
77 0 0 0 0 0 77 77 
 microRNA-
seq 
65 0 0 0 0 0 65 65 
 single cell 
RNA-seq 
12 59 0 0 0 0 71 71 
 
Transcriptional 
regulation and 
replication 
DNase-seq 49 12 15 0 4 8 33 88 
 
ATAC-seq 27 7 2 0 0 1 10 37 
 
MRE-seq 0 0 2 0 0 0 0 2 
 
MeDIP-seq 0 0 2 0 0 0 0 2 
 
WGBS 72 0 0 0 0 0 72 72 
 ChIP-seq, 
histone 
638 18 46 0 6 20 564 728 
 ChIP-seq, 
TF 
45 9 106 0 15 10 16 185 
 ChIP-seq, 
control 
113 5 25 0 4 4 94 151 
 
Repli-ChIP 0 1 4 0 8 5 0 18 
 
Mouse Total        
1106 1715 
 
Grand Total 
       
4903 8811 11380 
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Table II-2 | Consolidated ChromHMM States 
Combined State     
TSS 1 Active 
Promoter 
2 Weak 
Promoter 
  
TSS Bivalent 3 Poised 
Promoter 
   
High Signal 
Enhancer 
4 Strong 
Enhancer 
5 Strong 
Enhancer 
  
Low Signal 
Enhancer 
6 Weak 
Enhancer 
7 Weak 
Enhancer 
  
Insulator 8 Insulator    
Transcription 9 Txn 
Transition 
10 Txn 
Elongation 
11 Weak Txn  
Repressed 12 Repressed 13 
Heterochrom/lo 
14 
Repetitive/CNV 
15 
Repetitive/CNV 
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Table II-3 | GWAS Studies 
First Author PMID Phenotype 
Anderson 21297633 Ulcerative colitis 
Anttila 23793025 Migraine 
Arking 24952745 QT Interval 
Barrett 19430480 Type 1 Diabetes 
Baurecht 25574825 Inflammatory skin disease 
Baurecht 25574825 Psoriasis 
Bentham 26502338 Systemic lupus erythematosus 
Berndt 23563607 Height 
Berndt 23563607 Obesity 
Cai 25130324 Heschl's gyrus morphology 
Chasman 19936222 Lipid metabolism phenotypes 
deVries 26561523 Fibrinogen levels 
Dubois 20190752 Celiac disease 
Dupuis 20081858 Fasting glucose-related traits 
Fox 22589738 Subcutaneous adipose tissue 
Fox 22589738 Visceral adipose tissue adjusted for BMI 
Fox 22589738 Visceral adipose tissue/subcutaneous adipose tissue ratio 
Fox 22589738 Visceral fat 
Franke 21102463 Crohn's disease 
Gieger 22139419 Platelet count 
Gieger 22139419 Mean platelet volume 
Gudbjartsson 18391951 Height 
Hromatka 25628336 Motion sickness 
Imboden 22424883 Pulmonary function decline 
Jostins 23128233 Inflammatory bowel disease 
Kaplan 21216879 Insulin-like growth factors 
Kapoor 24962325 Alcohol dependence (age at onset) 
Kottgen 23263486 Urate levels 
Lango 20881960 Height 
Lemaitre 21829377 Phospholipid levels (plasma) 
Lesch 18839057 Attention deficit hyperactivity disorder 
Li 26252872 Cognitive decline rate in late mild cognitive impairment 
Li 26301688 Pediatric autoimmune diseases 
Liu 26192919 Crohn's disease 
Liu 26192919 Inflammatory bowel disease 
Liu 26192919 Ulcerative colitis 
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Michailidou 23535729 Breast cancer 
Mozaffarian 25646338 Trans fatty acid levels 
Patsopoulos 22190364 Multiple sclerosis 
Perry 25231870 Menarche (age at onset) 
Porcu 23408906 Thyroid hormone levels 
Rietveld 25201988 Educational attainment 
Ripke 25056061 Schizophrenia 
Sawcer 21833088 Multiple sclerosis 
Shin 24816252 Blood metabolite levels 
Shin 24816252 Blood metabolite ratios 
Speedy 24292274 Chronic lymphocytic leukemia 
Suhre 21886157 Metabolic traits 
Surakka 25961943 Cholesterol, total 
Surakka 25961943 HDL cholesterol 
Surakka 25961943 LDL cholesterol 
Surakka 25961943 Triglycerides 
Teslovich 20686565 Cholesterol, total 
Teslovich 20686565 HDL cholesterol 
Teslovich 20686565 LDL cholesterol 
Teslovich 20686565 Triglycerides 
vanderHarst 23222517 Red blood cell traits 
Wain 21909110 Blood pressure 
Wang 20889312 Bipolar disorder and schizophrenia 
Willer 24097068 Cholesterol, total 
Willer 24097068 HDL cholesterol 
Willer 24097068 LDL cholesterol 
Willer 24097068 Triglycerides 
Wood 25282103 Height 
Yucesoy 25918132 Diisocyanate-induced asthma 
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Table II-4 | Minor Allele Frequency 
 25% 50% 75% 
Minor Allele Frequency 0.06 0.18 0.33 
Distance to TSS 9,553 39,530 154,279 
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Table II-5 | PR Curve Results 
 
Peak Space Signal Hindbrain Limb Midbrain Neural 
Tube 
Average 
DNase DNase  0.3761 0.393 0.3671 0.2884 0.3562 
H3K27ac H3K27ac  0.3266 0.3264 0.4072 0.2639 0.3310 
H3K4me3 H3K4me3  0.2034 0.1239 0.2406 0.1316 0.1749 
H3K4me1 H3K4me1  0.2036 0.2481 0.3044 0.1559 0.2280 
  N=20,000 N=20,000 N=20,000 N=20,000 N=20,000 
       
Peak Space Signal Hindbrain Limb Midbrain Neural 
Tube 
Average 
DNase  DNase  0.3788 0.4159 0.3797 0.2951 0.3673 
DNase  H3K27ac  0.3113 0.3265 0.3959 0.2526 0.3216 
DNase  Average Rank 
DNase-
H3K27ac  
0.3764 0.3948 0.4148 0.3050 0.3727 
DNase  H3K4me3  0.2276 0.1828 0.2602 0.1615 0.2080 
 Average Rank 
DNase-
H3K4me3  
0.2584 0.2392 0.2933 0.1751 0.2415 
DNase  H3K4me1  0.2442 0.2799 0.3122 0.1762 0.2531 
 Average Rank 
DNase-
H3K4me1  
0.2527 0.2647 0.2901 0.1740 0.2454 
DNase  H3K9ac 0.2367 0.1977 0.2756 0.1721 0.2205 
DNase Average Rank 
DNase-
H3K9ac  
0.2831 0.2574 0.3250 0.2147 0.2700 
DNase  H3K36me3  0.1910 0.1776 0.1911 0.1265 0.1715 
DNase  Average Rank 
DNase-
H3K36me3  
0.2280 0.2262 0.2212 0.1548 0.2075 
DNase  WGBS 
methylation** 
0.2470 0.2151 0.2663 0.1550 0.2208 
DNase  Average Rank 
DNase-WGBS  
0.3127 0.3031 0.3278 0.1981 0.2854 
DNase  H3K27me3** 0.2187 0.1964 0.1853 0.1285 0.1822 
DNase  Average Rank 
DNase-
H3K27me3  
0.2700 0.2750 0.2325 0.1664 0.2360 
 ** inverse of 
signal 
N=130,754 N=151,790 N=268,062 N=162,801  
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Table II-6 | Promoter Prediction 
Peak 
Space 
Signal Hindbrain Limb Midbrain Neural 
Tube 
Average GM12878 K562 HepG2 Average 
DNase DNase 0.3454 0.3643 0.3973 0.4714 0.3946 0.4904 0.3848 0.4024 0.4258 
DNase H3K4me3 0.7332 0.7472 0.7507 0.7488 0.7450 0.7152 0.7310 0.7084 0.7182 
H3K4me3 DNase 0.2364 0.2603 0.2239 0.1055 0.2065 0.4122 0.3016 0.2469 0.3202 
H3K4me3 H3K4me3 0.5551 0.6112 0.5691 0.5555 0.5727 0.5833 0.6012 0.5484 0.5777 
 
Peak Space Signal GM12878 K562 HepG2 Average 
DNase DNase 0.4904 0.3848 0.4024 0.4258 
DNase H3K4me3 0.7152 0.7310 0.7084 0.7182 
H3K4me3 DNase 0.4122 0.3016 0.2469 0.3202 
H3K4me3 H3K4me3 0.5833 0.6012 0.5484 0.5777 
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II.10 Figures 
 
 
 
Figure II-1 | ENCODE Phase III data production as of February 1, 2017 
Human and Mouse ENCODE Phase III experiments available on the ENCODE Portal. 
Experiments are categorized by the following assay and biosample types: blue for 
immortalized cell lines, red for tissues, teal for in vitro differentiated cells, orange for 
primary cells, purple for stem cells, and pink for iPSCs. 
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Figure II-2 | New assays used in ENCODE Phase III 
Using the 5' ends of RAMPAGE reads, we can identify TSSs and quantify tissue- and 
transcript-specific transcription. a, In testis, we identified a novel, tissue-specific TSS for 
ARHGAP23 upstream of previous annotated TSSs. b, In spleen, we identified a novel 
TSS within exon 7 of ARHGAP23.  
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Figure II-3 | RAMPAGE data signal at EP300 
RAMPAGE signals across six human tissues at EP300 demonstrate that both the 
GENCODE- and UCSC-annotated TSSs for EP300 are active.  
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Figure II-4 | DNA replication timing (RT) programs 
Genome-wide RT programs were obtained for distinct human cell types, including 
embryonic stem cell (hESC)-derived, primary cells and established cell lines representing 
intermediate stages of endoderm, mesoderm, ectoderm, and neural crest development. 
Solid arrow lines depict the in vitro differentiation pathways of the distinct cell types 
from hESCs; dashed arrows depict the embryonic origin of the cell types not derived 
from hESCs (primary cells and cell lines). Dataset and protocol ENCODE IDs are shown 
in blue and brown for each cell type. 
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Figure II-5 | DNA replication timing (RT) programs are cell type-specific 
a: Schematic diagram showing the three germ layers and the neural crest during the early 
stages of human development and differentiation pathways of the distinct cell types 
analyzed. b: Hierarchical clustering of RT programs from the distinct human cell types. 
Branches of the dendrogram were constructed based on the Pearson correlation 
coefficients between cell types (distance = 1 – correlation value). Clusters of cell types 
are indicated at the bottom: pluripotent, definitive endoderm (DE), liver and pancreas, 
neural crest and mesoderm cell types, neural precursors (NPC), myeloid and erythroid 
progenitors, and lymphoid cells. (NC) neural crest; (MED) mesendoderm; (DE) definitive 
endoderm; (LPM) lateral plate mesoderm; (Splanc) splanchnic mesoderm; (Mesothel) 
mesothelium; (SM) smooth muscle; (Myob) myoblasts; (Fibrob) fibroblasts; (MSC) 
mesenchymal stem cells; (NPC) neural progenitor cells. 
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Figure II-6 | New assays used in ENCODE Phase III 
c–d, Integrative analyses of RBP data can identify genetic variants that may impact RBP 
regulation. c, Control and RBFOX2 knockdown RNA-seq of exons 65–67 of the UTRN gene in 
HepG2 cells. Inclusion of the alternatively spliced exon 66 is reduced from 87% in control cells 
to 29% in RBFOX2 KD cells. d, (right) A strong RBFOX2 eCLIP binding peak in the 
downstream intron is consistent with this splicing factor enhancing inclusion of the upstream 
alternative exon. The minor allele of an ExAC SNP in the eCLIP peak in is expected to abrogate 
RBFOX2 binding as it abolishes the high affinity binding site determined from RNA Bind-n-Seq 
(RBNS). d, (left) Effect of the ExAC variant on the RBFOX2 binding site as determined from 
RBNS data. The G->C SNP in the eCLIP peak changes the most enriched 5-mer that likely 
mediates RBFOX2 binding (GCAUG R = 13.78) to a 5-mer with no detectable in vitro binding 
(CCAUG R = 0.89). 
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Figure II-7 | Overview of the ENCODE Encyclopedia  
Overview of the ENCODE Encyclopedia. The Encyclopedia consists of two levels 
(ground and integrative) which utilize data processed by the uniform processing 
pipelines. SCREEN integrates these data and annotations and allows users to visualize 
them on the UCSC genome browser  
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Figure II-8 | SCREEN display of gene and TSS expression levels. 
Left: Gene expression of EP300 from whole-cell RNA-seq assays shown in tags per 
million (TPM).  
 
Right: RAMPAGE signal at the TSS of ENST00000263253.7 (averaged over ± 50 bp 
window). Bars are colored according to the tissue of origin indicated on the left. 
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Figure II-9 | | Enhancer prediction using the average ranks 
For each tissue, we sorted DNase peaks by the average rank of the DNase signal (green) 
and the H3K27ac signal (yellow) and estimated enhancer boundaries using the 
overlapping H3K27ac peaks. 
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Figure II-10 | In vivo validation of ENCODE-predicted enhancers 
Shown are representative transgenic embryonic day 11.5 (e11.5) mouse images for all 
predicted enhancers that displayed reproducible activity in the expected tissue type. 
Enhancer predictions were performed using a combination of H3K27ac and DHS 
profiling for E11.5 mouse hindbrain, midbrain, and limb tissue. Predicted enhancers were 
selected for validation from three different rank classes (Top, Middle, Bottom) and tested 
for activity using transgenic mouse assays (see Methods for further details). Blue staining 
indicates enhancer activity, and the unique identifier below each embryo (mm number) 
corresponds to the name of the enhancer in the VISTA Enhancer Browser 
(www.enhancer.lbl.gov). 
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Figure II-11 | Validation rates 
Validation rates of 151 enhancer-like regions tested using transgenic mouse assays. Dark 
color indicates the region was active in the predicted tissue while light color indicates a 
lack of activity in the predicted tissue but with activity in other tissues.  
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Figure II-12 | Prediction of mouse embryonic enhancers 
c–e, Examples of enhancers (orange boxes) that were predicted based on DNase signal 
(green) and H3K27ac signal (orange) and validated in c, midbrain, d, hindbrain and e, 
limb. H3K27ac signal (yellow) in across tissues accurately predicts additional observed 
activity. 
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Figure II-13 | Selection of cREs  
 
We begin by clustering high quality 
DHSs (FDR > 0.1%) to create 
representative DHSs (rDHSs). For each 
assay (DNase, H3K4me3, H3K27ac or 
CTCF), we calculate a Z-score for every 
rDHS in a particular cell or tissue type. 
We then obtain the maximum Z-score 
across all cell types, known as the Max-
Z. Using the Max-Z as well as the 
distance to the nearest TSS, we classify 
cREs into three cell-type agnostic 
groups using the decision tree: cREs 
with promoter-like signatures (n = 
254,880), cREs with enhancer-like 
signatures (n = 991,173), and cREs 
bound by CTCF only (64,099). The total 
number of cREs is the sum of the three 
groups: 1,310,152. 
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Figure II-14 | Assignment of cREs to cell type-specific 9 state and 5 group 
b, Given a cell type (shown for GM12878), we assign cREs into nine states based on 
whether they have high Z-scores (> 1.64) for H3K4me3, H3K27ac, CTCF, and DNase in 
that cell type. Each cRE is either proximal (≤ 2 kb) or distal (> 2 kb) to the nearest 
GENCODE-annotated TSS, and the bar graph shows the tally for each state in GM12878. 
Icons mark the states to the left of the bars. Colored boxes (for proximal cREs) and pies 
(for distal cREs) represent high Z-scores while white ones represent low Z-scores. c, 
Assignment of cRE states to five groups: with promoter-like signatures, with enhancer-
like signatures, CTCF-only, DNase-only, and inactive. The bar plot shows the median 
ChIP-seq signal for POL2, EP300 and RAD21 in GM12878 for cREs in each category. 
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Figure II-15 | GM12878 cRE states 
Summary the cREs states, with each state further stratified by TSS proximity. The bar 
graph reveals that cREs with high H3K4me3 are mostly TSS-proximal, regardless of 
whether or not they have high H3K27ac or CTCF, while cREs with low H3K4me3 are 
mostly TSS-distal. 
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Figure II-16 | Overlap of cREs with chromHMM states 
In GM12878, we ranked cREs with a, promoter-like signatures 
and b, enhancer-signatures by H3K4me3 and H3K27ac Z-scores 
respectively. For each bin of 1 k cREs, we calculated the percent 
of cREs overlapping each chromHMM state.  
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Figure II-17 | General architecture of SCREEN 
ENCODE data is pre-processed by a C++ and Python pipeline before import into the 
PostgreSQL and Cassandra databases. SCREEN’s webserver is CherryPy-based and 
serves ReactJS and Redux UI code compiled by a Webpack server. The client renders the 
majority of the UI and communicates with CherryPy via AJAX requests. In addition to 
SCREEN’s own visualizations, links are provided to external resources including 
Ensembl, the UCSC Genome Browser, and GeneCards. 
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Figure II-18 | Core of SCREEN’s PostgreSQL schema 
Key icons indicate primary keys; U indicates a field guaranteed to be unique for a row; I 
indicates an indexed field; square brackets denote array types. The cREs themselves are 
stored in the hg19_cre_all table; identifying information (accession, coordinates) are in 
the top of the left column, with information related to conservation and nearby genes in 
the center and bottom left, respectively, and Z-scores for the core four marks in the right 
column. Indices for values in the Z-score arrays are stored in the 
hg19_rankCellTypeIndexex table’s idx field by assay (rankMethod field). Nearest 
gene_all (coding and non-coding) and gene_pc (coding only) IDs correspond to the 
hg19_gene_info table’s geneid field. 
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Figure II-19 | Overview of SCREEN cRE-centric search view 
Using the facets on the main search page (top), the user can retrieve cREs (center) by 
genomic coordinates and activity profiles in a particular cell type; here, two cREs active 
in K562 are shown on chromosome 11. Both cREs are marked with blue stars, indicating 
that they have high DNase and high H3K4me3, H3K27ac, or CTCF in the same cell type, 
i.e., they have "concordant" support. The top cRE is marked with a "P", indicating that it 
is promoter-proximal (within 2 kb of an annotated promoter); the bottom cRE is marked 
with a “D” for promoter-distal. Four colors correspond to high values (>1.64) for the four 
epigenetic signals: DNase (green), H3K4me3 (red), H3K27ac (yellow), CTCF (blue). 
Gray indicates a Z-score below 1.64 for the given mark. The cRE details view shows 
neighboring genes, bound transcription factors, and mini-peaks epigenetic signals 
(bottom left, shown here for the top cRE in the search table). A trackhub is custom built 
for visualizing a cRE or a gene and the supporting data using the UCSC genome browser 
(bottom right, top cRE from the table highlighted in blue).  
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Figure II-20 | Overview of SCREEN gene-centric view 
SCREEN’s gene-centric view provides RNA-seq and RAMPAGE derived expression 
levels for the genes and TSSs near the cRE of interest. c, SCREEN’s SNP-centric view 
displays cREs that overlap SNPs from published GWAS studies and lends insight into 
which cell types may be relevant to a particular phenotype. The top two cell types are 
shown for an inflammatory bowel disease GWAS study, along with two cREs active in 
CD4+ T-cells which contain SNPs from the study. 
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Figure II-21 | GWAS App 
The “Browse GWAS” button on SCREEN’s homepage (left) produces the GWAS app 
(right). Selecting a study displays the number of linkage disequilibrium blocks from the 
study which overlap a cRE, as well as the cell types with the most active cREs 
overlapping LD blocks. 
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Figure II-22 | Results are shown here for a 2012 IBD GWAS study 
Selecting a cell type produces a list of cREs active in the selected cell type which overlap 
SNPs from the study 
 
  
109 
 
 
 
 
Figure II-23 | SCREEN Search Results 
Results are shown here for a T-cell line from a 37 year-old male donor. The symbols in 
the left columns indicate that the top result, EH37E1089569, is proximal to a TSS (“P”) 
and is enriched for H3K4me3 (red), H3K27ac (yellow), and CTCF (blue) ChIP-seq 
signal. Clicking the SNP and gene links lead to the corresponding Ensembl and 
GeneCards pages, respectively; clicking the cRE link performs a search for that cRE. 
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Figure II-24 | SCREEN and UCSC Genome Browser 
The configure genome browser view (left), accessed via the UCSC buttons in the search 
results table, provides access to SCREEN’s custom UCSC Genome Browser trackhubs 
(right). Shown here are the condensed 5-group tracks for GM12878 and a T-cell line. 
EH37E1089569 is highlighted in blue within the browser, and shows strong H3K4me3 
and H3K27ac signal in the two selected immune cell types, with the 5-group tracks 
coloring EH47E1089569 red in these cell types to indicate that it is active and promoter-
like. The RefSeq tracks show that this cRE falls less than 1kb downstream of the first 
transcription start site and exon of LSP1. 
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a) 
 
b) 
 
Figure II-25 | SCREEN cRE Details View 
a. EH37E1089569 displayed in the locus-centric search app after following the 
link from the GWAS app. b. cRE details view for EH37E1089569 showing Z-
scores for H3K4me3 and CTCF, high in immune cells (left) and signal profile 
view revealing the underlying strong H3K4me3 and H3K27ac signals in various 
immune cell types (right). 
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Figure II-26 | Gene expression view for LSP1 
RNA-seq (left) reveals strong expression in immune cells (blood, red bars), spleen, and 
adrenal gland (gold bars); RAMPAGE (right) reveals that the TSS nearest 
EH37E1089569, corresponding to the first exon of LSP1, is most active in spleen. 
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Figure II-27 | SCREEN Differential Gene Expression 
Analyzing differential gene expression and cRE activity across developmental time 
points. a, Comparison between Limb e11.5 and e15.5 gene expression and cRE activity. 
Blue bars indicate differentially expressed genes while red and yellow dots indicate cREs 
promoter-like and enhancer-like signatures. The heights of bars or dots indicate changes 
(Log2 FC or difference in Z-score) between time points. c, Ogn gene expression and 
nearby cRE activity increase coordinately across time points. The increase in gene 
expression lags behind the increases in cRE-PLS and cRE-ELS activities. 
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Figure II-28 | Signals around Ogn locus 
Genome browser view of the Ogn locus with H3K27ac, H3K4me4, DNase, and RNA-seq 
signals for the limb across all surveyed time points. Promoter-like cREs are designated by 
red bars and enhancer-like cREs are designated by orange bars.  
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Figure II-29 | Overall cell type enrichments for variants reported by GWAS 
Heatmap indicates enrichment a -log(p-value) of the variants associated with each disease (rows) in 
cREs active in each cell type (columns). Activity is defined as H3K27ac Z-score > 1.64. Color values 
in each row are scaled per study. 
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Figure II-30 | Top cell type enrichments for variants reported by GWAS 
For each GWAS included in SCREEN, we report the cell or tissue type of which active cREs are 
significantly enriched in the disease variants. Cell types that do not meet FDR threshold of 0.05 are in 
gray. The majority of studies have multiple significantly enriched cell types but only the top hit is 
reported here. Traits listed multiple times are from different studies. 
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Figure II-31 | Annotating GWAS variants using SCREEN 
a, The user can select from a preloaded list of GWAS. For each study, we included all 
tagged SNPs it reported and all SNPs in LD with them (r2 > 0.7). b, SCREEN reports the 
percent of LD blocks of a GWAS with at least one SNP overlapping a cRE. c, SCREEN 
ranks cell and tissue types based on enrichment in H3K27ac signals. The top 5 cell and 
tissue types are displayed here for each study. d, The user can narrow the search by 
selecting a cell type, such as GM12878 for multiple sclerosis (MS), and analyze the 
overlapping cREs.  
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Figure II-32 | Annotating GWAS variants using SCREEN 
e, Zoomed in genome browser view of MS-associated SNP rs1250568, which overlaps an 
ELF1 ChIP-seq peak (blue box) and an ELF1 motif. f, Zoomed out genome browser view 
of the locus showing POL2 ChIA-PET links between rs1250568 and two genes ZMIZ1 
and PPIF. 
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Figure II-33 | SCREEN display of the ZMIZ1 gene and TSS levels 
a, Gene expression of ZMIZ1 from whole-cell RNA-seq assays shown in tags per million (TPM). b, 
RAMPAGE signal at the TSS of ENST00000472035.1 (averaged over ± 50 bp window). Bars are 
colored by tissue of origin indicated on the left 
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Figure II-34 | SCREEN display of PPIF gene and its TSS expression levels 
a, Gene expression of PPIF from whole-cell RNA-seq assays shown in tags per million (TPM). b, 
RAMPAGE signal at the TSS of ENST00000225174.3 (averaged over ± 50 bp window). Bars are 
colored by tissue of origin indicated on the left. 
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Figure II-35 | SCREEN display of AGAP1 expression levels 
a, In human. AGAP1 is expressed across many adult tissues. b, In mouse. Agap1 is primarily 
expressed in embryonic brain tissues. Expression values were calculated from whole-cell RNA-seq 
experiments and displayed in tags per million (TPM). 
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Figure II-36 | Fine mapping GWAS variants using SCREEN 
a, H3K4me3 and H3K27ac Z-scores for cREs containing SNPs in LD with the 
schizophrenia-associated SNP rs13025591. H3K4me3 Z-scores and H3K27ac Z-scores 
are displayed in red and yellow, for cREs with promoter-like and enhancer-like 
signatures respectively. 
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Figure II-37 | Fine mapping GWAS variants using SCREEN 
b, SCREEN's Activity Profile tool allows the user to view DNase peaks at cREs across 
all cell types. Both the human cRE EH37E0579839 and its orthologous mouse cRE 
EM10E0042440 show high DNase signals in developing brain and eye tissues. c, 
H3K27ac signal at EM10E0061453 over developmental time in mouse forebrain (red), 
midbrain (green) and hindbrain (blue). d, Zoomed-in view of EH37E0579839. The SNP 
rs13031349 overlaps both EH37E0579839 and the orthologous mouse cRE 
EM10E0042440. The SNP also overlaps an SP3 motif, resulting in a change in the motif 
score. 
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Figure II-38 | EM10E0042440 H3K27ac signal across mouse tissues 
H3K27ac signal measured as fold-change between ChIP and input is displayed across 12 
tissues and 8 time-points. Tissues without H3K27ac ChIP-seq data are left blank. The 
maximal height of signal is 10. 
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Figure II-39 | Method for normalizing epigenomics signals 
a, distribution of the H3K27ac signals at rDHSs from five cell types (B cell, Liver, K562, 
T cell, and GM12878; shown in different colors). b, Distributions of the Log of the 
H3K27ac signals in a. Individually, log(signal) values of the rDHSs in each cell type 
roughly follow a normal distribution. c, Distribution of the Z-scores corresponding to the 
log(signal) values in b. Zero signal values are assigned a Z-score of -10. 
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Figure II-40 | Precision-Recall (PR) curves for VISTA Enhancer prediction 
PR curves for a, limb, b, hindbrain, c, neural tube, and d, midbrain enhancers at e11.5. 
Colours indicate peaks and signals used for anchoring and ranking the enhancer 
predictions. All peaks were set to 300 bp centred on their summits and the 20k top-ranked 
peaks were used for each tissue to ensure consistent genome coverage. 
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Figure II-41 | PR curves for VISTA Enhancer prediction anchored on DHSs 
PR curves for a, limb, b, hindbrain, c, neural tube, and d, midbrain enhancers at e11.5. 
All predictions were anchored on DHSs in the respective tissue. Colours indicate signals 
used for ranking predictions; black indicates the average of DNase and H3K27ac signals. 
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Figure II-42 | Correlation of gene expression with epigenomic signals  
Scatterplots demonstrating correlation of expression with a) DHSs ranked according to 
the DNase signal (r = 0.34), b) DHSs ranked according to the H3K4me3 signal (r = 
0.73), c) H3K4me3 peaks ranked according to the DNase signal (r = 0.24), and d) 
H3K4me3 peaks ranked according to the H3K4me3 signal (r = 0.56). 
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Figure II-43 | POL2 signals for GM12878 cREs  
Violin plots show the average POL2 signal for cREs belonging to each of the nine cRE 
states. cREs proximal and distal to the nearest TSSs are displayed separately. Median 
values are displayed along with the number of cREs in each state. 
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Figure II-44 | EP300 signals for GM12878 cREs 
Violin plots show the average EP300 signal for cREs belonging to each of the nine cRE 
states. cREs proximal and distal to the nearest TSSs are displayed separately. Median 
values are displayed along with the number of cREs in each state 
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Figure II-45 | cRE states cluster into groups 
Scatterplots of a, the median EP300 signal or b, the median RAD21 signal vs. the median 
POL2 signal for each cRE state in GM12878. The size of an icon is proportional to the 
number of cREs in that state except for the inactive state. Proximal cREs are represented 
by square icons. Distal cREs are represented by circular icons. 
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Figure II-46 | POL2 signals at cREs  
Violin plots of POL2 signals for cREs with promoter-like and DNase-only signatures; 
these cREs belong to three states, and are stratified on the basis of whether the cREs are 
proximal (±2 kb) or distal to a GENCODE V19 TSS. p-values were calculated using a 
Wilcoxon test. 
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Figure II-47 | UCSC Genome Browser views of cREs around the HNF4a TSS 
Browser views of hepatocyte, bipolar spindle neuron, and B cell cREs in a, five-group 
and b, nine-state classifications, revealing that the promoter region of HNF4a is active in 
hepatocytes but not in neurons or B cells. 
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Figure II-48 | UCSC Genome Browser views of cREs around the SPI1 TSS 
Browser views of hepatocyte, bipolar spindle neuron, and B cell cREs in a, five-group and b, 
nine-state classifications, revealing that the promoter region of SPI1 is active in B cells but not in 
neurons or hepatocytes. 
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Figure II-49 | UCSC Genome Browser views of cREs around NPAS4 TSS 
Browser views of hepatocyte, bipolar spindle neuron, and B cell cREs in a, five-group and b, 
nine-state classifications, revealing that the promoter region of NPAS4 is active in bipolar spindle 
neurons but not in B cells or hepatocytes. 
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III. Chapter III: Factorbook V5: Peak-centric ENCODE 
Visualizer 
III.1 Preface 
This research chapter encompasses work performed in conjunction with Henry Pratt, 
Arjan van der Velde, Jill Moore, Eugenio Mattei, and Zhiping Weng, and is being drafted 
into a manuscript.  
Transcription factors (TFs) are DNA-binding proteins that regulate transcription 
of genetic information from DNA to RNA. TFs have activating or repressive activity via 
many potential mechanisms, and differential TF binding dependent upon cell type 
specificity, phase of development, and experimental design. I found that better 
understanding of TF binding is critically necessary for not only elucidation of gene 
regulation through building transcription factor network models (Rieck and Wright 
2014), but also for increased comprehension of disease mechanisms, such as TF binding 
changes found in cancer (Liu et al. 2017).  
Factorbook originated in the Weng lab several years before I joined (Wang et al. 
2013), but was years out of data with the experimental data being collected at ENCODE, 
and lacked many of the analysis products and data visualizations needed to better 
investigate TFs. I completely rewrote and re-implemented Factorbook, tripling the 
number of TF datasets in humans, and entirely adding the mouse component. By 
expanding and redesigning the heatmap comparisons component of Factorbook, I greatly 
added to the ability to compare binding patterns of TF in relation to other TFs and histone 
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modifications. I am also one of the first to incorporate crowdsourcing to rate and 
comment on motifs. This feature will become a critical feature, as many motifs found by 
the common de novo motif discovery packages are invalid, and cannot, with total 
accuracy, be filtered by machine. Having a collection of motifs validated by experimental 
literature and manually curated will be invaluable for future work in deciphering how, for 
example, SNPs modulate TF binding.  
III.2 Introduction 
Factorbook is a pack-centric data visualizer for ChIP-seq and DNase-seq experiments 
from ENCODE. The tool, now more than 5 years old, has undergone numerous 
improvements and expansions since its original inception (Wang et al. 2013; Wang et al. 
2012). The site now encompasses both human and mouse for more than 2,000 ChIP-seq 
transcription factor (TF) experiments, more than 4 times the number of experiment in 
Factorbook V1. The pipeline for analyzing these experiments has been drastically 
expanded, and produces >16TB of analysis products, taking >10 years of total compute 
time (>1 week on 500 CPUs) to run on a high performance compute cluster. The 
Factorbook user interface has been completely rewritten, incorporating the knowledge 
and experience gained from implementing SCREEN, our visualizer for candidate 
Regulatory Elements (cREs) for ENCODE (see II.5 SCREEN: A Web Engine for 
Searching and Visualizing cREs on page 36).  
We have developed several workflows over the past few years. The Factorbook 
workflow for processing ChIP-seq datasets now encompasses all steps needed to take raw 
data, find sites of signal enrichment and sequence similarity, aggregate and analyze these 
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data, and finally produce downstream JSON data products suitable for D3 visualizations 
in a user’s web browser (Bostock, Ogievetsky, and Heer 2011). The pipeline produces 
more than 10 million separate data products for factorbook.org, and requires >60,000 
compute jobs. This workflow has proven an essential tool to better elucidate epigenetic 
regulation of the genome, and could be utilized for other types of data by other 
researchers. Using our insights gleaned from developing the Factorbook workflow, we 
have also extensively reworked and refactored the ENCODE ChIP-seq processing 
pipeline to better suite our computing environment. This pipeline is now also being 
utilized by psychENCODE to process all ChIP-seq data. Our workflow pipelines are also 
open-sourced are also open-sourced on GitHub (github.com/weng-lab) using Apache, 
MIT, or GPL licenses. The workflows are also developed to run on Linux, FreeBSD, or 
Mac OS X, and only utilize open-source external tools. 
III.3 Methods 
To accommodate the large expansion of ChIP-seq TF and histone data from ENCODE2 
and ENCODE3, we have completely redesigned our analysis pipeline. Utilizing 
SnoPlowPy as the metadata core, we then developed a flexible pipeline for Factorbook 
that would permit us to develop and test the pipeline, then run it on large multi-core 
machines or on a cluster. The pipeline has more than a dozen stages, with each stage 
spawning 100s to 1000s of jobs. For more information on our solution for managing 
these jobs, see Chapter V: SnoPlowPy: Advanced ENCODE Data Manipulation Tool on 
page 205. The Factorbook TF pipeline works as follows. First, using the SnoPlowPy 
metadata system, all required data files from ENCODE DCC are downloaded. These files 
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include ChIP-seq signal files in Jim Kent's BigWig format (Kent et al. 2010) that indicate 
fold change signal level over control genome-wide. Narrow peak files from the ENCODE 
DCC processing pipeline are also downloaded. These files indicate genomic regions 
where fold change signal strength exceeds that of computed background, using MACS2 
peak calling algorithm. In addition, these peak files have been further filtered using the 
Irreproducibility Discovery Rate (IDR) framework, an algorithm that compares peak 
ranking across files, allowing one both measure consistency across biological and/or 
technical replicates, as well as determine a significance threshold to keep only peaks that 
are reproducible (Li et al. 2011). 
Next, for all ChIP-seq experiments, the pipeline performs de novo motif discovery 
using the MEME-ChIP software suite (Machanick and Bailey 2011). Discovery is 
performed on 100-basepair regions centered on the summits of the top 500 ChIP-seq 
peaks as determined by signal rank. Up to five motifs are discovered for each set of 500 
regions. To accommodate for the TF peak summit being offset from the true center of the 
motif, as well as to potentially find multiple motifs near, if not at, the peak summit, we 
have expanded our pipeline to perform a sliding-window de novo MEME-ChIP motif 
search. This discovery is performed for regions centered from 1 to 30 basepairs to the left 
of the top 500 peak summits and from 1 to 30 basepairs to the right of peak summits. The 
resulting sets of sliding-window motif logos are displayed via drop down menus (Figure 
Figure III-4 on page 148). 
Furthermore, we have performed motif filtering, as well as kmedoid cluster 
analysis, across these sliding-window motifs, as well as across all experiments for a given 
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TF (Wang et al. 2012; Wang et al. 2013). Motifs are assessed for quality using the FIMO 
tool from the MEME software suite (Bailey et al. 2009). The regions used to generate 
each set of five motifs constitutes a “training set” during FIMO analysis. For each 
training set, we generate a “testing set” consisting of 300-basepair regions centered on the 
summits of the top 501-1000 ChIP-seq peaks ordered by signal rank. We also generate 
one hundred “control sets” per training set consisting of 500 randomly-sampled GC-
matched regions of the genome that do not overlap the training set regions. We then use 
FIMO to determine the average number of control set regions containing the five 
discovered motifs per control set and the number of testing set peaks containing the five 
motifs. The number of testing set occurrences for each motif is tested against its normal 
distribution for the control sets; motifs not meeting an FDR threshold of 1e-5 are 
considered to have failed quality assessment and are grayed out on final display. 
Motifs are further assessed for quality by comparing the number of occurrences of 
the motifs within 300-basepair regions centered on all peaks ranked 501 and above 
(“testing set 2”) versus 300-basepair regions directly flanking the testing set 2 regions on 
either side (“control set 2”). Motifs that do not occur in at least 10% of testing set 2 
regions or whose ratio of testing set 2 occurrences to control set 2 occurrences is not at 
least 1.25 are considered to have failed quality assessment and are grayed out on final 
display. 
The motifs from all 61 offsets are grouped using kmedoid clustering (Romer, 
Kayombya, and Fraenkel 2007). Distance between individual motifs is computed by first 
determining the optimal alignment of the two motifs and then calculating the average 
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difference between values within the two motifs’ position weight matrices, trimmed to 
the length of the shorter motif. Average motifs are produced for each cluster by averaging 
the position weight matrices of the member motifs, trimmed to the length of the shortest 
member motif. These average motifs are displayed as an overview of all the motifs 
discovered for each experiment. Averaged motifs are also indexed to allow a full-text 
search for motifs of interest, and clicking on an individual motif provides a list of the 
most similar motifs discovered in other experiments. 
Motif discovery is one of the most time-consuming stages of the pipeline, with 
runs taking ~12 hours per experiment. During this stage of the pipeline, jobs are spawned 
to compute the background distributions needed for later automated filtering of motifs. A 
large number of small files are produced during this stage. To combat inefficiencies in 
storing and transferring these small files, the entire MEM-chip runs for each ChIP-seq 
experiment is combined into one tar file. This tar file will be utilized directly by the 
Factorbook website backend later. These files are also highly compressible, often being 
compressed to 60% of their original size. Our analysis, though, is still highly 
computationally expensive, and our current computational model poses a number of 
challenges. Moving the computational demands of these large-scale projects to the cloud 
would provide a unified environment which would facilitate collaboration between 
ENCODE groups, improve reproducibility, and allow for greater flexibility in optimizing 
pipeline parameters and resource usage. Cloud-storage of data would save time, improve 
security, and facilitate access control among groups. As such, we will soon start 
developing ENCLOUD, an ENCODE-related Cloud Compute Engine, that will allow us 
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to fully move the pipeline to the Amazon and/or Google clouds. We recently were 
awarded a NIH Commons Credits to implement this environment.  
All of the tools and pipelines we develop are open-sourced on GitHub 
(github.com/weng-lab) using Apache, MIT, or GPL licenses. The tools are developed to 
run on Linux, FreeBSD, or Mac OS X, and only utilize open-source external tools. The 
software languages utilized are typically Python, C++14, or BASH, and are designed in a 
modular fashion to promote reuse and repurposing. Input and output data formats follow 
those allowed by the UCSC Genome Browser1, with PostgresQL open-source relational 
databases often used to store metadata. Our tools are currently designed to work on 
ENCODE data (~200TB of data). We are developing FAQs and user documentation for 
our tools using pydoc and doxygen. Most tools are designed to automatically scale when 
run: jobs can be tested on a single computer with 1 or many cores, and then be deployed 
on our cluster to run in parallel on hundreds of datasets. 
III.4 Uses 
Factorbook utilizes a menu-based user interface to categorize and organize the data 
analysis products the user can view; an example of its overall structure is presented in 
Figure III-1 on page 145. The first ChIP-seq TF page the user sees (Figure III-2) shows 
the TF grid, an alphabetized matrix of TFs (as rows) and biosamples (as columns). Cells 
in the grid with integers indicates the number of ChIP-seq experiments available for that 
TF for a given biosample. Clicking on the TF name or the cell integer brings the user to 
the next level of Factorbook, the TF Function page. This page shows information about 
                                                 
1 https://genome.ucsc.edu/FAQ/FAQformat 
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the TF, including a brief overview of its molecular function, one or more 3D structures of 
the TF from the Protein Data Bank (Berman et al. 2000), and mined from online 
references, including RefSeq (Pruitt, Tatusova, and Maglott 2005) and Gene Card 
(Stelzer et al. 2002). Next, the user can select the Histone Profiles menu (Figure III-3); 
here, averaged, aggregated profiles of histone modifications are displayed on a +/- 2kb 
(inclusive) window around TF peak summits (when available from the MACS2 
NarrowPeak pipeline) or in the center of the peak. The aggregation profiles are organized 
by distance to the nearest TSS, with proximal profiles have peaks within 1 kb of a TSS, 
and the distal profiles grouping all other peaks. Similarly, on the Nucleosome Profiles 
page (Figure III-7), averaged, aggregated profiles of MNase data for GM12878 
and K562 are displayed.  
Next, we have the Motif menu entry (Figure III-4), which displays the top 5 
motifs from MEME-ChIP, their e-value scores, sequence, the number of peaks in the top 
500 peaks had that motif, as well as our filtering information. Lastly, we have heatmaps 
for histones and TFs (Figure III-5 and Figure III-6). Here, users can compare a given TF 
in a specific cell type against the histone marks and other TFs in same cell type. Each 
column in a heatmap row indicates a ChIP-seq peak of the currently selected (“pivot”) 
TF. For each heatmap row, columns are sorted by descending order of ChIP-seq fold-
change signal (from the BigWig file). On the page, heatmap rows themselves are sorted 
by decreasing Pearson correlation value. Histone heatmaps enrichment is represented in a 
normalized scale over a 10kb window centered on the peak summit (for NarrowPeaks) or 
on the center of the peak. Likewise, for TF heatmaps, binding strengths are represented in 
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a normalized scale over a 2kb window, also centered on the peak summit (or peak 
center).  
III.5 Discussion 
Factorbook is a web-based analysis tool that integrates all public ENCODE ChIP-seq 
transcription factor, histone, and DNase-seq data. Factorbook is peak-centric, with peak 
data being summarized and displayed in several different manners. For TFs, aggregation 
plots display average histone mark signals in a +/-2kb regions centered on TF peak 
summits; peaks are separated by their distance to the nearest TSS, with proximal peaks 
being defined as being within 2kb of a TSS, and the distal peaks being all remaining 
peaks. Nucleosome profiles show the effect of TF binding on the location of nucleosomes 
using MNase-seq data, and peaks are similarly split into proximal and distal by TSS 
distance.  
Factorbook has become a canonical resource for TF motif information; it has been 
cited by more than 127 publications2, its motif tracks have been integrated into the UCSC 
Genome Browser (Rosenbloom et al. 2015), and it is even being mined for machine 
learning competitions (Keilwagen, Posch, and Grau 2017). Factorbook’s centralization of 
ENCODE TF motif information has assisted finding many biological insights. Recently, 
Factorbook motifs assisted the search for SNPs that could disrupt TF binding in chronic 
lymphocytic leukemia (Law et al. 2017). Likewise, gene regulatory networks have been 
built incorporating RNA-seq data with Factorbook motifs to better elucidate breast 
cancer-related TF networks (Janky et al. 2014).  
                                                 
2 https://scholar.google.com/scholar?cites=16586749045503397316&as_sdt=40000005&sciodt=0,22&hl=en 
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III.6 Figures 
 
 
Figure III-1 | Factorbook TF UML 
Overview of the TF portion of the Factorbook online database. Figure created by 
(Cloutier, Kpodjedo, and Boussaidi 2016) 
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Figure III-2 | Factorbook: ChIP-seq TF Index 
Home page of Factorbook, showing the sparse grid of TFs (running vertically) vs 
biosamples (running horizontally). The numbers in each non-zero cell indicate the 
number of TF experiments available for that particular TF in the given biosample.  
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Figure III-3 | Factorbook: Histone Profiles 
Average histone modification profiles are shown for the [-2 kb, +2 kb] window around 
the summits of TF ChIP-seq peaks. Profiles are shown separately for peaks that are 
proximal ([-1 kb, +1 kb]; ending in '-p') to an annotated transcript start site (TSS) and for 
peaks that are distal (>1 kb; ending in '-d') to all annotated TSS. TSS-proximal profiles 
are arranged such that the nearest transcript proceeds towards the right. (Wang et al. 
2013) 
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Figure III-4 | Factorbook: Motifs 
The top 500 TF ChIP-seq peaks were used to identify enriched motifs de novo, using the 
MEME-ChIP suite of tools. Up to five motifs are reported (1 to 5) if they meet the criteria 
defined by our filtering pipeline. (Wang et al. 2013) 
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Figure III-5 | Factorbook: Histone Heatmaps 
ChIP-seq peaks (left to right in the heatmap) for the current TF are sorted by descending 
TF ChIP-seq signal. The ChIP-seq signals of histone modifications are plotted for the 
genomic regions that correspond to the peaks of the current TF in the same order. (Wang 
et al. 2012) The Pearson correlation coefficient (r) of the histone modification ChIP-seq 
signal with the TF ChIP-seq signal is also computed.   
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Figure III-6 | Factorbook: Transcription Factor Heatmaps 
ChIP-seq peaks (left to right in the heatmap) for the current TF are sorted by descending 
TF ChIP-seq signal. ChIP-seq TF signals are plotted for the genomic regions that 
correspond to the peaks of the current TF in the same order. (Wang et al. 2012) The 
Pearson correlation coefficient (r) of the TF ChIP-seq signals signal is also computed.   
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Figure III-7 | Factorbook: Nucleosome Profiles 
Average nucleosome occupancy profiles in GM12878 and K562 cells are shown for the 
[-2 kb, +2 kb] window centered on the summits of the TF ChIP-seq peaks, separately for 
peaks that are proximal to an annotated transcription start site (red lines) and for peaks 
that are distal to all annotated transcription start sites (blue lines), as defined in the 
Histone section. (Wang et al. 2012) 
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IV. Chapter IV: Machine Learning Epigenomic Data 
IV.1 Preface 
This research chapter encompasses unpublished work performed primarily in conjunction 
with Arjan van der Velde and Zhiping Weng, along with Bill Noble, Sowmya Iyer, Jill 
Moore, Anurag Sethi, and Eugenio Mattei.  
Locating sites with non-random, potentially functional sequence is a 
computational problem more than 20 years old (Bailey and Elkan 1994). The importance 
of locating a subclass of these non-random sequences—transcription factor binding sites 
(TFBSs)—is increasing, as the number, cost, and complexity of generating perhaps 
millions of ChIP-seq TF experiments to cover all possible cell and tissues types, 
developmental time points, and experiment conditions is obviously becoming intractable 
(Ebert and Bock 2015). I saw applying supervised machine learning techniques that 
incorporated the large volume of ChIP-seq data ENCODE already had collected as a 
potential new avenue to whole-genome prediction of TFBSs. Previous supervised and 
unsupervised models focused on DNA sequence features, conservation, etc., but did not 
incorporate expensive, hard-won experiments already collected. Additionally, I was the 
first to perform base-pair resolution prediction across the whole genome on across 
hundreds of datasets. Most previous approaches used genomic binning to reduce the 
computational burden in time and space. I was able to apply techniques I learned from 
this approach to other large-scale data problems, such as predicting enhancer activity. 
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IV.2 Imputation of ChIP-seq TF Data 
IV.2.1 Introduction 
Transcription factors (TFs) are proteins that regulate transcription of genetic information 
from DNA to RNA. Typically having multiple functional domains, TFs can activate or 
repress transcription via many mechanisms: they may complex with other TFs (Maston, 
Evans, and Green 2006), RNA polymerase II, chromatin remodeling complexes, and/or 
noncoding RNA molecules (Phillips 2008). DNA-binding TFs recognize short (6-15 base 
pair) sequence motifs in the genome. These motifs are highly conserved evolutionarily. 
Particular instances of the motif in genomic DNA that a TF binds to are called motif sites 
or TF binding sites. TF binding regions in living cells can be mapped genome wide using 
the ChIP-seq technique—chromatin immunoprecipitation using an antibody specific for 
the TF, followed by deep sequencing of the genomic DNA (Johnson et al. 2007). Public 
databases such as the Cistrome Project have indexed more than 7,000 ChIP-seq datasets 
(Liu et al. 2011). With thousands of different DNA-bound TFs in the human genome 
(Wilson et al. 2008), there are large numbers of TFs for which no ChIP-seq currently 
exist. This situation is compounded by differential TF binding dependent upon cell type 
specificity, phase of development, or experimental design. Lack of a detailed overview of 
TF binding and interactions with other molecules has hampered development of a more 
comprehensive understanding of regulation and limited development of transcription 
factor network models (Rieck and Wright 2014). To overcome these limitations, several 
different models for predicting TF binding sites have been pursued (Pique-Regi et al. 
2011; Elemento and Tavazoie 2005). Input data for these models typically include 
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sequence information, DNase-seq data, and/or histone modification data (Cuellar-Partida 
et al. 2012; Sherwood et al. 2014). 
These models, though, don’t exploit the hundreds of experimental ChIP-seq 
datasets already collected to improve model prediction; ChIP-seq data was only used to 
benchmark the predictive ability of the computational models. Recently, machine 
learning algorithms have been used for enhancer prediction (Erwin et al. 2014) and 
imputation of complete signal tracks for ChIP-seq histone marks (Ernst and Kellis 2015b) 
with great success. Locations of TFBSs inherently varies across cell types and 
experimental conditions. However, many TFs exhibit binding similarity that can be 
exploited in predicting TFBS in other cell types. Machine learning models can exploit 
these similarities in binding or open chromatin to build models predicting TF binding.  
Historically, several different models for predicting TF binding sites have been 
pursued, with limited success (Pique-Regi et al. 2011; Elemento and Tavazoie 2005). 
One major shortcoming of these predictive models is the restriction of input data to 
sequence information, DNase-seq data, and/or histone modification data (Cuellar-Partida 
et al. 2012; Sherwood et al. 2014); when utilized, ChIP-seq data was only used to 
benchmark the predictive ability of the computational models. These models all assume 
TFs bind to DNA directly, and at canonical motif sites. Direct use of TFBS motif 
sequence with DNase-seq data is insufficient to capture the complexity of TF binding 
(Farnham 2009). TFs may: a) directly bind DNA as well as another TF; b) only bind 
another TF; c) bind DNA after stabilization by another TF; or d) bind DNA after other 
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molecules create a more favorable chromatin state. No software package as of yet is 
accurate enough to displace the need for ChIP-seq experiments.  
Accurate prediction of TF binding sites could eliminate the need for large 
numbers of ChIP-seq TF experiments on new cell types, and allow experimentalists to 
focus on a core set of experiments (composed, at the minimum, of DNase-seq and a core 
set of ChIP-seq experiments). These data, combined with cell type genomic sequencing, 
etc. accurately predict TFBS for all other TFs in that cell type. Additionally, these models 
could also be used to impute data values for missing or noisy data in previously run 
experiments and improve overall experimental accuracy. Accurate TF motif site data 
would potentially allow construction of more comprehensive models of TF binding 
during development or disease states (Maurano et al. 2012; Rieck and Wright 2014). For 
example, models could be run on cancer biopsy samples to determine what TFs are 
involved in producing the disease state, thus allowing development and selection of 
future therapeutic interventions that target the epigenome.  
IV.2.2 Methods 
IV.2.2.1 Epigenetic datasets 
In this study, we used all publicly available ENCODE data and downloaded from the 
ENCODE consortium website (Sloan et al. 2016); Figure IV-1 on page 179 shows a part 
of the ENCODE TF matrix. We selected all cell types in which at least one DNase-seq 
experiment and at least one ChIP-seq TF experiment were available. We downloaded 
bigwig files of raw signal data. For the datasets with multiple biological replicates, we 
averaged the bigwig files of raw signal data across the replicates. For ChIP-seq TF 
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datasets, we also downloaded the peak files generated using the ENCODE uniform 
processing pipeline (Consortium 2012). When multiple ChIP-seq TF experiments were 
available for a given cell type and TF, we chose one by lab preference and the most 
recent experiment. We also download the corresponding JSON metadata and parsed them 
using SnoPlowPy. We used the HG19 reference genomic sequence, downloaded from 
UCSC Genome Browser.  
IV.2.2.2 Preprocessing 
We preprocessed all signal and peak files to reduce memory and I/O intensity of later 
model-building steps. These data files were split by chromosome, processed, and stored 
in custom binary memory-mapped (citation?) files using custom C++ software. For 
DNase-seq, bigwig signal files were read using the UCSC genome browser utilities 
library, smoothed using a MJP base-pair sliding window, normalized, and thresholded 
based upon background signal levels. A similar process of smoothing and normalizing 
was applied to ChIP-seq TF data files. Additionally, per-base FIMO scores (Grant, 
Bailey, and Noble 2011) for all TFs were computed using position weight matrices 
(PWMs) from Factorbook. Regions of the human genome that were either IDR 
blacklisted (Li et al. 2011) or ambiguous were assigned the average signal level in a MJP 
window during preprocessing, and later excluded from analysis. Pearson correlation 
coefficients of DNase-seq data were computed per chromosome over 10 kb bins for all 
pairs of cell types; these values form an estimation of cell type similarity, and are used 
during feature selection. 
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IV.2.2.3 Features  
Two features were formulated for each DNase-seq and ChIP-seq dataset, one feature 
representing the average signal over a 200-bp window centered on each genomic 
position, and one feature quantifying the percent of the window that contained signal 
above the threshold determined during pre-processing. We used one feature for FIMO 
scores: the maximum FIMO score in a 200 bp window centered on each genomic 
position. In addition, we computed the average ChIP-seq signal for each TF by averaging 
all ChIP-seq signal tracks for a particular TF across all available cell types (excluding the 
testing and training cell types). Potential motif sites from the JASPAR, TRANSFAC, and 
UniPROBE databases were retrieved, and motif binding prior probabilities computed for 
each motif using FIMO (Grant, Bailey, and Noble 2011). Mono- and di-nucleotide 
frequencies were also computed for the hg19 human genomic sequence. 
We performed feature selection in several stages to evaluate the contribution of 
each feature to the overall model performance. Figure IV-2 on page 180 demonstrates the 
iterative approach to adding a new feature, then reevaluating the model. For each stage, 
training and testing were performed using the same set of features, but in two different 
cell types. For example, we may train a model based on the DNase-seq and E2F1 ChIP-
seq datasets to predict CTCF binding in GM12878 cells, and then test this model using 
the DNase-seq and E2F1 ChIP-seq datasets to predict CTCF binding in HepG2 cells. 
IV.2.2.4 Model building 
In supervised learning, the learning algorithm used for model training is given input 
training data (as described above), as well as the desired output data the algorithm is to 
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attempt to match. This approach will be performed genome wide on base-pair resolution, 
with a set of features computed for each base. 
Logistic regression is a canonical binary classifier. Logistic regression computes 
the probability P(output is true | input data) for each sample in the input dataset. For an 
intuitive explanation of how the model works, consider an input dataset x: logistic 
regression will take x and assign a weight (𝛽) to each piece of data in x such that the 
(hypothesis) function 𝛽0 + 𝛽1x1 + 𝛽2x2 + … = 𝛽
Tx can be converted to a probability by 
the logistic (or sigmoid) function 
1
1+𝑒−𝑎
=
1
1+𝑒−(𝛽0+𝛽1x1+⋯ )
. For example, for our logistic 
regression model to predict TF binding probability at a base b, the hypothesis function 
would equal (bias constant) + (average DNase-seq data at base b over a given window) + 
(% of window with DNase-seq data > threshold) + (average TF1 data at base b over a 
given window) + (% of window with TF1 > threshold) + [remaining features]. More 
technically, logistic regression will ultimately find a decision boundary that separates the 
input data samples into two categories. Solving the weights in the hypothesis function can 
be computed by transforming the problem into a numerical minimization problem that 
can be solved using methods such as Newton’s method. Logistic regression models can 
be rapidly trained on large datasets using software such as LIBLINEAR, and provide a 
good performance baseline. 
In addition to logistic regression, we also trained Support Vector Machines 
(SVMs) to locate TFBSs. Like logistic regression, SVMs work by finding a decision 
boundary that separates the input data into two classification categories. Unlike logistic 
regression, though, SVM will find a decision boundary that maximizes the minimum 
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distance from the samples; finding this “large margin” occurs as a consequence of the 
optimization function used in SVM (Marsland 2009). Another consequence of this 
optimization function is the ability to transform the input data to improve the margin 
between categories; these kernel functions allow transformation of input data into higher-
dimensional space in a computationally cost-effective (i.e. linear) manner (Marsland 
2009). Many different kernel functions exist, giving SVMs a rich parameter space; this 
may be particularly useful for finding relationships between data experiments when 
learning TFBSs. The core optimization problem to be numerically solved in SVMs can be 
solved in polynomial time using quadratic programming, making SVM efficient. SVM 
software packages capable of handling large datasets include LIBLINEAR and SVMlin 
(Sindhwani and Keerthi 2006). We ultimately found little performance difference 
between logistic regression and SVM, and moved on to gradient boosting. 
We also used boosting methods to perform supervised learning. In boosting, a 
collection of simple predictive classifiers are combined by a weighting or voting system; 
this allows the predictive power of the group of learning methods to exceed the predictive 
power of any individual predictors. Boosting happens sequentially: early classifiers make 
simple predictions; these predictions are then analyzed, and training of later classifiers 
focuses on the errors made earlier. Errors made by early predictors indicate data samples 
that are difficult to predict. Ultimately, very simple predictive methods get convolved 
into a complex, weighted classifier. For example, AdaBoost, an early and now canonical 
boosting algorithm, uses an adaptive approach to boosting. Initially, all data samples are 
weighed equally. After each stage of prediction, before weight renormalization, samples 
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that were erroneously classified get additional weight, while the weights for samples 
correctly identified are left unchanged (Marsland 2009). Data samples that are incorrectly 
predicted receive more weight in an attempt to minimize error. Gradient boosting applies 
the same technique to regression: a basic regression is first made, the error residual is 
calculated, and the next regression step attempts to reduce the fitting error. Boosting may 
also be quite helpful for the experimental datasets being used, given that each dataset 
may only contribute a small amount of information towards predicting TFBSs. For 
boosting, we evaluated several packages, starting first with rt-rank, an open-source 
package with several different boosting algorithms designed for large datasets (Mohan, 
Chen, and Weinberger 2011), and ultimately used xGBoost (Chen and Guestrin 2016). 
The volume of data processed did require extensive time and compute resources. 
The time complexity for logistic regression on a single compute core is O(sf2 + f3), where 
s represents the number of training samples and f the number of features; SVM has a 
runtime of O(s2f) (Chu et al. 2006). There are several possible strategies to reduce 
runtime. The first and simplest is to train and test the models on a single chromosome 
instead of working genome wide; this immediately reduces the sample number from 
3x109 samples to ~1.5x108, with corresponding reduction in time and memory usage. 
Further reduction in time and memory, though, was required, and achieved by sampling 
on just a subset of the training data; in-house experiments indicated training on 10 million 
samples for a small (<50) number of features does not adversely affect the model 
accuracy; additional bootstrapping techniques could also be used. Additionally, training a 
model on a single chromosome, and then using that model to test on the rest of the 
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genome, also reduced the time cost of training a separate model for every chromosome, 
without dramatically changing aucPR. Parallel programming techniques were also used 
to speed up parts of the supervised learning pipeline; data preparation (such as 
windowing and normalization) benefited from straightforward applications of 
programming libraries such as OpenMP (Eichenberger et al. 2014).  
We built L1-regularized logistic regression models as implemented by the 
LIBLINEAR software package (Fan, Chang et al. 2008). For each chromosome, we 
randomly selected 15% of the genomic positions as training data, with the ratio of bound 
to unbound TF sites preserved. We then applied the trained model predict a binding 
probability for every genomic position per target TF in a different cell type. We did not 
use more than 15% genomic positions in the training cell type because the complexity of 
our models did not require more training data. We also utilized xGBoost to implement 
gradient boosting models. 
IV.2.2.5 Performance evaluation 
All models trained output a probability of a transcription factor binding at each base 
position in the genome. Traditionally, a confusion matrix could be created with the total 
number of true positive, true negative, false positive and false negative predicted given a 
probability cutoff threshold, and thus leading to calculation of a sensitivity, specificity, 
positive predictive value, etc. for each model. Metrics such as receiver operator 
characteristic (ROC) and precision-recall (PR) curves, however, allow better 
characterization and visualization of model performance, as the cutoff threshold is moved 
through the range [0,1]. ROC curves plot false positive rates vs true positive rates (aka 
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sensitivity), demonstrating how the number of correctly predicted examples varies with 
the number of incorrectly predicted negative examples. The area under the ROC curves 
(after being normalized) signifies the probability that the classifier will classify a 
randomly chosen positive sample higher than a randomly chosen negative sample. In PR 
curves, the true positive rate (sensitivity) is plotted vs the positive predictive value (aka 
precision).  
Mathematically, so long as models are predicting on the same datasets, ROC and 
PR curves are inter-convertible, and curves that dominate in ROC space will also 
dominate in PR space (Davis and Goadrich 2006). What distinguishes use of one curve 
over another (for our purposes) is how each curve visualizes highly asymmetric datasets. 
Given that <1% of a chromosome will have binding sites for a particular transcription 
factor, the set of negative examples for each model constitutes the majority of what must 
be predicted. In asymmetric data cases like these, PR curves offer a better way of 
representing actual performance of the models (Davis and Goadrich 2006). 
While building models on a per-base resolution permits maximum resolution, 
ultimately the output binding probability vector for a given model is scaled and run 
through a peak caller such as MACS2 (Zhang et al. 2008). This permits direct visual 
comparison between the predicted data and actual experimental data, as shown in Figure 
IV-5 on page 183. Peak overlaps between predicted and actual ChIP-seq data can then be 
computed. A smoothing process was applied to the prediction vector. 
Ultimately, for each TF in each cell type, we custom built a model by selecting all 
available features based on ENCODE data. Other available TFs in the cell type were 
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used, given the potential interaction of other TFs in the cell type with the desired TF. 
Also, the same TF from other cell types was used, since there is some correlation 
between the same TF in different cell types.  
We evaluated the performance of the model by comparing the binding 
probabilities computed by the model with the peaks called from the ChIP-seq data of the 
TF in the corresponding cell type. We initially plotted precision-recall (PR) curves at 
nucleotide resolution using ROCR (Sing et al. 2005), but this method was extremely 
slow. Given that a chromosome may have up to 250 million bases, a naïve algorithm to 
calculate the PR curve will also output millions of points to plot. We implemented a 
custom algorithm to generate PR curves that downsamples the output curves to 10,000 to 
20,000 points for reasonable plotting times.  
We built a peak caller in C++, and called peaks using the predicted binding 
probabilities; we then compared these predicted peaks with the peaks called from the 
corresponding ChIP-seq data. An overlap of at least one nucleotide was counted as a 
correctly predicted peak. We also plotted PR curves at peak resolution. These curves 
were then monotonized to compute the sensitivity (also known as recall) at q-value 
cutoffs of 0.5 and 0.25. We compared the performance of our models with the 
performance of single features DNase-seq, FIMO scores, or average ChIP-seq signal in 
other cell types. 
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IV.2.3 Results 
IV.2.3.1 Initial Model 
To demonstrate the potential of improved TFBS prediction, we implemented a proof-of-
concept model using logistic regression as implemented by the LIBLINEAR software 
package (Fan et al. 2008). We utilized DNase-seq data and 19 transcription factor 
datasets from the ENCODE and Roadmap Epigenomics projects; the TFs were chosen to 
avoid any with known functional interactions or binding partnerships. We built a model 
using LIBLINEAR on the GM12878 cell line using DNase-seq and 18 TF datasets as the 
input data, with a 100 base-pair smoothing window; the model was trained on 5% of the 
data on chromosome 7 to predict the 19th TF (ATF3 for this example). We then used the 
trained model to predict ATF3 using data for the HepG2 cell line. For a baseline of 
comparison, I ranked DNase-seq data to directly predict TF binding—a predictive 
strategy that has been noted to be competitive with more complex models (Cuellar-
Partida et al. 2012). As demonstrated by Figure IV-3 on page 181, the addition of 18 TFs 
substantially improved model sensitivity. 
IV.2.3.2 Full Models 
We can predict where transcription factors bind on the basis of the DNA sequence, 
DNase-seq and ChIP-seq for this TF from other cell types, and DNase or other TFs in this 
cell type. In general, our models perform better than DNase-seq strawman, FIMO, or 
average of other ChIP-seq experiments, and compete with more complex methods such 
as ChromImpute. Our methods nearly always have increased performance over using an 
individual ChIP-seq assay from another cell type to predict binding for a given cell type.  
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Straightforward methods of imputing ChIP-seq datasets have poor performance at 
both base-pair and peak-centric levels. Simply using DNase-seq (an indicator of open 
chromatin) gives poor performance (Figure IV-3 on page 181). For example, for CTCF in 
HepG2, DNase-seq performs poorly (Figure IV-4 on page 182). Utilizing the average of 
other TFs in the same cell type also performs poorly, as does the average of the TF across 
all other cell types, and FIMO scores (surrogates for sequence). Machine learning 
techniques can be utilized to better capture information between assays and other 
features. For instance, using logistic regression, we build increasingly complex models. 
We find that many ChIP-seq TF datasets can be captured well using our methods. TFs 
such as CTCF, while having high correlation across cell types, can be imputed with 
strong performance.  
As another example, a model was built using LIBLINEAR on the GM12878 cell 
line using DNase-seq and 420 TF datasets as the input data, with a 200 base-pair 
smoothing window. The model was trained on 20% of the data on chromosome 7, and 
used to predict a binding probability for every base for a given target TF.  We then used 
the trained model to predict the same target TF in the HepG2 cell line. For a baseline of 
comparison, we ranked DNase-seq data to directly predict TF binding—a predictive 
strategy that has been shown to be competitive with more complex models (Cuellar-
Partida et al. 2012). As Figure IV-6 on page 184 demonstrates, most ChIP-seq TF models 
benefitted from features added beyond simply DNase-seq. This trend generally continues 
when examining predicted TF experiments grouped by TF, as shown in Figure IV-7 on 
page 185; careful examination of predictions in just HepG2 in Figure IV-8 on page 186 
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does demonstrate feature engineering is often required, as merely adding 420 other ChIP-
seq datasets does not guarantee improved performance. Our performance metrics did 
improve when switching from base-pair resolution imputation to peak-level (via our 
internal peak caller), as generally demonstrated in Figure IV-9 on page 187. 
ChomImpute, a regression tree-based imputation software package utilized for 
imputing DNase, DNA methylation, and ChIP-seq histone marks for ROADMAP 
Epigenetics datasets, was also run. Both our logistic regression models and gradient 
boosting models failed to consistently outperform ChomImpute (see Figure IV-10 and 
Figure IV-11) when run on the exact same feature matrices.  
IV.3 DREAM in vivo Transcription Factor Binding Site Prediction 
Challenge 
IV.3.1 Introduction 
The DREAM (Dialogue for Reverse Engineering Assessments and Methods) Challenges 
support open scientific, computational-centric research on biological data (Stolovitzky, 
Monroe, and Califano 2007). Anshul Kundaje from ENCODE DAC recently helped lead 
an effort for in-vivo transcription factor binding prediction. This challenge used a 
restricted set of data, over a binned set of genomic coordinates (Figure IV-12 on page 
190) to help advance machine learning approaches to TF prediction. We applied lessons 
learned from out ChIP-seq TF imputation (which used base-pair resolution, over a large 
set of data) to work on the challenge.  
We took a multiscale approach to generating features using DNase-seq, RNA-seq 
and sequence totaling to about 65 features per 200bp window. Since the 200bp windows 
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are overlapping and have step size of 50bp, we effectively generated features for the 
middle 50bp each window. Based on correlation of DNase-seq datasets, for each target 
cell type we chose the most appropriate training cell type. The same feature sets were 
used for all TFs (motif-based features were omitted for TFs without a motif present in 
jasper), and the same methods were used for leaderboard and final submission. We then 
applied gradient boosting (using xGBoost) as the machine learning technique of choice. 
This allowed for efficient training on all ~50M genomic locations and for inherent feature 
selection and modeling of interactions between features, with each feature being on 
(potentially) different scale/ranges. An partial example of the boosted tree xGBoost 
outputs is shown in Figure IV-15 on page 193). 
IV.3.2 Methods 
IV.3.2.1 Processing DNase-seq data 
DNase-seq data was processed into counts (normalized to 1M reads) of just the 5`-ends of 
the reads. BigWig files were generated for both Watson and Crick strands separately. For 
samples for which more than one technical replicate exists, the BAM files were merged. 
An all-to-all correlation matrix was generated for all tracks (using BigWigCorrelate (Kent 
et al. 2010)). The signal files were then further processed in the following ways: 
1. Gaussian smoothing using kernel with standard deviations of 0.5, 1, 2, 3, 4, 5, 10, 
15, 20, 30, 40, 50, 100, 125, 150, 200, 300, 400, 500, 1,000, 2,000, 3,000 was 
applied and for each 50bp center of the training/testing regions the maximum of 
the smoothed signal was taken. 
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2. The sum of the signal in the 50bp center of the training/testing windows was 
taken. 
3. The sum of the signal in the 200bp center of the training/testing windows was 
taken. 
4. The maximum of the signal in each 200bp window was taken. 
5. The average footprint score (described below) for the 50bp center of each window 
was taken (covered bases only). 
6. The maximum footprint score for the 50bp center of each window was taken. 
In 1, 5 and 6, for every 50bp window, the cleavage signal was normalized to the mean 
signal in the local region of 10,000bp (counting only covered bases). 
IV.3.2.2 Footprint score 
The entire genome was scanned using a kernel constructed to pick up the characteristic 
footprint signal (flanking region on one strand, followed by a cleavage-depleted region 
and the same signal mirrored on the opposite strand, as noted in (Piper et al. 2013). For 
the Watson strand signal, we used a kernel based on the first derivative of a Gaussian 
PDF and for the Crick strand we used the same kernel (see Figure IV-14 on page 192) but 
mirrored. Figure IV-14 also shows the kernel for both Watson and Crick strand in black 
and yellow. The convolution was run at several scales and summed. 
IV.3.2.3 Features for RNA-seq 
The provided RNA-seq data were transformed into BED files containing regions for each 
expressed gene and their associated TPM value. These regions we then used to produce 
multiscale features similar to what was done for DNase-seq. That is, for each expressed 
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gene (TPM > 1.0) a region around the transcription start site (TSS) was marked with a 
flag. The sizes of the marked regions we used were 1kb, 2kb, 3kb, 5kb, 10kb, 20kb, 50kb, 
100kb and 500kb. Also, several different types of marks were used: a simple binary flag, 
a Gaussian smoothed binary flag, the actual Gaussian smoothed TPM and a smooth 
neglog(p-value) for the f-score of each gene (i.e. indicating the variance of the respective 
gene’s expression across all training cell types). Colloquially known as the “eugenio-
score,” for its inventor.  
IV.3.2.4 Features based on sequence 
For the all provided 200bp regions, the GC content was calculated and provided as a 
feature. Also, for all TFs, if a PWM was found in the JASPAR 2016 core motif database 
(as part of the MEME suite (Bailey et al. 2009)), the maximum -log(p-value) was 
calculated in each 200bp window, using FIMO. 
IV.3.3 Results 
We generated a series of 4 whole genome models, using different combinations of 
features and model parameters: 
1. DNase + FIMO features (tree depth 10) 
2. DNase + FIMO + gene expression (tree depth 10), +/- 200 bp offsets 
3. DNase + FIMO + gene expression (tree depth 10) 
4. DNase + FIMO + gene expression (tree depth 6) 
Comparison of these models for the Leaderboard training TFs appears in Figure IV-17 on 
page 195, with model 4 having best performance across the board. While this result may 
initially appear surprising—model 4 utilizes trees not as deep as model #3—this is a 
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common scenario in machine learning (and frequently with XGBoost) where the model 
either is overfitting the data, or other model parameters were not tuned in concordance 
with the tree depth (Hawkins 2004). We examined the models for feature importance; as 
shown in Figure IV-16 on page 194, TF motif and DNA sequence (via FIMO and GC 
content) were the most highly important features.  We then utilized model #4 for the TFs 
being publically tested on the DREAM leaderboard. Our performance in general was 
highly competitive; as shown in Figure IV-18 and Figure IV-19, a sub-selection of the TF 
Leaderboard, we scored second for AIRD3A and REST and fourth for ATF7, by team. 
We ultimately finished Round 1in 9th place in the competition. Figure IV-20 on page 198 
shows a comparison of our performance against the best performing model for the 
Leaderboard TFs. On average, our model trailed the best-performing model by an 
average aucPR of 0.17 with a standard deviation of 0.13 aucPR. We were the best or 
near-best model for several TFs, including REST and STAT3, as well as TCF7L2, a TF 
with established involvement in glucose metabolism and Type 2 diabetes (Savic et al. 
2011). 
IV.4 Enhancer Prediction 
IV.4.1 Introduction 
Enhancers are sequences of DNA involved in increasing gene expression. This cis-acting 
regulatory elements are typically short (50 to 1500 bp) and activate their target genes 
under specific cellular conditions or developmental time points (Blackwood and 
Kadonaga 1998). The structure of the enhancer complex and formation of the 
enhanceosome were first studied structurally in the human IFNβ gene; activation of this 
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gene in response to viral infection required recruitment of multiple transcription factors 
and HMG-1Y (Thanos and Maniatis 1995). Studying enhancers has become increasingly 
complex. While hundreds of enhancers were found through discovery of 
ultraconservative regions of the mouse, rat, and human genomes (Bejerano et al. 2004), 
we now know the number of putative enhancer regions is in the hundreds of thousands 
(Shen et al. 2012): far higher than the approximately 20,000 protein-coding genes in the 
human genome (Ezkurdia et al. 2014).  
Enhancers are typically within a ~1 MB window upstream or downstream of a 
gene (Gillies et al. 1983), but are scattered through the 98% of the genome that doesn’t 
code for protein—billions of bases (Pennacchio et al. 2013). This distal regulation by 
enhancers is possible through loops in the 3D structure of the genome (Sanyal et al. 
2012), allowing multiple distal elements to interact and regulate multiple target genes 
(Mohrs et al. 2001), furthering complicating determination of the target gene for a 
particular enhancer. Additionally, since enhancers may only be activated under very 
particular cellular states or developmental time points, or only in specific cell types or 
disease conditions, experimental validation of enhancer activity is also fraught with 
difficulty (Pennacchio et al. 2013).  
Experimentally, mouse transgenic assays have had success in decoding in vivo 
enhancer activity for a limited number of enhancer regions. In the transgenic assay, 
candidate regions are selected, amplified by PCR from human genomic DNA, and then 
cloned into a reporter vector containing a minimal promoter (Hsp68) and a LacZ reporter 
gene (Kothary et al. 1988). Primer designs must be done semi-automatically, since 
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primers must be long enough to be effective but are sensitive to exons and highly 
repetitive sequences in the flanking regions around candidate regions3. These vectors are 
packaged into plasmids that are inserted into mouse eggs, and allowed to grow. The 
mouse embryos are ultimately viable are harvested on embryonic days 10.5 through 16.5; 
regions with blue LacZ expression are visually inspected, and, if the same region is found 
active in at least 3 embryos, the region is classified as active by that enhancer 
(Pennacchio et al. 2006). Initial studies using this technique found half of ultraconserved 
regions had enhancer-like activity at a specific developmental time point in a very 
specific CNS subregion (Visel et al. 2008). These studies also found that, while many 
enhancer regions have conservation, an even greater number of enhancers are not 
conserved in vertebrate evolution (Blow et al. 2010; Schmidt et al. 2010).  
Patterns of transcription factor binding and histone modification have also been 
found in enhancer regions, with, unfortunately, no single TF or mark distinguishing all 
enhancer sites (Visel, Rubin, and Pennacchio 2009). The EP300 transcription factor, a 
known acetyltransferase and transcriptional coactivator, binds to enhancer regions; only a 
few thousand EP300 binding sites, though, are found in the genome in ChIP-seq 
experiments (Visel et al. 2009). Likewise, DNA must be accessible for transcription 
factors to bind, and DNase-seq experiments have establish many putative enhancer 
locations (with a corresponding large number of false positives) (Dorschner et al. 2004; 
Thurman et al. 2012). H3K4me1 was the first histone modification to be found enriched 
at enhancers (Heintzman et al. 2007), but the mark is broad, covering large genomic 
                                                 
3 http://wiki.encodedcc.org/index.php/ENCODE_Teleconference_Information 
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regions well beyond the enhancer, and is also found at the 5’ end of actively transcribed 
genes (Calo and Wysocka 2013). The H3K27ac histone modification has been 
experimentally demonstrated to distinguish active from inactive enhancers (Creyghton et 
al. 2010), and we have utilized this mark extensively when building the ENCODE 
Encyclopedia (see Chapter II: Building and Visualizing an Encyclopedia of ENCODE 
candidate Regulatory Elements on page 9). These TFs and histone modifications have 
been utilized in computational models to predict enhancer locations in supervised and 
unsupervised models (Ernst and Kellis 2012; Rajagopal et al. 2013; Erwin et al. 2014). 
These models all suffer from lack of experimentally validated true positive enhancer 
regions, though, and either find a fraction of putative enhancers (Erwin et al. 2014), or 
have a large number of false positives (Zacher et al. 2017).  
NHGRI and the ENCODE Project have recently made functional characterization 
of putative enhancers a priority for the consortium4. ENCODE now helps not only select 
regions for transgenic mouse assays for enhancer activity, but also sponsors “bakeoffs” to 
compare sensitivity and specificity of computational models predicting enhancer activity 
in a cell-type specific fashion. I have been developing and refining supervised machine 
learning models for the last several rounds of ENCODE enhancer predictions, building 
upon the work of Sowmya Iyer (Iyer 2015).  
IV.4.2 Methods 
As the basis for our models, we utilized experimentally validated enhancers as found in 
the VISTA Enhancer Browser (Visel et al. 2007), which contains a list of all mouse 
                                                 
4 https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-16-003.html 
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transgenic enhancer assays. We have worked on combining hundreds of new ENCODE 
mouse datasets into multiple machine learning models to best predict whether a given 
genomic region acts as an enhancer in vivo. We have also now trained models across 
multiple mouse embryonic developmental time points. The goal is to ultimately produce 
a genome-wide set of predictions predicting enhancer activity for different biosamples 
and developmental time points.  
We used up to 723 ENCODE mouse ChIP-seq histone experiments, as well as 2 
mouse bisulfide experiments, from embryonic days 10.5 through 16.5. We also used 
RNA-seq data, GC content, and mouse conservation datasets. Features were based upon 
the interval mean of q-values (when available) or signal from narrowPeak or broadPeak 
files. Features were variance normalized and rescaled to be [0,1]. To select regions for 
training and testing, we binned the whole genome into 1500 bp bins with 500 bp overlap. 
Training was done in two stages (like EnhancerFinder): first, a model was trained on 
positive enhancers in any tissue. Then, the genomic intervals with p-value >0.5 were 
selected, and used as intervals to train separate random forest models on biosample 
specific VISTA enhancers. Models were trained on 80% of the samples in the feature 
matrix, with 30x cross-validation.  
Training labels were collected from the VISTA enhancer set of experimentally 
validated true positives and true negatives; Table IV-1 on page 178 shows the number of 
tested enhancer regions per biosample. Negatives were re-shuffled using “bedtools 
shuffle” to avoid areas of high evolutionary conservation. While 8 classifiers were 
initially used, random forest and gradient boosting consistently performed best. When 
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then tested the models on the remaining 20% of the data. We also the R package 
RankAggreg to combine output from random forest and gradient boosted models 
methods using weighted rank aggregation (Pihur, Datta, and Datta 2009). 
IV.4.3 Results 
We trained models on the entire VISTA Enhancer set, and tested on genomic coordinates 
provided by the assay lab. During testing, we found no one optimal machine learning 
methods or feature set. For example, for predicting forebrain enhancer activity in 
forebrain tissue, building a random forest model on the entire ChIP-seq dataset performed 
best (Figure IV-21 on page 199). On the other hand, to predict forebrain enhancers that 
also may share enhancer activity in other tissues, a gradient boosting model with a more 
limited set of developmental time point-specific enhancers had an aucPR improvement of 
0.059 over the above random forest model on a large set of features (Figure IV-22 on 
page 200). Likewise, for heat-specific enhancers, a gradient boosting model on 
developmental time point-specific data combined with whole genome bisulfide data 
outperformed all other models (Figure IV-23 on page 201), while a random forest model 
on developmental time point-specific data bested models for heart enhancers active in 
other tissues (Figure IV-24 on page 202).  
For predicting enhancers in midbrain on embryonic day 11.5, my gradient 
boosting model with 823 ENCODE ChIP-seq datasets surpassed all other models 
(including ensemble approaches combining all models together) for predicting midbrain-
specific enhancers (Figure IV-25 on page 203). For predicting midbrain e11.5 enhancers 
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active in other tissues, random forest on the same feature matrix was the best performer, 
bested only by ensemble learners based on all models (Figure IV-26 on page 204).  
IV.5 Overall Machine Learning Discussion 
Machine learning of epigenetic data is on the precipice of heralding in a new world of 
hybrid experimental and computational techniques; while experiment will always be gold 
standard for data, predictive computational techniques can help bridge the gap when 
experiments are too expensive, technically difficult, or numerous. Imputation of 
experimental data is also one possible source of quality control for when the actual 
experiment is performed (Ebert and Bock 2015). Imputation of transcription factor 
binding sites may shed light on more intricate co-binding and tethered binding patterns: 
for instance, we purposefully eliminated CTCF as a feature when predicting members of 
the complex SMC3 or RAD21 (and vice-versa), since inclusion of these known co-
binding partners made the models artificially accurate (Holwerda and de Laat 2013).  
Several TFs demonstrate high difficulty in imputing. Reasons for poor 
performance can be broken down into several categories: too few datasets to impute on, 
low quality data, and large differences in TF binding as indicated by low Pearson 
correlation between cell types for a given TF. Some experiments (in particular DNase-
seq) have datasets from labs that use incompatible protocols, making combination of 
replicates across labs infeasible; just arbitrarily selecting one lab’s experiment, though, 
may skew the results in unintentional ways. Many of the cell lines present in these 
projects are cancerous; this could skew the model training and evaluation of model 
performance, as we notice in Figure IV-7 on page 185. Two recent studies on ChIP-seq 
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data have noted an increase in false positive reads from genomic areas with high rates of 
transcription (Teytelman et al. 2013; Park et al. 2013); this problem is intrinsic to the 
ChIP-seq experiment, and reduces the accuracy of models.  
We feel we have found a viable core combination of features and machine 
learning algorithms. Due to our own time constraints, we did not fully determine the 
optimal combination of XGBoost parameters. We also didn’t have sufficient time to add 
in offsetted features in additional to the multi-scale features. After examining the feature 
importance using XGBoost python scripts, motif is by far the most important feature. A 
winning group from the first 2 rounds of DREAM also noted sequence and motif-based 
features were the two most important features (Keilwagen, Posch, and Grau 2017). In the 
future, we will further investigate this feature, as well as making sure all TFs have motif 
information. We will also better explore the parameter space. For TFs that don’t bind 
with sequence-specificity, motif will not help, and other approaches may be required.  
Machine of learning of enhancers in different tissues and developmental time 
points poses a different set of challenges. Some tissues undergo significantly less 
developmental dynamics at the developmental time points we were predicting in. This 
developmental stability lead to better predictive models, since the state of enhancers was 
not changing as drastically between time points.  The relatively small number of samples 
from VISTA, though, has made machine learning enhancers difficult, as does the intrinsic 
bias when selecting regions to test (since regions have been selected by high conservation 
or high DNase and H3K27ac signal, thereby skewing results towards models using those 
features).  
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IV.6 Tables 
 
# enhancers Tissue 
75 Facial mesenchyme 
588 Brain 
73 Nose 
0 Kidney 
298 Midbrain 
262 Hindbrain 
50 Cranial nerve 
356 Forebrain 
192 Heart 
41 Trigeminal V (ganglion, cranial) 
196 Neural tube 
80 Eye 
136 Branchial arch 
227 Limb 
65 Dorsal root ganglion 
 
Table IV-1 | VISTA Datasets 
~2600 enhancers (as of August 2015) 
 
  
179 
 
 
 
IV.7 Figures 
 
Figure IV-1 | Validate predictions for known ChIP-seq experiments 
Matrix of ENCODE TFs vs biosamples; note great sparsity of matrix.  
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Figure IV-2 | Imputation Flowchart 
Typical supervised machine leaning approach; feature engineering is typically the most 
difficult—and important—step.  
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Figure IV-3 | Predict ATF3 binding sites 
Predict ATF3 binding sites using just DNase (black line) and DNase with 18 other 
transcription factors (red line). Smoothing window size of 100 was used for both 
models. 
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Figure IV-4 | CTCF PR Curve 
PR curves for predicting CTCF TFBSs in HepG2 after training in GM12878 
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Figure IV-5 | Actual vs Imputed TFBS in UCSC Genome Browser 
MACS2 output of logistic regression imputed TFBSs. 
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Figure IV-6 Predicting TFBSs in 246 ChIP-seq Datasets 
Scatter plot of aucPRs at base-pair resolution in hg19 chromosome 7 
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Figure IV-7 | Predicting TFBSs in 246 ChIP-seq Datasets 
Scatter plots of aucPR, grouped by biosample, at base-pair resolution in hg19 
chromosome 7 
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Figure IV-8 | Predicting TFBSs in HepG2  
Recall/FDR curves of predictions in HepG2 at base-pair resolution on hg19 chromosome 
7. Features include DNase-seq, FIMO, 420 ChIP-seq, and average of target TF. Note: for 
these plots, highest performance occurs when curves extend furthest into upper-left hand 
corner of plots.  
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Figure IV-9 | Predicting TFBSs in HepG2  
Recall/FDR curves of predictions in HepG2 at peak resolution on hg19 chromosome 7. 
Features include DNase-seq, FIMO, 420 ChIP-seq, and average of target TF. Note: for 
these plots, highest performance occurs when curves extend furthest into upper-left hand 
corner of plots.  
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Figure IV-10 | aucPR Curves for ChomImpute vs LR 
prAUCs are computed for a test set of ChIP-seq TF experiments for both ChomImpute 
and logistic regression, and plotted pair-wise. 
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Figure IV-11 | aucPR curves ChromImpute vs xGBoost 
prAUCs are computed for a test set of ChIP-seq TF experiments for both ChomImpute 
and xGBoost, and plotted pair-wise.  
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Figure IV-12 | DREAM Genomic Binning 
Binning of hg19 into 50bp bins as dictated by the DREAM planners. This binning greatly 
simplifies computational time and space requirements.  
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Figure IV-13 | Machine Learning Approach 
We mostly utilized DNase-seq and RNA-seq data (as dictated by the DREAM planners), 
and used xgBoost for the supervised machine learning.  
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Figure IV-14 | Kernel 
Kernel based on the first derivative of a Gaussian PDF. For the Crick strand, we used the 
same kernel but mirrored. The plot shows the kernel for both Watson and Crick strand in 
black and yellow. 
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Figure IV-15 | Gradient Boosting Tree Example 
Tree of depth 10 for FOXA1 on MCF-7 
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Figure IV-16 | Feature Importance  
Example feature importance plot for testing of REST (64 features, 6 tree depth) 
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Figure IV-17 | Performance Comparison 
Comparison of aucPR curves across different biosamples and TFs for each of our models 
(numbered 1-4) during Leaderboard Training Round 1 
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Figure IV-18 | Leaderboard Training Performance 
aucPR values across competitors for Leaderboard Training Round 1 for ARID3A and 
ATF7 
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Figure IV-19 | Leaderboard Training Performance 
aucPR values across competitors for Leaderboard Training Round 1 for CTCF and REST 
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Figure IV-20 | DREAM Leaderboard Testing Performance  
Line plots of aucPR across all Leaderboard TFs in Round 1.  
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Figure IV-21 | Method Comparison for Predicting Forebrain Enhancers 
Comparison of our 9 methods for predicting forebrain enhancers in forebrain tissue on 
training data. Random forest on 498 ENCODE ChIP-seq mouse datasets performs best. 
 
 
  
200 
 
 
 
 
Figure IV-22 | Method Comparison for Predicting Forebrain Enhancers 
Comparison of our 9 methods for predicting forebrain enhancers in any tissue on training 
data. Generalized boosting on 138 ENCODE ChIP-seq mouse datasets (just on 
embryonic days 11.5 and 14.5) performs best. 
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Figure IV-23 | Method Comparison for Predicting Heart Enhancers 
Comparison of our 9 methods for predicting heart enhancers in heart tissue on training 
data. Generalized boosting on 138 ENCODE ChIP-seq mouse datasets (just on 
embryonic days 11.5 and 14.5) with 2 mouse whole genome bisulfide experiments 
performs best. 
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Figure IV-24 | Method Comparison for Predicting Heart Enhancers 
Comparison of our 9 methods for predicting heart enhancers in any  tissue on training 
data. Random forest on 138 ENCODE ChIP-seq mouse datasets (just on embryonic days 
11.5 and 14.5) performs best. 
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Figure IV-25 | Round 2 Midbrain Prediction Results 
Round 2 results for predicting midbrain enhancers in midbrain tissue on embryonic day 
11.5 for 150 regions. Gradient boosting with an enlarged set of ENCODE mouse data 
performed best across all competitors and ensemble models.  
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Figure IV-26 | Round 2 Midbrain Prediction Results 
Round 2 results for predicting midbrain enhancers in any tissue on embryonic day 11.5 
for 150 regions. Random forest with an enlarged set of ENCODE mouse data performed 
best across all competitors and almost equaled the ensemble models. 
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V. Chapter V: SnoPlowPy: Advanced ENCODE Data 
Manipulation Tools 
V.1 Preface 
This research chapter encompasses work performed in conjunction with Henry Pratt, 
Arjan van der Velde, and Xiao-Ou Zhang, and will be drafted into a bioinformatics 
applications note.  
 As I’ve discussed at the start of this thesis, ENCODE data and metadata are 
difficult to work with for many reasons. I particularly found the ENCODE metadata to be 
difficult to work with in bulk: trying to parse metadata for thousands of experiments for 
Factorbook, ChIP-seq imputation, and SCREEN took hours for operations that should 
complete in minutes. I started work on my own tool to store and manipulate this 
metadata; it has grown into quasi-metadata system in its own right, and, if not elegant, it 
is straightforward to adapt and expand. The tools described here have severed the needs 
for several users in the lab for processing datasets hundreds of thousands of times.   
V.2 Introduction 
The ENCODE datasets we utilize as input data to our pipelines and analysis tools are all 
publically available, versioned, stored in the cloud, and have rich and actively maintained 
metadata (Davis et al. 2017). Objects are all uniquely identifiable, and cannot be deleted. 
Ontological information is built into the metadata, as ENCODE has helped develop some 
of the ontologies. The datasets themselves are of high quality and individually curated, 
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with strict quality-control metrics. File formats are regulated, and tools developed to 
make sure submitted files adhere to the format their metadata reports. Our analysis 
products follow similar standards: we submit results back to ENCODE with appropriate 
metadata, which is reviewed before the products are publically released. Analysis 
metadata even contains the list of files the product was derived from, as well as the 
software tools and parameters used, so that the product can be reproduced by others. 
While the experiment metadata available from the ENCODE portal is very rich, 
and provides most of the pertinent metadata information needed per experiment, the 
JSON data is large, bulky, and difficult to process on a large-scale in a timely fashion. 
The JSON metadata itself is >3GB of data. Our solution to manipulating these data 
resulted in our construction of an efficient, performant metadata tool called SnoPlowPy. 
SnoPlowPy forms the core of our large analysis pipelines, and allows us to walk across 
core metadata for thousands of ENCODE experiments in a few minutes. A microcosm of 
tools to support the analysis pipeline and metadata manipulation have also been 
integrated into SnoPlowPy. 
V.3 Tools 
V.3.1 Experiment and experiment file metadata objects 
The core of SnoPlowPy is an Experiment class (named Exp) that wraps and abstracts 
whatever experiment we are trying to manage (ENCODE, ROADMAP, psychENCODE, 
etc.). The overview of this class is available in Figure V-1 on page 210. This class can be 
loaded in multiple ways: directly from on-disk JSON files (updated daily or on-demand); 
directly from a web request from ENCODE DCC (slower, but with the most recent 
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metadata); or from our metadata web service API (updated weekly, but fastest). The Exp 
class can contains information on what type of assay the experiment is, lab, release date, 
etc. It also contains Experiment File classes (ExpFile) that wrap metadata for particular 
files for that experiment. These ExpFile classes contain both the metadata for that file 
(MD5 checksum, size in bytes, etc.), but also methods to automatically download and 
store the file on the local file system in an organized fashion, and has been refactored into 
its own set of classes (Figure V-2 on page 211 and Figure V-3 on page 212). In addition, 
I have written QueryDCC to directly query the ENCODE DCC metadata system, and 
merge results into our on-disk metadata store (Figure V-4 on page 213). Overall, these 
classes are lightweight, and easily manageable; they form the core objects for which the 
entire Factorbook pipeline is designed. These classes are also flexible enough to be 
adapted to other datasets; essentially, any experiment that can be represented as an 
Experiment object with files can be housed in the system.  
V.3.2 ENCODE submission system 
The ENCODE DAC has become a submitter of original data and analysis products to 
ENCODE DCC. We have now submitted several TBs of data to DCC, ranging from our 
own analysis products (such as the cREs from Chapter II: Building and Visualizing an 
Encyclopedia of ENCODE candidate Regulatory Elements), missing NarrowPeak files 
for ChIP-seq TF analysis, all the way to entire HiC experiments and a majority of the 
ROADMAP data. We have developed our own system for doing the data upload, both to 
simplify the process, but also the handle the wide range of data and metadata we have to 
submit. We automatically login and authorize to the ENCODE portal with our submitter 
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credentials, then can upload most of the common ENCODE metadata and data objects 
(including biosamples, documents, files, epigenomes, and cREs). The system also 
uploads files to the ENCODE DCC AWS bucket, and can automatically resume file 
transfers if it detects an interruption.  
V.3.3 api.wenglab.org 
The increasingly large amount of data and metadata (both in bytes and in number of 
objects) that must be retrieved for projects such as Factorbook, SCREEN, etc. requires 
more formalized data abstraction layers. These layers can provide unified access 
interfaces to the data (called APIs), and allow easy programmatic manipulation of the 
data, far exceeding what can be done using conventional file systems. Centralized 
location of these webservices also allows the public a way to access the data in a coherent 
manner. We have migrated our webservices for Factorbook, SCREEN, and metadata to 
api.wenglab.org, and will be providing specifications in GraphQL language for the public 
to access the data.  
V.3.4 JobRunner and JobMonitor 
To better automate creating jobs, we implemented JobRunner, which can automatically 
create the execution files necessary to run 10,000s of Factorbook jobs (see Figure V-5 on 
page 214). We also implemented JobMonitor, to monitor the succeeded and failed jobs. 
JobMonitor can also synchronize the output analysis products from the cluster back to 
our central store, a necessary task, given the 16 TBs of data produced by the pipeline. In 
addition, in order to speed-up rerunning of partially-completed jobs, a Checkpoint system 
was developed that permits just to be resume from the last-known good stage of the 
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pipeline. This was especially important when large Factorbook jobs exceeded their 
allowed run-time on the cluster, a frequent problem encountered while developing jobs 
pipeline.  
V.3.5 Helpers 
Finally, I have collected all our common-used Python code into several helper classes. In 
particular, the Utils class (Figure V-7 on page 216) contains code commonly used 
throughout many of the projects in the Weng lab. Utils has been unit tests for most, if not 
all, of its methods. In addition, much of the logic needed to parse and manipulate 
NarrowPeak/Broad Peak/Gapped Peak files has also been refactored and condensed into 
a helper class Peaks (Figure V-6 on page 215). 
V.4 Discussion 
Managing and manipulating >70TB of locally-stored ENODE data and metadata is a 
challenge. We’ve developed several tools to help addresses these problems, while 
allowing them to be light-weight enough to be adapted to other datasets, and easy 
modified and extended. Our approach has enabled running hundreds of thousands of jobs 
on the cluster, even as the metadata at ENCODE changes and evolves. I hope these tools 
will continue to improve, simplifying use of the vast wealth of ENCODE data.    
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V.5 Figures 
 
Figure V-1 | Exp and ExpFile Class Diagram 
Overview of classes, and the methods and attributes in each class.   
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Figure V-2 | File and Paths Class Diagram 
Overview of classes, and the methods and attributes in each class. 
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Figure V-3 | Downloader Class Diagram 
Overview of classes, and the methods and attributes in each class. 
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Figure V-4 | QueryDCC Class Diagram 
Overview of classes, and the methods and attributes in each class. 
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Figure V-5 | Job Runner Class Diagrams 
Overview of classes, and the methods and attributes in each class. 
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Figure V-6 | Peaks Class Diagram 
Overview of classes, and the methods and attributes in each class. 
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Figure V-7 | Utils Class Diagram 
Overview of classes, and the methods and attributes in each class. 
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VI. Chapter VI: Discussion 
VI.1 Preface 
This discussion is based on my discussions in chapters II, III, IV, and V.  
VI.2 Introduction 
The work in this thesis describes efforts to better understand the epigenome through 
creation of an Encyclopedia of candidate Regulatory Elements and a visualizer 
(SCREEN) for these elements. We have also described Factorbook, another visualization 
tool to help understand aggregated histone mark and transcription factor occupancy 
patterns around TF peaks. We also described our work on computationally predicting 
transcription factor binding using supervised machine learning methods. Lastly, we 
described a set of programming tools we have implemented to aid in the large scale 
processing needed for the above work. 
VI.3 ENCODE Encyclopedia and SCREEN 
With ~90% of disease-associated Single Nucleotide Polymorphisms (SNPs) occurring to 
be in intronic or intergenic regions (Hindorff et al. 2009), the systematic location and 
study of genetic variants outside of protein-coding regions is critical to better 
understanding and potentially treating disease pathology. There are millions of these 
potentially functional regions in the genome, working as enhancer, promoters, repressors, 
or insulators; having a catalog of these elements, and a way to easily interrogate these 
regions, will be essential to keep researchers afloat in an ocean of data. Researchers 
require tools to aid in both biological questions and practical bioinformatics problems; 
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users require an encyclopedia synthesizing the low-level data into a more manageable 
product that can be analyzed and effectively investigated.  
We have identified the first real catalog of putative regulatory regions, locating 
nearly 2 millions cREs across human and mouse genomes in regions with open chromatin 
and enhancer-like or promoter-like signatures (based on histone modification marks and 
other genomic distance information). These elements are numbered and versioned, 
permitting direct reference in future papers. cREs are anchored on DNase-seq 
representative DHSs (rDHSs), condensed first from >30 million DHS sites across more 
than 400 individual samples into a set of non-overlapping regions number ~1.3 million in 
human and ~400 thousand in mice. 
The tools we have developed have enabled an integrated approach to discovering 
new biological insights. For example, as we discussed in Chapter 2, the Ogn mouse gene 
that encodes osteoglycin was known to increase expression on mouse embryonic day 12, 
in concordance with increased bone formation (Taher et al. 2011). Not only do we 
demonstrate this differential change on expression using our SCREEN Differential Gene 
Expression tool in Figure II-27a on page 113, as well as on the UCSC Genome Browser 
in Figure II-28 on page 114, but we also find putative regulatory elements whose own 
expression levels change in step with the Ogn gene expression increases. The human 
homolog of this gene—OGN—has been correlated with left ventricular hypertrophy 
(Petretto et al. 2008), and may account for hypertrophic responses to hypertension or 
aortic stenosis. Future studies could utilize our candidate Regulatory Elements in mouse 
models to pursue several experimental approaches (including mouse transgenic assay or 
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CRISPR/Cas9 targeted gene editing) to definitely define the elements regulating this 
gene, and start on the path to therapeutic control.  
We have also explored developing new hypotheses for epigenetic malfunctions in 
autoimmune and immune-mediated diseases like inflammatory bowel disease. We cross-
referenced our curated set of GWAS SNP studies with our cRE database to determine 
which biosamples are most enriched in active cREs overlapping SNPs. We hypostasized 
that we could locate a putative promoter involved in autoimmune dysregulation in 
inflammatory bowel disease. For the top 10 most active biosamples for a IDB study, we 
found that 9 were in leukocyte biosamples, and the tenth biosample was from rectal 
mucosa. We pursued the top-ranked leukocyte biosample, and then located a putative 
promoter region within 2kb of a TSS for LSP1, an immune-related gene. We 
demonstrated that LSP1 was immune-related, as well as active in immune-related tissues, 
based upon ENCODE RNA-seq gene expression and RAMPAGE TSS data. We then 
cross-reference our putative promoter with Ensembl, and found the region overlapped a 
SNP whose A allele was already correlated with LSP1 isoform expression changes. To 
enable possible future mouse model studies, we also located an orthologous region in 
mouse, and verified putatively regulated the promoter in the first exon of Lsp1, also an 
immune-related gene.  
The registry of Elements is a powerful new research paradigm, but there are a 
number of limitations to our approach. Of the hundreds of biosamples used in the 
Encyclopedia, less than two dozen actually had all 4 of our core assays (DNase-seq, 
H3K4me3, H3K27ac, and CTCF). This sparsity of core data complicates cross-biosample 
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comparison of elements, and, obviously, limits the possibility of looking for, say 
enhancer-like signature cREs in biosamples without any histone experimental data. Our 
z-score based ranking system is practical but overly simplistic; it deals with the many 
problems of data normalization across experiments, but leaves a great deal of room for 
more mathematically powerful future models. There are many subtle complications posed 
by the processed ENCODE data: can ChIP-seq experiments from different labs, using 
different approaches to controls, be integrated together, or even comparable? Many older, 
core experiments performed during early years of ENCODE have (by today’s standards) 
very low read counts; at what point do they get replaced by newer, more deeply 
sequenced experiments? The ENCODE pipelines are composed of a large number of 
different software packages and “glue” code; how do we verify that the final analysis 
products are valid and “correct,” especially if only one analysis pipeline exists? 
During the primordial creation of the Encyclopedia, the epigenome did not fail to 
remind us of its innate complexity. As we have shown, the classical picture of enhancers 
and promoters having particular histone modification signatures is only a rough first 
approximation: it is well established. for instance, that regions with H3K4me3 marks can 
indicate active enhancers (Pekowska et al. 2011). The current classification scheme of 
enhancer, promoter, silencer, etc., is overly simplified, and, in many cases, doesn’t reflect 
the more nuanced, complex reality of the genome. Future versions of the Encyclopedia 
have great potential to bring a more nuanced classification system to life, and more finely 
elucidate exactly how, and why, each regulatory element works.  
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The rapid pace of advancements in sequencing technology has exceeded the 
technology speed increases Moore’s Law predicts (Hayden 2014), with the cost of 
sequencing a human genome falling from >$100 million (International Human Genome 
Sequencing 2001) to less than $10,000. Sequencing a human genome for $1,000 has gone 
from the realm of science fiction to near inevitability (Hayden 2014). At this rate, whole 
exome, if not whole genome sequencing, of patients for medical purposes is inevitable. 
The amount of genomic information to be collected will be a vast ocean of data. In light 
of this, the Encyclopedia’s utility in selecting a stable set of cREs to—at least—start 
filtering and distilling this ocean of data is especially important. While future datasets 
will no doubt greatly expand the Encyclopedia beyond its current scope, our selection of 
the top 5% of regions to begin with (as demonstrated by saturation analysis) should prove 
to be an important subset of functional regions for a long time. It is inevitable that the 
Encyclopedia will need to incorporate weaker putative regulatory regions in some 
manner—if even to provide a way of annotating regions for future research.  
To interrogate the cREs we selected in this version of the Encyclopedia, we 
needed a tool with several requirements, including dynamic and interactive interfaces that 
allow users to search and filter cREs in real time, as well as display interactive plots of 
cREs. The tool needed to integrate and view all the low-level data in some sort of 
genome browser. The interactive plots also needed to be reproducible, and near-
publication quality. Finally, we also needed a mechanism to facilitate users’ generation of 
these figures with custom data. The tool needed to be extensible, providing for the 
inclusion of analyses involving external annotations and user-submitted annotations.  
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To fulfill these requirements, we developed SCREEN, the visualizer for cREs. 
This tool is maturing into an integrated approach to examining cREs in the context of the 
genome and epigenome. We already a multi-part visualization platform, with 
mechanisms to search and investigate cREs, show gene expression information, and 
explore GWAS studies for SNP overlap with cREs. SCREEN is the start of central 
repository for accessing information on functional regions of human and mouse genomes, 
integrating cRE searching, sorting, and visualization.  
The genomic visualization field, though, is just in its infancy, with many hurdles 
to overcome in data scale, complexity of information, and visualization techniques. 
SCREEN is most definitely still in its infancy, with many improvements to be made; 
hopefully, though, SCREEN will become an increasingly powerful platform of 
epigenome discovery, especially with the experiments being performed in the 
ENCODE4. 
VI.4 Factorbook 
As demonstrated by the chapter, Factorbook is a web-based analysis tool that integrates 
all public ENCODE ChIP-seq TF data in a peak-centric manner. Factorbook enjoys use 
by researchers within the ENCODE community and beyond. Factorbook has become a 
canonical resource for TF motif information; it has been cited by more than 127 
publications5, its motif tracks have been integrated into the UCSC Genome Browser 
(Rosenbloom et al. 2015), and it is even being mined for machine learning competitions 
(Keilwagen, Posch, and Grau 2017). Factorbook’s centralization of ENCODE TF motif 
                                                 
5 https://scholar.google.com/scholar?cites=16586749045503397316&as_sdt=40000005&sciodt=0,22&hl=en 
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information has led to many biological insights: for example, Factorbook motifs assisted 
the search for SNPs that could disrupt TF binding in chronic lymphocytic leukemia (Law 
et al. 2017). Likewise, gene regulatory networks have been built incorporating RNA-seq 
data with Factorbook motifs to better elucidate breast cancer-related TF networks (Janky 
et al. 2014). Gene expression data visualization was first incorporated into Factorbook 
because of the known association between genes and increased TF occupancy in the local 
genomic neighborhood (Wang et al. 2012). 
We will continue expanding Factorbook as more ChIP-seq experiments become 
available at ENCODE during its 4th phase. This expansion includes not only 
incorporating new raw data to improve the quality and utility of annotations, but also 
continuing to develop novel analyses and visualizations. Inspired by the representational 
DHS sites used to initially select cREs, we will be creating representation Transcription 
Factor Binding Sites (rTDBS) from ChIP-seq TF data to help simplify and anchor the set 
of motif sites in the genome for each TF. In many ways, the future of Factorbook and 
SCREEN are intermixed: users will wish to know, for instance, what TFs overlap her 
enhancer-like signature cRE of interest, or what TFBSs overlap a particular SNP in a 
given cRE. Ultimately, we will combine SCREEN and Factorbook (“SCREENbook”) for 
this deep integration; time will tell. Another important future development of Factorbook 
is the integration of a genome browser with the Factorbook motifs, aggregation plots, 
signal tracks, and cREs; this unified view might greatly aid users, and expand 
Factorbook’s usefulness and utility. Additional crowdsourcing tools must be further 
developed to help centralize discussion on TF ChIP-seq motifs. 
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VI.5 Machine Learning Epigenomic Data 
Machine learning of epigenetic data is on the precipice of heralding in a new world of 
hybrid experimental and computational techniques; while experiment will always be gold 
standard for data, predictive computational techniques can help bridge the gap when 
experiments are too expensive, technically difficult, or numerous. Imputation of 
experimental data is also one possible source of quality control for when the actual 
experiment is performed (Ebert and Bock 2015). Imputation of transcription factor 
binding sites may shed light on more intricate co-binding and tethered binding patterns: 
for instance, we purposefully eliminated CTCF as a feature when predicting members of 
the complex SMC3 or RAD21 (and vice-versa), since inclusion of these known co-
binding partners made the models artificially accurate (Holwerda and de Laat 2013).  
We demonstrated viability in predicting transcription factor binding sites using 
supervised machine learning methods. For some TFs (like CTCF), similarity of TF 
binding across cell types greatly improved performance of TF binding prediction. For 
TFs with highly variable, biosample specific binding, though, getting good performance 
from the learned models was difficult. While good performance can be obtained from 
standard machine learning techniques like logistic regression, gradient boosting, and 
random forest, it seems inevitable that deep learning will supersede these approaches. 
The inherent complexity of the epigenome intuitively dictates this—only computational 
models that can deal with this complexity seem likely to ultimately succeed. The 
intersection of experimental mapping with imputation appears inevitable. The combined 
power of both approaches may be maximally leveraged by performing mapping for 
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important, experimentally viable biosamples, while using imputation for biosamples 
experimentally more difficult to assay (such as primary cancer samples) (Ebert and Bock 
2015).  
Machine of learning of enhancers in different tissues and developmental time 
points poses a different set of challenges. Some tissues undergo significantly less 
developmental dynamics at the developmental time points we were predicting in. This 
developmental stability lead to better predictive models, since the state of enhancers was 
not changing as drastically between time points.  The relatively small number of samples 
from VISTA, though, has made machine learning enhancers difficult, as does the intrinsic 
bias when selecting regions to test (since regions have been selected by high conservation 
or high DNase and H3K27ac signal, thereby skewing results towards models using those 
features).  
VI.6 SnoPlowPy 
Managing and manipulating >70TB of locally-stored ENODE data and metadata is a 
challenge. We’ve developed several tools to help addresses these problems, while 
allowing them to be light-weight enough to be adapted to other datasets, and easy 
modified and extended. The core purpose of SnoPlowPy—to support our research 
pipelines and ease use of ENCODE metadata—has been proven in the hundreds of 
thousands of cluster jobs it has helped organize and run. We are planning expansion of 
the system to handle Cistrome and psychENCODE metadata, as well as support other 
labs and projects at UMassMed. The API portion of SnoPlowPy will also house a future 
central warehouse for all “peak” files (Narrow/Broad/Gapped peaks, DHSs, rDHSs, 
226 
 
 
 
cREs, etc.), and will allow coordinate-based searching. This simplifies some of our 
analyses which require large number of peak file intersection. As mentioned above, the 
API site will also handle the effective merge of “SCREENbook”, providing one common 
API for data for web/tablet/desktop versions of SCREEN/Factorbook. A major task we 
have not yet performed is to make SnoPlowPy available to the general public, with better 
documentation and an automated way of installing locally for the user. We also pursuing 
development of R and C++ wrappers, so users have a unified way of accessing the API 
regardless of programming language.  
VI.7 Conclusion 
We have utilized the tools developed in this thesis to begin to build new hypotheses for 
which elements may be involved in functional regulation of genes; in particular, we have 
shown ways of finding putative regulators for diseases such as left ventricular 
hypertrophy and inflammatory bowel disease that, once experimentally validated and 
targeted through pharmacology or gene editing, could translate into new therapeutic 
treatments at the bedside.  
ENCODE3 has greatly increased the number and variety of experiments available 
from the ENCODE portal. These new data are allowing a much richer, expansive analysis 
of the epigenome. There is finally sufficient data to undertake create of an Encyclopedia 
of candidate Regulatory Elements. While still in its early age, this Registry of cREs is 
already proving itself to be a useful contribution to the scientific community. For the first 
time in ENCODE, we are accessioning putative functional regions of the genome, with 
the hope that papers in the future can directly reference these cREs. We have found a 
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wealth of putative regulatory regions that correlate with experimental datasets within and 
outside of ENCODE. These regions greatly simplify the search for putative regulatory 
regions genes or SNPs of interest.  
SCREEN, the visualizer for cREs, is maturing into a tool providing an integrated 
approach to examining cREs in the context of the genome and epigenome. SCREEN is 
already a multi-part visualization platform, with one app providing cRE search and 
investigation, another app providing gene expression display, and a third allow GWAS 
studies to be interrogated for SNP overlap with cREs. Factorbook, a peak-centric 
visualizer of transcription factor data, has helped centralize TF motif information, TF/TF 
interactions, and TF/histone interactions, providing another vehicle for developing 
biological insights. Our machine learning approaches are starting to help shed light on 
patterns in TF binding, as well as the set of epigenetic markers that truly distinguish 
enhancer regions.  
This thesis has sought to illuminate several new insights into how the epigenome 
works, and how we can apply computational techniques to better elucidate and visualize 
functional regions of the epigenome. We’ve also developed a number of new tools to aid 
in pipeline development for these projects. In the context of today, we hope we’ve 
enabled researchers with new ways of interrogating and investigating the epigenome for 
both basic research purposes, and for clinical applications for the good of humanity. 
Decades from now, I hope this work is recognized as a useful—if primitive—stepping 
stone, rendered obsolete and primordial compared to the scientific discoveries ahead of 
us.   
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VII. Appendix A: Encyclopedia V2 
VII.1 Preface 
This appendix is based off work I performed with Zhiping Weng for version 2 of the 
Encyclopedia; the methods and tracks are available through ENCODE6. This was the first 
version of the Encyclopedia to be publically disseminated and presented at conferences 
by myself and Zhiping.  
VII.2 Introduction 
Annotations made for version 2 of the Encyclopedia expanded Sowmya Iyer’s work (Iyer 
2015) on version 1. This version directly annotated hg19 (mm10 was drafted7 but not 
released) with candidate promoters and enhancers through integration of DNase-seq, 
histone mark ChIP-seq, and transcription factor (TF) ChIP-seq datasets. In total 177 
ENCODE2 and ROADMAP cell types are annotated in this release; among them 94 cell 
types have both DNase-seq data and ChIP-seq data for one or more of the histone marks 
H3K27ac, H3K4me1, H3K4me3, H3K9ac (see Table VII-1 on page 232). For each of 
these 94 cell types, we annotated the DNase peaks with the percentile of each histone 
mark signal in the matching cell type.  
VII.3 Methods 
The Stamatoyannopoulos (Stam) Lab (University of Washington) merged all DNase peak 
data from the Stam and Crawford (Duke University) labs. This merging process formed 
one combined DNase-seq dataset with non-overlapping DNase hypersensitive regions. 
                                                 
6 https://www.encodeproject.org/data/annotations/v2/ 
7 https://zlab.umassmed.edu/~purcarom/bib5/mouse_pedia/beta1/ucsc_trackhub.txt 
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The Stam lab then identified the “master” peak in each region, defined as the peak in the 
region with highest peak height. I then separated the master DNase peaks into TSS 
proximal and TSS distal groups based on whether or not they intersected a 2000bp 
window centered on any GENCODE TSS.  
I downloaded signal files from Roadmap and ENCODE (using a primordial 
version of SnowPlowPy). For each DNase master peak, the average histone signals in the 
matching cell type was calculated in a 1000bp window around the center of the peak. 
This signal was converted to a percentile using the background distribution of histone 
signal in the matching cell type in randomly chosen 1000bp genomic regions that were 
outside all DNase peaks and ENCODE blacklisted regions. DNase master peaks that have 
at least one cell type with histone signal > 95th percentile of background were retained. 
Likewise, ChIP-seq TF files were also downloaded from ENCODE project. For each of 
the distal and proximal DNase master peaks, overlapping TF ChIP-seq peaks across all 
cell types available were identified. The TF peaks with maximum score in each master 
DNase peak were retained. All resulting peaks were transformed into bigBed tracks, and 
a trackhub generated for the UCSC Genome Browser (Figure VII-7 on page 239) and 
WashU Genome Browser (Figure VII-8 on page 240). 
VII.4 Results 
My pipeline located 3,166,489 candidate enhancer and promoter regions in hg19, and 
1,200,491 candidate enhancer and promoter regions in mm10. To gauge how well the 
DNase master peaks intersected regions with enhancer-like signatures (i.e. high H3K27ac 
signal, or called peaks from the ENCODE pipeline), a multitude of ‘bedtools intersect’ 
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operations were performed. In general, as shown in Figure VII-2 on page 234 for human 
and in Figure VII-5 on page 237 for mouse, H3K27ac peaks intersected DNase master 
peaks more than 75% of the time. As a sanity check, DNase master peaks were also 
intersected with H3K27ac peaks; since DHSs indicate genomic areas of open chromatin, 
where many other post-transcription modifications can occur besides acetylation of 
H3K27, less than half of the DNase master peaks overlapped with our enhancer histone 
modification mark, as shown in Figure VII-2 on page 234 and Figure VII-4 on page 236. 
I also examined master peak distance distributions across biosamples in mm10. As shown 
in  Figure VII-3 on page 235, distances to nearest master peak for different histone marks 
did vary. Ideally, master peaks should have relatively similar peak distributions for the 
same histone marks across different biosamples. Very short distances, though, may 
indicate large number of weak peaks, which was a problem. These DNase master peak 
“clouds” (Figure VII-9 on page 241) indicated too many master peaks with weak signal 
were being selected; these weaker peaks increase the number false positive enhancer-like 
elements found. Lastly, I examined how well master peaks made from just individual 
biosamples overlapped H3K27ac; as show in Figure VII-6 on page 238, biosample-
specific master peaks generally intersected the H3K27ac peaks for the particular 
biosample well, with some exceptions.  
Version 2 of the Encyclopedia was the first to incorporate Roadmap data, and we 
started exploring the techniques and problems associated with building what would be 
known as the registry of Candidate Elements. This was the Encyclopedia first presented 
at several conferences; feedback (in particular, the master peak “cloud” problem, and 
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difficulties with finding elements in the UCSC Genome Browser) encouraged our 
development of Version 3 of the Encyclopedia.   
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VII.5 Tables 
 
 
Table VII-1 | Datasets Used 
List of biosamples and assays used for V2 of hg19 Encyclopedia 
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VII.6 Figures 
 
Figure VII-1 | Fraction of H3K27ac peaks that overlap DNase peaks (hg19) 
DNase-seq “master peaks” overlap most (if not all) H3K27ac peaks, indicating we’re 
identifying the majority of sites with enhancer-like epigenetic signals based on H3K27ac.  
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Figure VII-2 | Fraction of DNase peaks overlapping H3K27ac peaks (hg19) 
DNase-seq “master peaks” indicate open regions of chromatin; many of these regions 
have H3K27ac marks, but many other epigenetic activities (TF binding, other histone 
modifications, etc.) may be taking place.  
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Figure VII-3 | Encyclopedia Master Peak Distances (mm10) 
Distances to nearest master peak for different histone marks across different biosamples. 
Ideally, master peaks should have relatively similar peak distributions for the same 
histone marks across different biosamples. Very short distances may indicate large 
number of weak peaks. 
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Figure VII-4 | Fraction of DNase peaks overlapping H3K27ac peaks (mm10) 
DNase-seq “master peaks” indicate open regions of chromatin; many of these regions 
have H3K27ac marks, but many other epigenetic activities (TF binding, other histone 
modifications, etc.) may be taking place. 
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Figure VII-5 | Fraction of H3K27ac peaks that overlap DNase peaks (mm10) 
DNase-seq “master peaks” overlap most (if not all) H3K27ac peaks, indicating we’re 
identifying the majority of sites with enhancer-like epigenetic signals based on H3K27ac. 
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Figure VII-6 | | Cross-biosample master peak overlap 
Compare intersection of master peaks in single cell type against peaks in all other cell 
types. 
  
239 
 
 
 
 
 
 
Figure VII-7 | UCSC Visualization 
Example region showing V2 candidate promoter and enhancer regions. 
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Figure VII-8 | WashU Genome Browser 
Example region showing V2 candidate promoter and enhancer regions 
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Figure VII-9 | Problems with early versions  
Large number of “weak” DNase master peaks 
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VIII. Appendix B: Encyclopedia V3 
VIII.1 Preface 
The unpublished work described in this appendix was performed along with Jill Moore 
and Zhiping Weng; the methods and tracks are available through ENCODE8. 
VIII.2 Introduction 
Version 3 of the Encyclopedia incorporated many suggestions based upon feedback from 
Version 2. This version selected candidate enhancer and promoter elements based upon 
ranking of DNase-seq, H3K27ac, and H3K4me3 signals. This approach was developed in 
the context of improving our enhancer predictions for VISTA regions (see IV.4 Enhancer 
Prediction on page 170). We also started development of our own visualizer, to better 
ease selecting and intersection of datasets of intersect.  
Lastly, we started to formalize the overall structure of the ENCODE 
Encyclopedia, including what assays would and would not be incorporated, and how 
particular analysis products should be grouped. This hierarchy of data (Figure VIII-1 on 
page 245) placed data in the context of what information it provided. First, ground level 
annotations are typically derived directly from the experimental data. Next, middle level 
annotations integrate multiple types of experimental data and multiple ground level 
annotations. Finally, top level annotations integrate a broad range of experimental data 
and ground and middle level annotations. For instance, chromatin states in the Top Level 
of the Encyclopedia could be made from enhancer-like and promoter-like elements 
determined at the Middle Level which, themselves, depended upon peaks calls made in 
                                                 
8 https://www.encodeproject.org/data/annotations/v3/ 
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the Ground Level of the Encyclopedia. Files such as raw reads or alignments are too data 
and uncondensed to be formally incorporated in the Encyclopedia; they just form the 
input to the Ground Level.  
VIII.3 Visualizer 
The visualizer for Version 3 needed to fulfill certain requirements. First, it needed to 
provide an integrated interface to query annotations by gene, SNP, or genomic position. 
Second, it also needed a way to present the user with a list of available cell types 
(including developmental time points, ontology information, etc.). Lastly, it had to 
provide a gateway to view signal and annotations files in the UCSC Genome Browser.  
The main page of the visualizer is show in Figure VIII-2 on page 246, and demonstrates 
the integrated interface for search and cell type selection (Figure VIII-5 on page 249). 
This page ultimately produces a dynamically-made UCSC Trackhub, as shown in Figure 
VIII-4 on page 248. 
This visualizer was the first to allow download of bed files containing the 
intersecting candidate elements, as well as the first to color predicted promoters near 
TSSs differently from enhancers. I experimented with best normalization techniques for 
overlay DNase with H3K27ac signals in the UCSC Genome Browser. This is also the 
first visualizer to exploit ENCODE’s ontology information (and to note how incomplete 
the ontology information was). 
This visualizer ultimately proved to be a useful proof-of-concept for candidate 
enhancer visualization; many of the techniques and approaches used ended up as the 
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basis for SCREEN. It also greatly helped stir discussion and feedback from the ENCODE 
community.  
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VIII.4 Figures 
 
Figure VIII-1 | Overview Of ENCODE Encyclopedia V3 
Version 3 of the Encyclopedia incorporated 3 levels of annotations: 
 Ground level annotations are typically derived directly from the experimental data. 
 Middle level annotations integrate multiple types of experimental data and multiple 
ground level annotations. 
 Top level annotations integrate a broad range of experimental data and ground and 
middle level annotations. 
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Figure VIII-2 | Visualizer Main Page 
This page provide an integrated interface to query annotations by gene, SNP, or genomic 
position, as well as show available cell types, and link out to the UCSC Genome 
Browser. 
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Figure VIII-3 | Dynamic trackhubs 
The visualizer created trackhubs on-the-fly, permitting dynamic reconfiguration of what 
the user was viewing in both UCSC and WashU Genome Browsers. 
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Figure VIII-4 | UCSC Genome Browser 
Example trackhub for UCSC 
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Figure VIII-5 | Visualizer Search Interface 
Users could select cell types to display genome tracks based upon intersection of their 
coordinate region with our database of hundreds of millions of peaks from ENCODE bed 
files.  
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X. Chapter VIII: Fin 
 
 
 
 
 
 
 
 
Never trust to general impressions…  
but concentrate yourself upon details. 
–Sherlock Holmes, A Case of Identity 
 
